Design, Synthesis And Biological Evaluation Of Histone Deacetylase (hdac) Inhibitors: Saha (vorinostat) Analogs And Biaryl Indolyl Benzamide Inhibitors Display Isoform Selectivity by Negmeldin, Ahmed
Wayne State University
Wayne State University Dissertations
1-1-2017
Design, Synthesis And Biological Evaluation Of
Histone Deacetylase (hdac) Inhibitors: Saha
(vorinostat) Analogs And Biaryl Indolyl Benzamide
Inhibitors Display Isoform Selectivity
Ahmed Negmeldin
Wayne State University,
Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Biochemistry Commons, and the Organic Chemistry Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Negmeldin, Ahmed, "Design, Synthesis And Biological Evaluation Of Histone Deacetylase (hdac) Inhibitors: Saha (vorinostat)
Analogs And Biaryl Indolyl Benzamide Inhibitors Display Isoform Selectivity" (2017). Wayne State University Dissertations. 1853.
http://digitalcommons.wayne.edu/oa_dissertations/1853
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF HISTONE 
DEACETYLASE (HDAC) INHIBITORS: SAHA (VORINOSTAT) 
ANALOGS AND BIARYL INDOLYL BENZAMIDE INHIBITORS 








Submitted to the Graduate School of  
 




in partial fulfillment of the requirements 
 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
2017 
                                            MAJOR: CHEMISTRY (Organic) 
 
              Approved By: 
 

















To my beloved mother, father, wife and children, 



































I would like to sincerely thank my supervisor Dr. Mary Kay H. Pflum for her 
continuous support, encouragement, valuable guidance, and patience given throughout 
the period of this work. During the last five years, I learned a lot of scientific, writing, 
presentation and mentoring skills from her. She is an amazing and outstanding mentor. 
I would like also to convey my gratitude to the committee members, Dr. Jeremy J. 
Kodanko, Dr. Young-Hoon Ahn, and Dr. Steven M. Firestine. I want to thank them for 
their valuable time, constructive comments and useful suggestions. 
My special thanks to all the lab members with whom I’ve worked together over 
the past few years in the Pflum lab, Geetha Padige, Danusha Nalawansha, Alexander 
Stark, Inosha Gomes, Satish Garre, Todd Faner, Thilani Anthony, Ahmed Fouda, 
Maheeka Embogama, Pavithra Dehigama, Cyprien Nanah, Nuan Acharige, Aparni 
Kaushalya, Vindya Mudiyanselage, and Michael Moussa. I had a great, wonderful, and 
an unforgettable time in the Pflum lab with you all. 
I want also to thank all the Lumigen Instrument Center staff and the Chemistry 
Department administrative staff for their support. 
I would like to thank my mother, father for their efforts, support and 
encouragement. Without their support, my success wouldn't have been possible. Last 
but not least, my gratitude goes to my wife for her great support, continuous support 
and encouragement through these years. Thank you for taking care of                 
everything during this long journey.
 iv 
 
TABLE OF CONTENTS 
DEDICATION............................................................................................................. ii 
ACKNOWLEDGEMENTS ........................................................................................ iii 
LIST OF TABLES ..................................................................................................... ix 
LIST OF FIGURES .................................................................................................... x 
LIST OF SCHEMES ............................................................................................... xiii 
CHAPTER 1 - Introduction ...................................................................................... 1 
1.1. Epigenetic mechanism and gene expression .................................................. 1 
1.2. Regulation of transcription by Histone Deacetylase (HDAC) Proteins ............. 2 
1.3. Classification of HDAC proteins ....................................................................... 4 
1.4. Catalysis mechanism of HDAC proteins .......................................................... 6 
1.5. HDAC proteins and cancers ............................................................................ 9 
1.6. Anti-tumor activity of HDAC inhibitors .............................................................. 9 
1.7. FDA approved HDAC inhibitors ..................................................................... 11 
1.8. Isoform selective HDAC inhibitors ................................................................. 14 
1.9. Dual HDAC6/HDAC8 selective HDAC inhibitors ............................................ 16 
1.10. Binding of HDAC inhibitors to HDAC active sites ......................................... 17 
1.11. Thesis Projects ............................................................................................ 19 
CHAPTER 2 - In vitro and in cellulo screening, enantioselective synthesis, and 
docking of C2-modified SAHA analogs ............................................................... 23 
2.1. Rationale for synthesis and screening of C2-modified SAHA analogs ........... 23 
2.2. In vitro screening of C2-modified SAHA analogs ........................................... 25 
2.3. In cellulo selectivity testing ............................................................................ 29 
2.4. In vitro cell growth inhibition ........................................................................... 30 
 v 
 
2.5. Enantioselective Synthesis and Screening of (R)- and (S)-C2-n-hexyl SAHA 32 
2.6. Docking Studies with HDAC2 and HDAC6 crystal structures ........................ 33 
2.7. Experimental Procedures .............................................................................. 37 
2.7.1. Materials and instrumentation ................................................................ 37 
2.7.2. Synthesis procedures for (S)-1i and (R)-1i ............................................ 39 
2.7.3. Procedures for biological screening ....................................................... 45 
2.7.4. Docking procedure ................................................................................. 50 
CHAPTER 3 - Synthesis, biological evaluation and docking of SAHA 
derivatives substituted at C4 position ................................................................. 52 
3.1. Rationale for synthesis of C4-modified SAHA analogs .................................. 52 
3.2. Synthesis of C4-substituted SAHA derivatives .............................................. 53 
3.3. In vitro screening of C4-modified SAHA analogs ........................................... 54 
3.4. In cellulo selectivity testing ............................................................................ 58 
3.5. In vitro cancer cell growth inhibition ............................................................... 59 
3.6. Enantioselective synthesis and screening of (R)- and (S)-C4-benzyl SAHA 
analog (19f). ......................................................................................................... 60 
3.7. Docking Studies ............................................................................................. 64 
3.8. Experimental Procedures .............................................................................. 69 
3.8.1. Materials and instrumentation ................................................................ 69 
3.8.2. Synthesis procedure .............................................................................. 69 
3.8.3. Procedures for biological screenings ..................................................... 99 
3.8.4. Docking procedure ............................................................................... 101 
CHAPTER 4 - Synthesis and biological evaluation of SAHA derivatives 
substituted at C5 position ................................................................................... 103 
4.1. Rationale for synthesis and screening of C5-modified SAHA analogs ......... 103 
 vi 
 
4.2. Synthesis of C5-substituted SAHA derivatives ............................................ 104 
4.3. In vitro screening of C5-modified SAHA derivatives .................................... 105 
4.4. In cellulo selectivity testing .......................................................................... 108 
4.5. In vitro cancer cell growth inhibition ............................................................. 109 
4.6. Experimental Procedures ............................................................................ 112 
4.6.1. Materials and instrumentation .............................................................. 112 
4.6.2. Synthesis procedure ............................................................................ 112 
4.6.3. Procedures for biological screenings ................................................... 122 
CHAPTER 5 - Docking Study of N-substituted SAHA analogs ........................ 123 
5.1. Rationale for synthesis, screening, and docking of N-substituted SAHA 
analogs  (35 a-e)................................................................................................. 123 
5.2. Docking studies with HDAC1 and HDAC3 crystal structures ....................... 127 
5.3. Experimental procedure ............................................................................... 132 
5.3.1. Docking procedure ................................................................................ 132 
CHAPTER 6 - Synthesis and screening of biaryl indolyl benzamide HDAC 
inhibitors .............................................................................................................. 134 
6.1. Rationale for design, synthesis and screening of biaryl indolyl benzamide 
HDAC inhibitors .................................................................................................. 134 
6.2. Docking studies of Cpd-60 with HDAC1, 2, 3, and 7 ................................... 136 
6.3. Synthesis of the biaryl indolyl benzamide HDAC inhibitors .......................... 137 
6.4. In vitro screening of biaryl indolyl benzamide HDAC inhibitors .................... 140 
6.5. Experimental Procedures ............................................................................ 142 
6.5.1. Materials and instrumentation .............................................................. 142 
6.5.2. Docking procedure ............................................................................... 143 
6.5.3. Synthesis procedure ............................................................................ 143 
 vii 
 
6.5.4. Procedures for biological screenings ................................................... 154 
CHAPTER 7 - Conclusion .................................................................................... 156 
APPENDIX A ......................................................................................................... 160 
A.1. Compound characterization data of (R) and (S)-C2-n-hexyl SAHA (1i) ....... 160 
A.2. In vitro HDAC activity screening data .......................................................... 174 
A.3. In cellulo selectivity data .............................................................................. 182 
A.4. Cell growth inhibition data ........................................................................... 183 
APPENDIX B ......................................................................................................... 186 
B.1. Compound characterization of the C4-modified SAHA analogs .................. 186 
B.2. Synthesis scheme for Mosher's esters ........................................................ 231 
B.3. In vitro screening with HDAC isoforms tables and figures ........................... 256 
B.4. In cellulo selectivity testing figure ................................................................ 266 
B.5. In vitro cancer cell growth inhibition tables and figures ............................... 267 
APPENDIX C ......................................................................................................... 270 
C.1. Compound characterization of the C5-modified SAHA analogs .................. 270 
C.2. In vitro screening with HeLa cell lysates and HDAC isoforms ..................... 296 
C.3. In cellulo selectivity testing .......................................................................... 302 
C.4. In vitro cancer cell growth inhibition ............................................................ 303 
APPENDIX D ......................................................................................................... 304 
D.1. Compound characterization of the biaryl indolyl benzamide inhibitors ........ 304 
D.2. In vitro screening with HDAC isoforms ........................................................ 316 
APPENDIX E ......................................................................................................... 319 
Copyrights permissions and reprint authorizations ............................................. 319 
REFERENCES ...................................................................................................... 326 
 viii 
 
ABSTRACT ........................................................................................................... 350 























LIST OF TABLES 
Table  1.1. IC50 values of the FDA-approved drugs and some selective HDAC 
inhibitors discussed in text. ...................................................................................... 14 
Table  2.1. IC50 values for SAHA, and C2-modified SAHA analogs (1a-g) with HeLa 
cell lysates. .............................................................................................................. 24 
Table  2.2. IC50 values for SAHA, tubastatin, SAHA analogs 1g-1i against HDAC1, 2, 
3, 6 and 8. ................................................................................................................ 28 
Table  2.3. EC50 values for SAHA and C2-n-hexyl (1i) SAHA analog against Jurkat, 
AML MOLM-13, and U937 cells using MTT assay. .................................................. 32 
Table  3.1. IC50 values for SAHA and C4-SAHA analogs (19a-19f) with HeLa cell 
lysates. ..................................................................................................................... 54 
Table  3.2. IC50 values for SAHA, tubastatin, SAHA analogs 19b-19f, and pure 
enantiomers of the C4-benzyl SAHA (R)-19f and (S)-19f against HDAC1, 2, 3, 6 and 
8. .............................................................................................................................. 57 
Table  3.3. EC50 values of SAHA and C4-butyl, C4-hexyl and C4-benzyl SAHA 
analogs with U937 cells. .......................................................................................... 60 
Table  4.1. IC50 values for SAHA, and C5-modified SAHA analogs (34a-e) with HeLa 
cell lysates. ............................................................................................................ 106 
Table  4.2. IC50 values for SAHA and C5-modified SAHA analogs 34c, 34d, and 34e 
against HDAC1, 2, 3, 6 and 8. ............................................................................... 108 
Table  5.1. IC50 values for SAHA, N-benzyl 35c, and N-biphenyl 35e against HDAC1, 
HDAC3, and HDAC6. ............................................................................................. 126 
Table  6.1. IC50 values and fold selectivity for Cpd-60 and Bnz-3 against HDAC1 and 





LIST OF FIGURES 
Figure  1.1. Chromosome structure showing the chromatin fiber and the nucleosome 
unit with the wrapping of DNA around histone proteins. ............................................ 2 
Figure  1.2. Role of histone deacetylase (HDAC) proteins in regulation of 
transcription. .............................................................................................................. 4 
Figure  1.3. Classification of HDAC proteins into metal dependent and NAD+ 
dependent, and the classification of the metal dependent into three classes. ........... 5 
Figure  1.4. Snapshots of the HDAC6 catalytic domain 2 during catalysis with the 
corresponding proposed reaction shown below each snapshot. ................................ 8 
Figure  1.5. Effect of HDAC inhibitors on cancer and normal cells. .......................... 11 
Figure  1.6. FDA approved HDAC inhibitors for treatment of cancer, with year of 
approval in parenthesis. ........................................................................................... 12 
Figure  1.7. Chemical structures of some isoform selective HDAC inhibitors 
discussed in the text. ............................................................................................... 16 
Figure  1.8. Chemical structures of dual HDAC6/HDAC8 selective HDAC inhibitors 
discussed in the text. ............................................................................................... 17 
Figure ‎1.9. The important structural pharmacophore of HDAC inhibitors and binding 
to HDAC active sites. ............................................................................................... 19 
Figure  1.10. Chemical structures of SAHA analogs modified in the linker region and 
at the hydroxamic acid moiety created in the Pflum lab. .......................................... 21 
Figure  2.1. Chemical structures of C2-modified SAHA analogs (1a-1i). .................. 23 
Figure  2.2. Principle of the ELISA based HDAC activity assay. ............................... 26 
Figure  2.3. Isoform selectivity screening of SAHA and C2-modifed SAHA analogs 
(1a-i) against HDAC1, 2, 3, and 6 using the ELISA-based HDAC activity assay. .... 27 
Figure  2.4. Cell-based selectivity testing of the C2-modified SAHA analogs. .......... 30 
Figure  2.5. Cytotoxicity screening of 1g, 1h, 1i, and SAHA with Jurkat cells. ........... 31 
Figure  2.6. Docked poses of (R)-C2-hexyl SAHA (A-D) and (S)-C2-hexyl SAHA (E-
H) in the crystal structures of HDAC6 and HDAC2 using Autodock 4.2. .................. 35 
Figure  2.7. Docking poses of SAHA in the HDAC6 (A) and HDAC2  crystal structures 
(B) using Autodock 4.2. ............................................................................................ 36 
 xi 
 
Figure  3.1. Chemical structures of C4-modified SAHA analogs (19a-f). .................. 52 
Figure  3.2. In vitro isoform selectivity screening of C4-modified SAHA analogs (19a-
f) against HDAC1, HDAC2, HDAC3, and HDAC6 using the ELISA-based HDAC 
activity assay............................................................................................................ 55 
Figure  3.3. Cell based selectivity testing of the C4-benzyl SAHA analog 19f. ......... 59 
Figure  3.4. Docked pose of (S)-C4-benzyl SAHA (A, B, E, F) and (R)-C4-benzyl 
SAHA (C, D, G, H) in the crystal structures of HDAC6 (PDB: 5G0H) and HDAC3 
(PDB: 4A69). ............................................................................................................ 65 
Figure  3.5. Docking poses of SAHA in the crystal structures of HDAC6 (PDB: 5G0H) 
(A) and HDAC3 (PDB: 4A69) (B). ............................................................................ 66 
Figure  3.6. Docked poses of (R)-C4-benzyl SAHA (R)-19f in the crystal structures of 
HDAC6 (A) HDAC3 (B). ........................................................................................... 67 
Figure  4.1. Chemical structures of C5-modified SAHA analogs (34a-e). ............... 104 
Figure  4.2. In vitro isoform selectivity screening of C5-modified SAHA analogs (34a-
e) against HDAC1, HDAC2, HDAC3, and HDAC6 using the ELISA-based HDAC 
activity assay.......................................................................................................... 107 
Figure  4.3. Cell based selectivity assessment of the C5-benzyl SAHA analog. ..... 109 
Figure  4.4. Cytotoxicity screening of SAHA and C5-modified SAHA analogs 34b, 
34c, and 34e with the Jurkat cells. ......................................................................... 110 
Figure  5.1. Structures of select HDAC inhibitors with the structural regions indicated 
at the top. ............................................................................................................... 124 
Figure  5.2. HDAC inhibitory activities of the N-modified SAHA analogs were 
measured at 125 μM against HDAC1, HDAC3 and HDAC6. ................................. 126 
Figure  5.3. Docking of SAHA (A), N-pentyl SAHA 35b (B), and N-biphenyl SAHA 35e 
(C) into the HDAC1 crystal structure (PBD 4BKX). ................................................ 128 
Figure  5.4. Docking of N-biphenyl SAHA 35e into the crystal structures of HDAC1 
and HDAC3. ........................................................................................................... 129 
Figure  5.5. Docking of SAHA (A), N-pentyl SAHA 35b (B), and N-biphenyl SAHA 35e 
(C) into the HDAC3 crystal structure (PBD 4A69). ................................................. 130 
Figure  5.6. Docking of N-biphenyl 35e into the HDAC1 crystal structure (PBD 4BKX).
 ............................................................................................................................... 130 
 xii 
 
Figure  6.1. Structures of HDAC1/3 selective inhibitor 36, HDAC1/2 selective inhibitor 
Cpd-60, and the biaryl indolyl benzamide HDAC inhibitors Bnz-1, Bnz-2, and Bnz-3.
 ............................................................................................................................... 135 
Figure  6.2. Docking of Cpd-60 into the crystal structures of (A) HDAC1, (B) HDAC2, 
(C) HDAC3 and (D) HDAC7. .................................................................................. 137 
Figure  6.3. In vitro isoform selectivity screening of SAHA, Cpd-60, Bnz-1, Bnz-2, and 




 LIST OF SCHEMES 
Scheme  2.1. Synthesis of C2-modified SAHA analogs performed by Dr. Anton 
Bieliauskas ............................................................................................................... 24 
Scheme  2.2. Enantioselective synthesis of (S)-C2-n-hexyl SAHA (S)-1i ................. 32 
Scheme  2.3. Enantioselective synthesis of (R)-C2-n-hexyl SAHA (R)-1i ................. 33 
Scheme  3.1. Synthesis of C4-SAHA analogs (19a-f). .............................................. 53 
Scheme  3.2. Enantioselective synthesis of intermediate alcohols (S)-22 (Part A) and 
(R)-22 (Part B) ......................................................................................................... 62 
Scheme  3.3. Synthesis of (R)-C4-benzyl SAHA analog (R)-19f .............................. 63 
Scheme  3.4. Synthesis of (S)-C4-benzyl SAHA analog (S)-19f ............................... 63 
Scheme  4.1. Synthesis of C5-SAHA analogs (34a-e) ............................................ 105 
Scheme  6.1. Synthesis of intermediates 44a and 44b ........................................... 138 
Scheme  6.2. Synthesis of the biaryl amine 49 ....................................................... 139 
Scheme  6.3. Synthesis of Bnz-1 and Bnz-3 ........................................................... 139 













CHAPTER 1 - INTRODUCTION  
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T.; 
Padige, G.; Bieliauskas, A. V.; Pflum, M. K. H., Structural Requirements of HDAC 
Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 
Selectivity, ACS Medicinal Chemistry Letters 2017, 8 (3), 281-286; Bieliauskas, A. 
V.; Weerasinghe, S. V. W.; Negmeldin, A. T.; Pflum, M. K. H., Structural 
requirements of histone deacetylase inhibitors: SAHA analogs modified on the 
hydroxamic acid, Arch. Pharm.  (Weinheim, Ger.) 2016, 349, 373-382; and 
Negmeldin, A. T. and Pflum, M. K. H., The structural requirements of histone 
deacetylase inhibitors: SAHA analogs modified at the C4 position display dual 
HDAC6/HDAC8 selectivity, European Journal of Medicinal Chemistry (Submitted) 
1.1. Epigenetic mechanism and gene expression 
The chromosome is an important X-shaped cellular structure that carry all the 
hereditary genetic information of the organism (genome) in the form of genes. In 
eukaryotes, the chromosome is a highly condensed structure of long chromatin fiber, 
which is a complex that consists of multiple nucleosome units  (Figure 1.1). DNA 
double strand (blue strand) that carries genetic information is wrapped around 
histone proteins forming each nucleosome unit (Figure 1.1).1-2 The compactness of 
the nucleosome structure is affected by different epigenetic modifications, which by 
its turn affects DNA accessibility.2   
Epigenetic modifications play an essential role in regulation of gene 
transcription, DNA repair, DNA replication, and cell growth through mechanisms 
independent of structure of DNA.3-4 Several epigenetic changes are known to date, 
such as DNA methylation and histone tail modifications. Post-translational 
modifications of histone proteins are among the major dynamic epigenetic changes 
that regulate DNA expression and replication. Several post-translational covalent 
modifications of histone proteins are known, such as acetylation, methylation, 




controlled by two main classes of enzymes, histone acetyltransferases (writers) and 
histone deacetylases (erasers)(Figure 1.1).2 
 
Figure ‎1.1. Chromosome structure showing the chromatin fiber and the nucleosome 
unit with the wrapping of DNA around histone proteins.2 Post-translational 
modifications of Histone N-terminal residues are governed by several enzymes 
including, histone acetyltransferases and histone methyltransferases (readers), 
histone deacetylases and lysine demethylases (erasers). Reused with permission 
from nature publishing group (see Appendix E). 
1.2. Regulation of transcription by Histone Deacetylase (HDAC) Proteins 
Histone Deacetylase (HDAC) proteins play an essential role in the regulation 
of transcription in a balanced process with histone acetyl transferases (Figures 1.2A 
and 1.2B). DNA double strands are tightly wrapped around histone proteins due to 
the electrostatic interaction between the positively charged free amines of lysine side 
chains that are abundant in the histone protein N-terminal tails, and the negatively 
charged DNA backbone (Figures 1.2A and 1.2C). As a result of the tight interaction, 




transcription is repressed (Figure 1.2A). Upon acetylation of the ε-amino group on 
the side chains of lysine amino acids with histone acetyl transferases (HATs), the 
compact structure will become loosened due to the acetylation of the amine groups 
and loss of the electrostatic interaction. In the acetylated state, the nucleosomal 
DNA will be accessible to transcription factors and will become transcriptionally 
active (Figures 1.2B and 1.2C). Several other key enzymes are involved in activation 
of transcription such as, lysine methyltransferases and lysine demethylases (Figure 
1.2B). On the other hand, HDAC proteins catalyze deacetylation of acetylated lysine 
residues, which will turn off transcription (Figure 1.2A and 1.2C).6 In addition, 
deubiquitination, methylation and demethylation of specific lysine amino acid 
residues can also lead to repression of transcription (Figure 1.2A). The overall 
acetylation levels and the dynamic balance of both acetylation and deacetylation 
reactions regulate gene expression as part of several post translational modifications 













             A)                           B) 
 
          C) 
 
Figure ‎1.2. Role of histone deacetylase (HDAC) proteins in 
regulation of transcription. A) The wrapping of double stranded 
DNA around histone proteins, makes the DNA inaccessible to transcription factors.5 
B) Acetylation, methylation, demethylation, or ubiquitination of lysine residues 
loosens the histone structure, making the DNA accessible to transcription factors.5 
C) Lysine residue acetylation with histone acetyltransferase and deacetylation with 
histone deacetylase (HDAC). Reused from open access article that permits 
unrestricted use or reproduction with proper citation (see Appendix E). 
1.3. Classification of HDAC proteins 
The HDAC family contains 18 different proteins (Figure 1.3), which are 
grouped into four classes according to phylogenetic analysis (homology with yeast 
HDAC proteins), size, cellular localization, and number of catalytic active sites.7  
Eleven of them are metal-dependent, while the rest are NAD+ dependent. The metal-




NAD+ dependent.7 The eleven metal-dependent HDAC proteins are the focus of this 
work. 
 
Figure ‎1.3. Classification of HDAC proteins into metal dependent and NAD+ 
dependent, and the classification of the metal dependent into three classes.8 
Reused with permission from Elsevier Ltd. (see Appendix E). 
Class I HDAC proteins include HDAC1, HDAC2, HDAC3, and HDAC8 (Figure 
1.3), which are relatively smaller proteins (377-488 amino acids) compared to class 
II HDACs and are predominantly nuclear enzyme.8-9 Both HDAC3 and HDAC8 can 
shuttle between the nucleus and the cytoplasm. HDAC1, 2, 3, and 8 are grouped in 
the same class due to homology to yeast RPD3, ubiquitous expression in almost all 
cell lines and tissues, and their key role in cell survival and proliferation (Figure 1.3).9  
Class II HDAC proteins are relatively large proteins (669-1215 amino acids), 
have sequence similarity with yeast HDA1, and maintain the ability to shuttle 




subclasses, class IIa and IIb. Class IIa includes HDAC4, HDAC5, HDAC7, and 
HDAC9 (Figure 1.3).9 On the other hand, class IIb includes HDAC6 and HDAC10, 
which are mainly cytoplasmic and contain two catalytic domains. HDAC11 is a 
unique member of the HDAC family with a size of 347 residues and a sequence 
similarity to both classes I and II.8-9, 11 
1.4. Catalysis mechanism of HDAC proteins 
All HDAC enzymes have high sequence similarity in their active sites.12 For 
the deacetylation reaction, several essential amino acids are important for catalysis. 
For example, based on the HDAC6 crystal structure, the zinc atom, histidine 573 
(H573), histidine 574 (H574), and tyrosine 745 (Y745) have a crucial role in the 
deacetylation mechanism (Figure 1.4).13-14 The metal ion and the three amino acids 
are conserved in most of the HDAC isoforms. The exception is class IIa enzymes, in 
which only the metal ion and two histidine amino acids are maintained. 13-23 The 
mechanism of deacetylation is believed to be similar among all of the HDAC 
isoforms, with differences in catalytic efficiency between them.24-26 The crystal 
structure of the HDAC6 catalytic domain 2 (CD2) was recently reported with several 
snapshots showing all the key mechanistic steps in catalysis (Figure 1.4).14 First, a 
water molecule (red sphere in Figure 1.4a) was chelated (red dashed line) with the 
zinc atom (grey sphere) and hydrogen bonded with the two histidine amino acids 
residue (black dashed lines with H573 and H574) (Figure 1.4a). In the same 
snapshot, an empty space between the chelated water molecule and Y745 is shown 
and is proposed to be where a substrate fits in the binding site. In order to study the 
binding of the substrate α-tubulin K40 peptide (orange structure in Figure 1.4b), 




HDAC6-substrate interaction. The second crystallographic snapshot showed the 
enzyme substrate-complex with the carbonyl of the ε-acetyl lysine coordinated to the 
metal ion without displacing the coordinated water molecule (Figure 1.4b). Next, 
H574, which is known to act as a general acid during catalysis, was mutated to 
alanine (H574A) in order to capture the enzyme during the transition state (Figure 
1.4c). The snapshot showed a tetrahedral intermediate, indicating that H573 acted 
as a general base to deprotonate the water molecule. Nucleophilic attack by the 
deprotonated water molecule on the substrate carbonyl formed the tetrahedral 
intermediate in the active site, which was stabilized by both the zinc atom and Y745 
(Figure 1.4c). Finally, the tetrahedral intermediate collapsed and yielded the free ε-
lysine side chain of the substrate (not obtained in the crystal structure), and an 
acetate anion that was observed and stabilized by the metal ion, H573, H574, and 





Figure ‎1.4. Snapshots of the HDAC6 catalytic domain 2 during catalysis with the 
corresponding proposed reaction shown below each snapshot. See text for complete 





1.5. HDAC proteins and cancers 
HDAC proteins regulate the expression of several cancer-related proteins 
involved in cell signaling, transcription, and tumor suppression through the 
deacetylation of nucleosomal histone proteins.27-30 Mutations of HDAC proteins in 
cancer are rare, while aberrant or overexpression of HDAC proteins is common with 
many types of cancers.9 Overexpression of HDAC proteins results in unregulated 
transcription and aberrant protein activity and function, which is linked to several 
diseases, including cancer.28 HDAC proteins are also implicated in several other 
diseases, such as asthma and schizophrenia.31-32 The aberrant expression of HDAC 
proteins in many cancers leads to poor expression of tumor suppressor proteins that 
are normally expressed in normal cells.33   
Several reports have shown aberrant expression of individual HDAC isoforms 
in different types of cancers. HDAC1 was overexpressed in lung,34 ovarian,35 
gastric,36 prostate,37 breast,38 and colon cancers.39 HDAC2 was overexpressed in 
colorectal and gastric cancers.40 HDAC8 was highly expressed in neuroblastoma 
patients, leading to cancer progression and poor survival rates.41 In addition, HDAC8 
inhibition showed promising results in T-cell lymphoma and leukemia.42 Class II 
HDAC6 was overexpressed in oral squamous cell carcinoma and ovarian cancer.43-
44 In addition, HDAC6 is implicated in several non-epigenetic cancer-related 
intracellular functions.45-46 Overexpression of both HDAC6 and HDAC8 was linked to 
breast cancer metastasis and invasion.47 
1.6. Anti-tumor activity of HDAC inhibitors 
Due to their key role in cancer, HDAC proteins have emerged as interesting 




proteins have been developed.6, 48-52 HDAC inhibitors, such as SAHA were found to 
decrease the sizes of lung, stomach, pancreas, mouth, ovaries, breast, and prostate 
tumors in mouse models.31, 53-54 The effect of HDAC inhibitors on the acetylation 
states of both histone and non-histone substrates can lead to cell signaling 
dysregulation, transcription and expression changes, and protein degradation. 
Through these effects on tumor cells, HDAC inhibitors can reduce proliferation, 
migration, and angiogenesis, enhance differentiation and immunogenicity, and 
promote apoptosis (Figure 1.5).50, 55-56 More specifically, HDAC inhibitors exhibited 
the ability to cause cancer cells differentiation, inhibition of the cell cycle, and  
induction of apoptosis.55, 57-60 Several studies showed that treatment of cancer cells 
with HDAC inhibitors induced cell cycle arrest in the G1 or G2 phases (Figure 1.5a 
and 1.5b). Subsequent cancer cell differentiation might be observed after cell cycle 
arrest in G1 phase (Figure 1.5b).61-62 Another crucial antitumor mechanism of HDAC 
inhibitors is based on apoptosis, where cancer cells that pass by the G1 cycle arrest 
can duplicate their DNA and get arrested at the G2 phase, where accumulated DNA 
and hyperacetylated histones lead to apoptosis (Figure 1.5a).61-62 Several known 
HDAC inhibitors cause cancer cell apoptosis.58, 63-66 HDAC inhibitors have the same 
effect on acetylation levels in both normal and cancer cells, but unlike cancer cells, 
normal cells can undergo a G2 checkpoint after the cell cycle arrest and survive after 





Figure ‎1.5. Effect of HDAC inhibitors on cancer and normal cells.55 A)HDAC inhibitor 
induced G2 cell cycle arrest, and subsequent apoptosis. B) HDAC inhibitor induced 
G1 cell cycle arrest and cancer cell differentiation. C) HDAC inhibitor effect on 
enhancement of immunogenicity of cancer cells and reduction of angiogenesis. 
Reused with permission from nature publishing group (see Appendix E). 
In addition to the main two mechanisms mentioned above, HDAC inhibitors 
have other  indirect secondary effects on cancer cells. HDAC inhibitors can enhance 
cancer cells immunogenicity by induction of transcription of several extracellular 
proteins, receptors, and complexes (Figure 1.5c). Among these extracellular proteins 
are major histocompatibility complex (MHC) proteins, activation molecules (CD40, 
CD80, and CD86), and intercellular adhesion molecule (ICAM1). The increased 
expression of these proteins and receptors can augment the recognition and activity 
of the immune system against cancer cells (Figure 1.5c).67-70 
1.7. FDA approved HDAC inhibitors 
Several HDAC inhibitors have been approved by the FDA for treatment of 
cancer.50 SAHA (suberoylamide hydroxamic acid, Vorinostat, Zolinza™) was 
approved in 2006 for treatment of cutaneous T-cell lymphoma (Figure 1.6).49, 71-72 
Romidepsin (FK-228, Istodax™) was approved in 2009 for treatment of cutaneous 
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T-cell lymphoma and in 2011 for treatment of peripheral T-cell lymphoma.48, 73 In the 
last three years, two more HDAC inhibitors gained FDA approval for cancer 
treatment. Belinostat (PXD101, Belodaq™) was FDA-approved in 2014 for treatment 
of relapsed or refractory peripheral T-cell lymphoma (Figure 1.6).51, 74 More recently 
Panobinostat (LBH-589, Farydak™) was approved in 2015 for treatment of multiple 
myeloma (Figure 1.6).52, 75 Several other HDAC inhibitors are currently in clinical 
trials as anti-cancer candidates.33, 76 
 
Figure ‎1.6. FDA approved HDAC inhibitors for treatment of cancer, with year of 
approval in parenthesis. 
Most HDAC inhibitors share a common pharmacophore that is essential for 
binding and inhibition. The pharmacophore is composed of three important structural 
regions: the metal binding group, the linker region, and the capping group (Figure 
1.6, see SAHA).25 Three of the FDA approved drugs (SAHA, Belinostat and 
Panobinostat) have a hydroxamic acid moiety as the metal binding group and an 




linker, while Belinostat and Panobinostat have unsaturated linkers with an aromatic 
rings. Romidepsin is a bicyclic depsipeptide prodrug that releases a thiol metal 
binding group upon reductive cleavage of the disulfide bond (Figure 1.6). 
Despite the successes of HDAC inhibitors in cancer treatment, they manifest 
side effects in patients, including gastrointestinal symptoms, bone marrow 
suppression, fatigue, cardiac arrhythmia, nausea, dehydration, thrombocytopenia, 
and anorexia.77-80 One hypothesis accounting for the observed side effects is the 
poor selectivity of the clinically tested HDAC inhibitors; most compounds inhibit all or 
many of the eleven HDAC isoforms (Table 1.1, see first four entries).12, 78 For 
example, the FDA approved drugs, including SAHA, inhibit most or all the eleven 
metal-dependent HDAC isoforms (Table 1.1). In addition, the non-selectivity of the 















Table ‎1.1. IC50 values of the FDA-approved drugs and some selective HDAC 
inhibitors discussed in text.a 
a  alues in table were collected from literature.   D  not determined.    " no data 
available. 
1.8. Isoform selective HDAC inhibitors 
While isoform selective inhibitors would be valuable on the bench top and in 
the clinic, only a few highly selective compounds have been identified (Figure 1.7 
and Table 1.1). For example, entinostat (KHK2375, SNDX-275, formerly MS-275) is 
a benzamide inhibitor currently in phase II clinical trials and is selective for class I 
HDAC proteins with 4- to 400-fold selectivity for HDAC1, 2, and 3 over the other 
isoforms.62, 78, 92 Apicidin is a cyclic peptide fungal metabolite that inhibits HDAC 
proteins with 17-230-fold selectivity towards class I HDAC2, 3, and 8.78 Cpd-60 is 
another benzamide inhibitor that displayed at least 204-fold selectivity for HDAC1 
Compound 
HDAC isoforms and the corresponding IC50 values (nM) 
1 2 3 4 5 6 7 8 9 10 11 
SAHA
78, 81-82
 68 164 48 101 ND 90 104 1534 107 58 35 
Romidepsin
83
 40 50  510  14,000      
Belinostat
78
 41 125 30 115  82 67 216 128   
Panobinostat
78
 3 3 4 12  61 14 248 3   
Entinostat
78
 181 1,155 2,311 >10,000  >10,000 >10,000 >10,000 505   
Apicidin
78
 >10,000 120 43 >10,000  >10,000 >10,000 575 >10,000   
Cpd-60
84
 7 49 10,000 >10,000 >10000 >10,000 >10,000 >10,000    
RGFP-966
85
 >15,000 >15,000 80 >15,000 >15,000 >15,000 >15,000 >15,000 >15,000 >15,000 >15,000 
Tubastatin
86
 16,400 >30,000 >30,000 >30,000 >30,000 15 >30,000 854 >30,000 >30,000 >30,000 
PCI-34051
87
 4,000 >50,000 >50,000   2,900  10  13,000  
VAHA
88
 560,000 680,000 340,000 170,000 37,000 16,000 99,000 39,000 91,000   
BRD-73954
89














and HDAC2 over HDAC3.84 RGFP966 belongs to the benzamide HDAC inhibitors 
and showed more than 188-fold selectivity for HDAC3 over the other isoforms 
(Figure 1.7 and Table 1.1).76 Tubastatin, which was developed as an HDAC6-
selective inhibitor, demonstrated 87-fold or 1000-fold selectivity for HDAC6 over 
HDAC1, 2, and 3 according to different reports.86, 93 Finally, PCI-34051 is a 
hydroxamic acid based HDAC8 selective inhibitor that was developed in 2008 and 
exhibited at least 290-fold selectivity for HDAC8 over HDAC1, 2, 3, 6, and 10 (Figure 





Figure ‎1.7. Chemical structures of some isoform selective HDAC inhibitors 
discussed in the text. 
1.9. Dual HDAC6/HDAC8 selective HDAC inhibitors 
HDAC inhibitors that target one or two HDAC isoforms will be valuable for 
development of new drugs with possibly fewer side effects than the non-selective 
inhibitors.94-97 More specifically, recent reports suggested that inhibition of both 
HDAC6 and HDAC8 can have several possible synergistic therapeutic applications 
in the treatment of various cancers.89-91 In addition, dual inhibition of HDAC6 and 
HDAC8 might have potential application in breast cancer angiogenesis and 
metastasis.42, 89 Recently, several dual HDAC6/8 selective inhibitors have been 
developed (Figure 1.8).88-91 
 In 2011, Haggarty and co-workers developed valpropylhydroxamic acid 
(VAHA), which showed modest selectivity for HDAC6 and HDAC8, but with weak 
potency (16 and 39 µM) (Figure 1.8 and Table 1.1).88 Two years later in 2013, 
Holson and co-workers reported the first dual HDAC6/HDAC8 selective inhibitor 
BRD-73954 (Figure 1.8).89 The dual inhibitor BRD-73954 demonstrated high fold 
selectivity towards HDAC6 and 8 (at least 75-fold) over the other metal dependent 
HDAC proteins, with IC50 values of 36 and 120 nM with HDAC6 and HDAC8, 
respectively (Table 1.1).89 In 2014, Tang et al. reported Aminotetralin 32 as another 
dual HDAC6/8 selective inhibitor (Figure 1.8). The compound exhibited at least 79-
fold selectivity to HDAC6 and 8, and IC50 values in the range of 50-80 nM against 
HDAC and HDAC8 (Table 1.1).90 Recently, another group reported the dual 
selective inhibitor N-acylhydrazone analog 3f (Figure 1.8), with IC50 values of 27 and 
130 nM with HDAC6 and 8, and at least 23-fold dual selectivity.91 The development 




enhance the efficacy of anti-cancer drugs compared to the current non-selective 
drugs. Moreover, selective HDAC inhibitors will be useful as chemical tools to study 
cancer-related HDAC cell biology. 
 
Figure ‎1.8. Chemical structures of dual HDAC6/HDAC8 selective HDAC inhibitors 
discussed in the text. 
1.10. Binding of HDAC inhibitors to HDAC active sites 
Most of HDAC inhibitors have three common important binding interaction 
regions (discussed in section 1.7), which are a capping group, a linker, and a metal 
binding group (Figure 1.9A). In all the metal-dependent HDAC proteins, these three 
regions form several essential interactions with the active site. As an example, 
SAHA docked into the active site of the HDAC1 crystal structure shows three 
significant binding interactions (Figure 1.9B).98 First, the hydroxamic acid (the metal 
binding group) interacts with the metal binding region with five key interactions for 
inhibition of the enzyme (Figure 1.9C). The carbonyl group of the hydroxamic acid 
moiety chelates with the metal ion in the binding site with two electrostatic 




acid group with H140, H141, and Y303 amino acids of the active site (Figure 1.9B 
and C). Moreover, the non-polar six carbons linker of SAHA interacts with the 
hydrophobic side chains of the amino acids lining the 11 Å channel (Figures 1.9A 
and 1.9B). Finally, the anilinamide  capping group interacts with the solvent exposed 
region (Figures 1.9A and 1.9B). Another important part of the active site is the 14 Å 
channel, which is located at the bottom of the active site and helps in acetate escape 
(Figure 1.9B).98 
HDAC inhibitors bind similarly to all the HDAC isoforms, with few variations 
with different HDAC isoforms active sites that impart isoform selectivity. Most of the 
metal-dependent HDAC crystal structures have been revealed, including HDAC1, 
HDAC2, HDAC3, HDAC4, HDAC7, and HDAC8 crystal structures 15, 19-21, 99-100, along 
with homology models of the other HDAC isoforms 22-23. Recently, several crystal 
structures of both catalytic domains of HDAC6 were reported (see section 1.4).13, 101 
All crystal structures have the three common binding interaction regions, with high 
similarity in both sequence and binding site shape. Some of the isoforms lack the 14 
Å channel (Figure 1.9B), including HDAC6 and HDAC8. On the other hand, several 
HDAC isoforms have a relatively wide 14 Å channel, such as HDAC1 and HDAC2, 
while others have a 14 Å channel with a constriction, like HDAC3. 
When comparing the 11 Å channel (Figure 1.9B), HDAC6 and HDAC8 have a 
wider and shorter active site entrance (11 Å channel) than HDAC1, HDAC2, and 
HDAC3, which helped to develop several HDAC6 or HDAC8 selective inhibitors, or 
dual HDAC6/HDAC8 selective inhibitors. The high similarity in the binding site of 




inhibitor to either HDAC1 or HDAC2. The availability of crystal structures for HDAC 
isoforms helped in developing isoform selective HDAC inhibitors, as well as in 
explaining the selectivity of several isoform selective HDAC inhibitors. 
 
Figure ‎1.9. The important structural pharmacophore of HDAC inhibitors and binding 
to HDAC active sites. A) Structure of SAHA showing key pharmacophoric binding 
groups for HDAC inhibition. B and C) Binding of SAHA to HDAC1 crystal structure 
(deep blue mesh; PDB: 4BKX). Binding distances between the hydroxamic acid 
atoms and active site residues (numbered in figure) or the metal are displayed in 
Angstroms. The metal ion (Zn2+) is represented as a grey sphere. Color-coded 
SAHA (C=green/white; O=red; N=blue, H=white). 
1.11. Thesis Projects 
While some selective compounds have been reported, identifying additional 
strictly isoform-selective HDAC inhibitors remains a challenge, especially for the 





















14 Å channel 





Selective inhibitors can be used as a biological tools to elucidate the function of each 
isoform in the development and progression of cancer. In addition, isoform selective 
HDAC inhibitors will be valuable for the design and development of new promising 
drugs with less side effects. Moreover, modification of pan-inhibitors currently used 
in clinic can possibly improve their selectivity and reduce their clinical side effects. 
Because most of the reported SAHA derivatives focus on modification of the 
capping group or metal binding group (Figure 1.9A). We are interested in our lab to 
modify the linker or the metal binding group with different groups.102-105 Previously, 
our lab published several derivatives modified at C2, C3, C6 and the nitrogen atom 
of the metal binding group (Figure 1.10). Some of these derivatives showed isoform 
selectivity.103-105 The C3-ethyl SAHA analog showed a modest preference for 
HDAC6 over HDAC1 and HDAC3.104 Among the C6-modified SAHA analogs, C6-t-
butly SAHA displayed a modest selectivity for HDAC1 and 6 compared to HDAC3.105 
In addition, several of the C7-modified SAHA analogs showed selectivity patterns to 
different isoforms, but with low fold selectivity.106 More interestingly, one of the C7-
SAHA analogs exhibited greater potency than SAHA both in vitro and with different 
cancer cell lines. 
C2-modified SAHA analogs (Figure 1.6) were also generated and showed µM 
potency with HeLa cell lysates, but no selectivity assessment was performed.103 In 
Chapter 2, the HDAC isoform selectivity of C2-SAHA analogs, including IC50 values, 
were assessed. In cellulo testing has also been performed, and docking studies 
were used to explain the observed selectivity of some of the C2-SAHA analogs. 




were performed, and both of the pure enantiomers were screened for potency and 
selectivity.  
 
Figure ‎1.10. Chemical structures of SAHA analogs modified in the linker region and 
at the hydroxamic acid moiety created in the Pflum lab. 
Chapters 3 and 4 discuss the synthesis of new SAHA derivatives substituted 
at the C4 and C5 positions of the linker region (Figure 1.10). The substituents 
chosen have different sizes and electronic properties to fit into active site of different 
HDAC isoforms (Figure 1.9) and to test the effect of these substituents on activity 
and/or selectivity. The newly synthesized derivatives were tested for their activity in 
vitro against HeLa cell lysates, as well as their selectivity with different HDAC 




In Chapter 5, docking studies for previously synthesized and screened SAHA 
analogs modified at the hydroxamic acid moiety was performed. The docking studies 
suggested  an explanation based on the analogs structures and the crystal 
structures of HDAC1 and HDAC3 the source of the observed HDAC1 preference, as 
well as the lower potency of the N-SAHA analogs compared to SAHA. Finally, 
Chapter 6 focuses on the development of an HDAC1 selective inhibitor in order to 
use it as a biological tool and understand the HDAC1 related cancer biology. The 
design, synthesis, and screening of several biaryl indolyl benzamide derivatives as 




CHAPTER 2 - IN VITRO AND IN CELLULO SCREENING, 
ENANTIOSELECTIVE SYNTHESIS, AND DOCKING OF C2-
MODIFIED SAHA ANALOGS 
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T.; 
Padige, G.; Bieliauskas, A. V.; Pflum, M. K. H., Structural Requirements of HDAC 
Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 
Selectivity, ACS Medicinal Chemistry Letters 2017, 8 (3), 281-286; and Padige, G.; 
Negmeldin, A. T.; Pflum, M. K. H., Development of an ELISA-Based HDAC Activity 
Assay for Characterization of Isoform-Selective Inhibitors, Journal of Biomolecular 
Screening 2015, 20 (10), 1277-1285) 
2.1. Rationale for synthesis and screening of C2-modified SAHA analogs 
Towards development of selective HDAC inhibitors, we previously created 
SAHA analogs containing substituents in the linker region between the hydroxamic 
acid and the anilide ends (Figure 1.6). A C3-modified SAHA analog showed modest 
preference for HDAC6, while C6-modified SAHA analogs displayed selectivity for 
HDAC1 and 6 compared to HDAC3.103-105 In addition, modifying the amine of the 
hydroxamic acid reduced potency, but enhanced preference for HDAC1.102 C2-
modified SAHA analogs (Figure 2.1) were also generated by Dr. Anton Bieliauskas 
and screened with HeLa cell lysates by Dr. Sujith Weerasinghe (Scheme 2.1), and 
showed µM potency with HeLa cell lysates (Table 2.1) But no selectivity assessment 
was performed.103 Because HeLa cell lysates contain all HDAC isoforms, the 
observed lower potency of the C2-SAHA analogs against HeLa cell lysates (Table 
2.1) suggests that they might be selective for some isoforms over the others 
compared to SAHA.  
 




Scheme ‎2.1. Synthesis of C2-modified SAHA analogs performed by Dr. Anton 
Bieliauskas 103 
 
Table ‎2.1. IC50 values for SAHA, and C2-modified SAHA analogs (1a-g) with HeLa 
cell lysates.a 
a Mean IC50 value and standard error of at least three independent trials are shown. 
Data provided by Dr. Sujith Weerasinghe.103 
We report here a selectivity assessment of C2-modified SAHA analogs both 
in vitro and in cellulo. Modification at the C2 position led to reduced potency but 
enhanced selectivity compared to SAHA, with preference for HDAC6 and 8 over 
HDAC1, 2, and 3. Enantioselective syntheses of both enantiomers of the most 
Compound R IC50 (µM) 
SAHA  0.090 ± 0.004 
1a methyl 134 ± 6 
1b ethyl 449 ± 17 
 1c n-propyl 154 ± 7 
1d n-butyl 72 ± 6 
1e allyl 144 ± 9 
1f propargyl 87 ± 5 




selective analog were also performed, with subsequent screening. Docking studies 
provided a structural rationale for the observed HDAC6/8 selectivity. The observed 
fold selectivities for some of the analogs were higher compared to known dual 
HDAC6/8 selective inhibitors (see section 1.9), but with submicro molar to 
micromolar IC50 values. HDAC6/8 dual inhibitors can be used as biological tools to 
study breast cancer metastasis.89, 107  In addition, SAHA analogs reported here are 
useful lead compounds for further development of pharmacological agents and anti-
cancer drug targeting HDAC6 and 8. 
2.2. In vitro screening of C2-modified SAHA analogs 
Herein we used the recently developed ELISA-based HDAC activity assay to 
screen the C2-modified SAHA analogs against mammalian-derived HDAC1, 
HDAC2, HDAC3, and HDAC6.93, 108 The ELISA-based HDAC activity assay was 
developed in our lab primarily by Dr. Geetha Padige for screening and identification 
of isoform selective HDAC inhibitors. The assay relies on the use of mammalian cell 
expressed HDAC proteins, which is more biologically relevant than the widely used 
assays that use baclovirus-expressed recombinant HDAC proteins.78 In addition, 
compared to other methods that use mammalian cell-expressed HDAC proteins, the 
ELISA-based HDAC activity assay is a robust and highly reproducible assay with 
much lower error rates.93, 109-110 The assay is modeled after the classic ELISA, in 
which antibodies are used to immobilize proteins from mammalian cell extract onto a 
plate. In the ELISA-based HDAC activity assay, polystyrene high-binding or 
secondary antibody–coated 96-well plates were incubated with a primary HDAC 
antibody (Figure 2.2.A), followed by HeLa cell lysates to immunoprecipitate the 




affixed onto the plate, deacetylase activity was tested using commercially available 
HDAC Glo I/II assay, which produces a highly stable and sensitive 
chemiluminescent signal after reaction with the HDAC enzyme (Figure 2.2.C).93, 111 
Screening of HDAC inhibitors involved incubation of compounds with the affixed 
HDAC protein and monitoring the deacetylase activity remaining in the form of 
reduced chemiluminescent signal  (Figure 2.2.C).93, 108 
 
Figure ‎2.2. Principle of the ELISA based HDAC activity assay. A) Secondary 
antibody-coated or high binding polystyrene 96 well plates were incubated with 
primary HDAC antibody (HDAC) to immobilize the antibody to the well, followed by 
washing.  B) Incubation with HeLa cell lysates affixed to the well the specific HDAC 
isoform recognized by the immobilized antibody, followed by washing. C) Addition of 
the HDAC-Glo™ substrate and developer to the active HDAC isoform affixed to the 
well generated a quantifiable chemiluminescent signal (yellow star).  Inclusion of an 
HDAC inhibitor in the reaction reduced the deacetylation activity of the affixed HDAC 
enzyme, resulting in a lower chemiluminescent signal.93 Reused with permission 
from SAGE publishing group. 
SAHA and analogs 1a-f were tested by Dr. Geetha Padige108, 112, while 
analogs 1g-i were tested in this work.112 As an initial test of selectivity, the potency 
of each C2-modified SAHA derivative was tested with HDAC1, 2, 3, and 6 at single 
concentrations of either 5 or 10 µM using the ELISA-based HDAC activity assay. All 
analogs (1a-i) displayed some selectivity for HDAC6 compared to HDAC1, HDAC2, 
and HDAC3 (Figure 2.3). Among them, the C2-benzyl (1g), C2-n-pentyl (1h), and 
C2-n-hexyl (1i) analogs showed the greatest difference in inhibitory activity 




SAHA analog was least selective, with similar activity against all the four HDAC 
isoforms tested (Figure 2.3).112 
 
Figure ‎2.3. Isoform selectivity screening of SAHA and C2-modifed SAHA analogs 
(1a-i) against HDAC1, 2, 3, and 6 using the ELISA-based HDAC activity assay.  93  
All analogs were tested at 5 µM concentration, except for 1d, which was tested at 10 
µM. SAHA was tested at 1 µM.93 Mean percent deacetylase activities from a 
minimum of three independent trials with standard errors were plotted (Table A.1). 
The substituent below each compound number corresponds to the R group in C2-
modified SAHA (Table 2.1). Data for analogs 1a-f was provided by Dr. Geetha 
Padige.112 
To further assess selectivity, IC50 values for the most selective compounds in 
the initial screen, compounds 1g-i, were determined with HDAC1, 2, 3, 6, and 8 
(Table 2.2). HDAC8 was also tested due to its similar active site compared to 
HDAC6.13 As controls, the IC50 values of both SAHA and tubastatin were included. 
As expected, SAHA displayed similar IC50 values with HDAC1-6, but 5-fold reduced 
activity with HDAC8, which is consistent with prior reports (see Table 1.1).78, 113 




3, but only 10-fold selectivity versus HDAC8.93 Interestingly, the C2-modified SAHA 
analogs showed selectivity for HDAC6 and HDAC8, with IC50 values in the sub-
micromolar to micromolar range (0.6-2.0 µM, Table 2.2). The C2-benzyl 1g and C2-
n-pentyl 1h analogs displayed 33 to 92-fold selectivity for HDAC6 and HDAC8 over 
the Class I isoforms (Tables 2.2, A.4, and A.5, and Figures A.31 and A.32). The 
most selective compound, C2-n-hexyl SAHA 1i displayed 49- to 300-fold selectivity 
for HDAC6 and HDAC8 compared to the class I isoforms (Tables 2.2 and A.6 and 
Figure A.33). 
Table ‎2.2. IC50 values for SAHA, tubastatin, SAHA analogs 1g-1i against HDAC1, 2, 
3, 6 and 8.a 
a Mean IC50 value and standard error of at least two independent trials are shown 
(Figures A.29-A.35 and Tables A.2-A.8). 
It is notable that the selectivity of C2-n-hexyl SAHA 1i for HDAC6 (˃163-fold) 
is elevated compared to tubastatin (˃87-fold), while showing 20-fold less potency 
than tubastatin (0.60 vs. 0.031 µM IC50 values). The conclusion is that C2-
substituents impart selectivity by discriminating against HDAC1, HDAC2, and 
HDAC3. 
Compound 
IC50 values (µM) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
SAHA 0.033 ± 0.001 0.096 ± 0.01 0.020 ± 0.001 0.033 ± 0.003 0.54 ± 0.01 
Tubastatin 2.7 ± 0.2 3.9 ± 0.4 2.9 ± 0.5 0.031 ± 0.004 0.33 ± 0.01 
1g (benzyl) 84 ± 6 110 ± 10 91 ± 4 1.5 ± 0.2 1.2 ± 0.1 
1h (pentyl) 48 ± 2 58 ± 2 43 ± 2 0.85 ± 0.05 1.3 ± 0.1 
1i (hexyl) 180 ± 20 180 ± 30 98 ± 10 0.60 ± 0.05 2.0 ± 0.1 
(S)-1i (hexyl) 330 ± 30 580 ± 30 530  ± 50 ND 3.1 ± 0.1 




2.3. In cellulo selectivity testing 
To assess the HDAC6 selectivities of the analogs in a biologically relevant 
context, C2-benzyl (1g), C2-n-pentyl (1h), and C2-n-hexyl (1i) SAHA were tested for 
their abilities to increase the acetylation levels of HDAC substrates. Acetylated-α-
tubulin (AcTub) was monitored as a known substrate of HDAC6, whereas 
acetylated-histone H3 (AcH3) was observed as a substrate for HDAC1, 2, and 3.  
U937 myeloid leukemia cells were used in these cellular HDAC6 selectivity studies. 
HDAC6 is overexpressed in several acute myeloid leukemia (AML) cell lines, 
suggesting that HDAC6 is a promising target for development of anti-leukemic 
drugs.114 SAHA or the analogs were incubated with U937 cells before lysis and 
western blot analysis of protein acetylation. As expected, SAHA increased the 
acetylation levels of both α-tubulin and histone H3 (Figure 2.4a, lane 2, AcH3 and 
AcTub), consistent with its broad inhibition. In contrast, the HDAC6 selective inhibitor 
tubastatin affected only α-tubulin acetylation (Figure 2.4a, lane 3, AcTub). Similar to 
tubastatin, the three analogs 1h-i increased acetylation levels of α-tubulin to a 
greater level than histone H3 (Figure 2.4a, lanes 4-6, AcH3). Quantification 
confirmed that 1h-i significantly increased acetylation of α-tubulin compared to 
DMSO, but not acetyl histone H3 levels (Figure 2.4b and Table A.9).  In addition, the 
C2-n-hexyl analog 1i promoted a dose-dependent increase in acetylation of α-tubulin 
(Figure 2.4c, lanes 2-7, AcTub), but not histone H3 (Figure 2.4c, lanes 2-7, AcH3), 
compared to the DMSO control (Figure 2.4c, lane 1). The HDAC6-dependent 
acetylation of tubulin observed in cellulo is consistent with the HDAC6 selectivity 





Figure ‎2.4. Cell-based selectivity testing of the C2-modified SAHA analogs. U937 
cells were treated with (a) DMSO (1%), SAHA (2 µM), tubastatin (2 µM), C2-benzyl 
SAHA (1g, 30 µM), C2-n-pentyl SAHA (1h, 30 µM), C2-n-hexyl SAHA (1i, 30 µM), or 
(c) increasing concentrations of C2-n-hexyl SAHA analog (1i, 10-60 µM) before lysis, 
SDS-PAGE separation, and western blot analysis of acetyl-histone H3 (AcH3) and 
acetyl-α-tubulin (AcTub). GAPDH was a load control. Repetitive trials are shown in 
Figures A.36 and A.37. (b) Fold increase in AcH3 or AcTub after quantification of 
bands intensity from part a, with mean fold increase from four independent trials and 
standard error (Table A.9).  
2.4. In vitro cell growth inhibition 
To test the anti-cytotoxic properties of the HDAC6-selective inhibitors, 
analogs 1g-i were tested in cell-based cytotoxicity assays using leukemia cell 
lines.114 First, the analogs were tested with the Jurkat cell line (T-cell lymphoma 
derived cancer cell line) at 1 and 10 µM concentrations using an MTT assay (Figure 
2.5, Table A.10).  SAHA was also tested as a control. All compounds showed 
reduced cytotoxicity compared to the SAHA (Figure 2.5).  Of the analogs, C2-n-hexyl 
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Figure ‎2.5. Cytotoxicity screening of 1g, 1h, 1i, and SAHA with Jurkat cells. 
Inihbitors were tested at 1 and 10 µM concentrations using MTT assay. Mean 
percent viability from at least three independent trials with standard error were 
plotted (Table A.10). 
To further assess cytotoxicity, both SAHA and the most potent analog 1i were 
tested to determine EC50 values against three leukemia cancer cell lines: Jurkat, 
AML MOLM-13 (Acute myeloid leukemia cell line), and U937 cells. SAHA showed 
potent cytotoxicity, with EC50 values of 0.72, 1.2, and 0.88 µM with Jurkat, AML 
MOLM-13, and U937 cell lines, respectively (Table 2.3). The observed EC50 values 
are consistent with previous reports.115-117 The high potency of SAHA may be due to 
its non-selectivity, as well as the high inhibitory activity against class I HDAC1, 2, 
and 3. The C2-n-hexyl SAHA analog 1i showed roughly 10-fold reduced cytotoxicity 
compared to SAHA, with EC50 values of 11.8, 10.5, and 13.8 µM with Jurkat, AML 
MOLM-13, and U937 cell lines, respectively (Table 2.3). The reduced cytotoxicity is 
consistent with the 18-fold reduction in potency against HDAC6 compared to SAHA 
(Table 2.2). In addition, the selectivity for HDAC6 and 8 over HDAC1, 2, and 3 might 





Table ‎2.3. EC50 values for SAHA and C2-n-hexyl (1i) SAHA analog against Jurkat, 
AML MOLM-13, and U937 cells using MTT assay.a 
a Mean EC50 value and standard error of at least three independent trials are shown 
(Figures A.38 and A39, and Tables A.11 and A12). 
2.5. Enantioselective Synthesis and Screening of (R)- and (S)-C2-n-hexyl SAHA 
C2-n-hexyl SAHA (1i) contains a stereocenter at the 2 position, and the 
compounds tested to this point were racemic mixtures. To test the selectivity of each 
enantiomer, an enantioselective synthesis of C2-n-hexyl SAHA (1i) was employed 
using Evans chiral auxiliary 8 and octanoyl chloride (Schemes 2.2 and 2.3).  Allyl 
bromide was added to the resulting amide 9 to generate chiral compound (R)-10 
from auxiliary (R)-8 (Scheme 2.2) or (S)-10 from auxiliary (S)-8 (Scheme 2.3).  After 
olefin metathesis with Grubbs' second-generation catalyst118 and removal of the 
auxiliary, the olefin was reduced to generate (S)-11 and (R)-11.  Finally, coupling 
with hydroxylamine generated the two enantiomers of C2-n-hexyl SAHA, (S)-1i or 
(R)-1i in 95 and 92% ee, respectively (Figures A.26-A.28). 
Scheme ‎2.2. Enantioselective synthesis of (S)-C2-n-hexyl SAHA (S)-1i 
 
Compound 
Cellular EC50 values (µM) 
Jurkat AML MOLM-13 U937 
SAHA 0.72 ± 0.13 1.2 ± 0.06 0.88 ± 0.13 




Scheme ‎2.3. Enantioselective synthesis of (R)-C2-n-hexyl SAHA (R)-1i 
 
    With the two C2-n-hexyl SAHA enantiomers in hand, IC50 values were 
determined (Table 2.2).  As expected, both enantiomers displayed low micromolar to 
submicromolar potency with HDAC8 (3.1±0.1 or 0.71±0.01 µM), similar to racemic 1i 
(2.0±0.1). The data suggested that (R)-1i is more potent than (S)-1i, although only 
by 4-fold. The (S)-1i enantiomer was further tested for selectivity against HDAC 1, 2, 
and 3. (S)-1i displayed 106- to 187-fold selectivity for HDAC8, which is greater than 
that observed with racemic 1i (49- to 300-fold). In total, studies with the enantiomers 
of C2-n-hexyl SAHA indicated that both are low micromolar to submicromolar 
potency HDAC8 inhibitors, with the expected HDAC8 selectivity compared to 
HDAC1, 2, and 3.   
2.6. Docking Studies with HDAC2 and HDAC6 crystal structures 
To rationalize the HDAC6/8 selectivity of the C2-n-hexyl SAHA (1i) analog, 
we performed docking analysis using the AutoDock 4.2 program.119 Both 
enantiomers of the analog were docked into the recently published HDAC6 crystal 
structure (pdb:5EEM)101 and both displayed similar binding interactions (Figure 2.6), 
consistent with the  similar IC50 values observed experimentally. For example, the 




residues (H573, H574, and Y745) and the catalytic zinc atom in HDAC6 active site 
(Figures 2.6A and E). For comparison, docking of the parent SAHA compound with 
HDAC6 showed similar distances between the hydroxamic acid and the active site 
(1.6-2.4 Å, Figure 2.7A).  To explore the HDAC6 selectivity, compound 1i was also 
docked into the HDAC2 crystal structure (pdb ID: 3MAX).19 In contrast to the 
bonding distances observed with HDAC6, elongated distances between the 
hydroxamic acid group and H145 (5.7-5.9 Å), H146 (3.8 Å), and Y308 (3.0-5.5 Å) 
were observed (Figures 2.6B and F). Metal binding was also weakened with longer 
bond distances (3.5-4.7 Å, Figures 2.6B and F). One possibility accounting for the 
weak binding with HDAC2 is that the bulky C2-n-hexyl substituent cannot favorably 
fit into the relatively narrow catalytic active channel of HDAC2.86 Consistent with this 
possibility, superimposition of the docked poses of compound 1i and SAHA with 
HDAC2 showed that the C2-n-hexyl substituent is positioned towards the solvent 
exposed surface of the active site, which consequently places the hydroxamic acid 
distant from the metal (Figure 2.6D and H). In contrast, the relatively wide catalytic 
pocket in HDAC6 allowed compound 1i and SAHA to similarly position the 
hydroxamic acid within bonding distances of the catalytic metal and nearby residues 









        (R)-C2-n-hexyl SAHA            (S)-C2-n-hexyl SAHA 
 
Figure ‎2.6. Docked poses of (R)-C2-hexyl SAHA (A-D) and (S)-C2-hexyl SAHA (E-
H) in the crystal structures of HDAC6 and HDAC2 using Autodock 4.2. Binding 
distances in HDAC6 (A, E) and HDAC2 (B, F) between the hydroxamic acid atoms 
and active site residues (numbered in figure) or the metal are displayed in 
Angstroms. The atomic radius of the metal (Zn2+) was set at 0.5 Å for clarity. Atom 
color-coding: C2-n-hexyl SAHA (C=purple/white; O=red; N=blue; H=White); amino 
acids (C=deep teal; O=red, N=blue); Zn2+ metal ion (grey sphere). C,D and G,H) 
Superimposition of SAHA (red) and (R) or (S) C2-n-hexyl SAHA 1i (yellow) in the 
crystal structure of HDAC6 (C, G) and crystal structure of HDAC2 (D, H), with the 
metal ion (Zn2+) represented as a grey sphere (1.35 Å radius). Notice that the metal 
sphere is in close proximity to the hydroxamic acid end of both SAHA and the 
analogs in the HDAC6 structures.  In contrast, the analogs are positioned farther 
from the metal sphere than SAHA in the HDAC2 crystal structure, consistent with the 
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Figure ‎2.7. Docking poses of SAHA in the HDAC6 (A) and HDAC2  crystal 
structures (B) using Autodock 4.2. Binding distances between the hydroxamic acid 
atoms and active site residues (numbered in figure) or the metal are displayed in 
Angstroms. The atomic radii of the metals were set at 0.5 Å for clarity. Color-coded 
SAHA (C=green/white; O=red; N=blue; H=White) and amino acid residues (C=deep 
teal; O=red, N=blue); Zn2+ metal ion (grey sphere). 
Because all HDAC isoforms show high conservation among their active site 
residues,98, 120 previous studies suggested that the shape of the active sites might 
explain the HDAC6 selectivity of reported compounds.22  In particular, HDAC6 
maintains a wider active site entrance compared to the class I isoforms.86 In 
previous work, HDAC6-selective inhibitors were generated by replacing the solvent-
exposed anilide group of SAHA with bulky aryl groups.86, 121-122  In addition, 
compounds with an aryl group attached directly adjacent to the hydroxamic acid 
demonstrated HDAC6 selectivity.123  For example, tubastatin is a highly HDAC6-
selective inhibitor that displays a series of bulky aryl groups near the hydroxamic 
acid.86 Based on these prior studies, one hypothesis accounting for the selectivity of 
the C2-modified SAHA analogs is that the bulky substituent adjacent to the 
hydroxamic acid takes advantage of the wider active site entrance of HDAC6.  In 
fact, the docking studies with C2-n-hexyl SAHA 1i suggest that the wide active site 
entrance of HDAC6 accommodates the C2 substituents (Figures 2.6A, C, E, and G), 





















whereas the narrow channel of HDAC2 does not (Figures 2.6B, D, F, and H). In 
total, the determination that C2-modified SAHA analogs are HDAC6-selective 
inhibitors confirms prior structural analysis suggesting that HDAC6 maintains a wide 
active site entrance. 
In conclusion, we report the synthesis and screening of several SAHA 
analogs substituted at the C2 position. C2-modified SAHA analogs displayed 
selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3. The highest selectivity 
observed was with C2-n-hexyl SAHA analog 1i, which displayed 49- to 300-fold 
selectivity for HDAC6 and 8 over HDAC1, 2, and 3.  Importantly, the selectivity of 
C2-n-hexyl SAHA is elevated compared to the widely used HDAC6-selective 
inhibitor, tubastatin.  Cell-based selectivity testing of analogs 1g-i reproduced the 
selectivity observed in vitro. The dual HDAC6/8 selective C2-modified SAHA 
analogs reported in this work can be useful as lead compounds to develop 
pharmacological tools and anti-cancer drugs targeting HDAC6 and HDAC8.  More 
generally, these studies with SAHA analogs suggest that modifying known drugs can 
significantly improve their properties. 
2.7. Experimental Procedures 
2.7.1. Materials and instrumentation 
Unless otherwise noted, chemicals were purchased from Sigma-Aldrich, 
Acros Organics, or Fisher Scientific. “Iron-free” glassware was prepared by rinsing 
glassware with 5 M HCl acid twice followed by washing with distilled de-ionized 
water. “Iron-free” silica gel was prepared by washing with 5M aqueous HCl, followed 
by washing with distilled de-ionized water until colorless, and subsequently drying 




230-400 mesh silica gel (Fisher Scientific). NMR spectra were taken on a Varian or 
Agilent 400, 500 or 600 MHz instruments. 1HNMR spectra showed NMR solvents 
peaks at 3.3 ppm (for CD3OD) and at 4.9 ppm (for trace amounts of water in NMR 
solvent), while 13CNMR spectra showed NMR solvent peaks at 77 (for CDCl3) or at 
47 (for CD3OD).
124 Infra red (IR) spectra were taken on Perkin Elmer Spectrum Two 
ATR-FTIR. Low resolution mass spectra (LRMS) were taken on Waters ZQ LC-
SQMS, while high resolution mass spectra (HRMS) spectra were taken on a Waters 
LCT-MS premier TOF. HPLC analysis to assess the purity of final compounds was 
performed with a Waters 1525 Binary HPLC pump and Waters 2998 Photodiode 
Array detector. The separation was performed on a reverse phase HPLC analytical 
column (YMC America, 250 x 4.6 mmI.D, 4µm, 8 nm) using a gradient of 90% to 
10% of buffer A over 30 minutes (buffer A = 0.1% HPLC grade trifluoroacetic acid 
(TFA) in water; buffer B = HPLC grade acetonitrile) at a flow rate of 1.0 mL/min at 
room temperature. Purity of the synthesized final compounds is indicated for each 
compound in the synthesis procedure. The enantiomeric excess (% ee) discussed in 
text was determined with the same HPLC system but with chiral analytical column 
(Chiracel OD-H, 250 x 4.6 mmI.D), eluting with 10% isopropanol in hexanes at a flow 
rate of 0.5 mL/min at room temperature. Optical rotations were measured in Perkin 






2.7.2. Synthesis procedures for (S)-1i and (R)-1i 
 
Synthesis of (S)-4-benzyl-3-octanoyloxazolidin-2-one ((S)-9). The 
compound was synthesized according to the reported procedure.125 Briefly, (S)-8 
(1.44 g, 8.15 mmol) was dissolved in dry THF (25 mL) followed by the addition of 
butyl lithium (3.26 mL of 2.5 M solution, 8.16 mmol) drop wise under argon at -78°C. 
The reaction was stirred at that temperature for 10 minutes, then octanoyl chloride 
(1.53 mL, 8.96 mmol) was added drop wise. Stirring was continued for 30 minutes at 
-78°C, then the reaction temperature was gradually raised to room temperature over 
30 minutes. The reaction was diluted with saturated solution of ammonium chloride 
(30 mL). THF was evaporated at reduced pressure and the reaction was extracted 
with ethyl acetate (2 x 30 mL). The organic extracts were then evaporated and the 
product was purified by flash silica-gel chromatography (5-10% ethyl acetate in 
hexanes) which yielded the product (S)-9 (1.95 g, 79%). 1HNMR (400 MHz, CDCl3)  
(ppm): 0.88 (t, 3H), 1.34 (m, 8H), 1.68 (m, 2H), 2.75 (dd, 2H), 2.93 (m, 2H), 3.29 (dd, 
1H), 4.18 (m, 2H), 4.66 (m, 1H), 7.21 (d, 2H), 7.27 (m, 1H), 7.33 (t, 2H); 13CNMR 
(100 MHz, CDCl3) δ (ppm): 14.09, 22.62, 24.26, 29.06, 29.09, 31.69, 35.54, 37.92, 
55.15, 66.14, 127.33, 128.95, 129.42, 135.33, 153.46, 173.46. LRMS (LC-SQMS, 
m/z); found: [M+H], 304.04, calculated for C18H26NO3, 304.18, found: [M+Na], 
326.01, calculated for C18H25NO3Na, 326.17. The spectral data for the synthesized 





Synthesis of (R)-4-benzyl-3-octanoyloxazolidin-2-one ((R)-9). The 
procedure for (S)-9 was followed, but yielding 2.18 g (84% yield) from (R)-8 (1.5 g, 
8.47 mmol). 1HNMR (400 MHz, CDCl3)  (ppm): 0.90 (t, 3H), 1.30 (m, 8H), 1.68 (m, 
2H), 2.76 (dd, 2H), 2.91 (m, 2H), 3.29 (dd, 1H), 4.16 (m, 2H), 4.66 (m, 1H), 7.2 (d, 
2H), 7.27 (m, 1H), 7.33 (t, 2H); 13CNMR (100 MHz, CDCl3) δ (ppm): 14.1, 22.62, 
24.26, 29.06, 29.09, 31.69, 35.54, 37.92, 55.15, 66.14, 127.32, 128.94, 129.42, 
135.33, 153.46, 173.44. LRMS (LC-SQMS, m/z); found: [M+H], 304.08, calculated 
for C18H26NO3, 304.18, found: [M+Na], 325.99, calculated for C18H25NO3Na, 326.17. 
The spectral data for the synthesized compound was consistent with the reported 
data in literature. 125 
 
Synthesis of (S)-3-((R)-2-allyloctanoyl)-4-benzyloxazolidin-2-one ((S)-10). 
To compound (S)-9 ( 1.95 g, 6.43 mmol) was added dry THF (25 mL) followed by 
reduction of the temperature to -78°C. NaHMDS (3.53 mL of 2 M solution, 7.07 
mmol) was added drop wise under Argon and the reaction was stirred at -78°C for 1 
hour. Allyl bromide (1.65 mL, 19.28 mmol) was then added drop wise, and the 
reaction was stirred at -78°C for 45 minutes, then the temperature was increased 
gradually to 0°C and stirring was continued for 1 hour at 0°C. The reaction was then 




room temperature for 15 minutes. The reaction was concentrated under reduced 
pressure, and the aqueous layer was extracted with ethyl acetate (3 x 30 mL). The 
extracts were evaporated and the product was purified by Flash silica-gel 
chromatography (3% ethyl acetate in hexanes) which yielded the product (S)-10 
(1.32 g, 60%). 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.27 (m, 8H), 1.49 
(m, 1H), 1.7 (m, 1H), 2.32 (m, 1H), 2.47 (m, 1H), 2.65 (dd, 1H), 3.31 (dd, 1H), 3.91 
(m, 1H), 4.16 (m, 2H), 4.66 (m, 1H), 5.05 (dd, 2H), 5.82 (m, 1H), 7.26 (m, 5H); 
13CNMR (100 MHz, CDCl3) δ (ppm): 14.06, 22.58, 27.21, 29.34, 31.58, 31.66, 36.81, 
38.11, 42.32, 55.53, 65.90, 117.09, 127.29, 128.93, 129.42, 135.33, 135.46, 153.16, 
176.15. LRMS (LC-SQMS, m/z); found: [M+H], 344.04, calculated for C21H30NO3, 
344.21, found: [M+Na], 365.99, calculated for C21H29NO3Na, 366.20. []D
23 = +74.5 
(c .76, CH2Cl2). 
 
Synthesis of (R)-3-((S)-2-allyloctanoyl)-4-benzyloxazolidin-2-one ((R)-10). 
The procedure for (S)-10 was followed, but yielding 1.56 g (64% yield) from (R)-9 
(2.15 g, 7.08 mmol). 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.27 (m, 8H), 
1.49 (m, 1H), 1.72 (m, 1H), 2.32 (m, 1H), 2.45 (m, 1H), 2.66 (dd, 1H), 3.29 (dd, 1H), 
3.91 (m, 1H), 4.15 (m, 2H), 4.68 (m, 1H), 5.06 (m, 2H), 5.82 (m, 1H), 7.27 (m, 5H); 
13CNMR (100 MHz, CDCl3) δ (ppm): 14.06, 22.58, 27.20, 29.34, 31.58, 31.66, 36.80, 
38.11, 42.32, 55.53, 65.89, 117.09, 127.29, 128.93, 129.41, 135.32, 135.46, 153.15, 




344.21, found: [M+Na], 366.02, calculated for C21H29NO3Na, 366.20. []D
23 = 70.7 
(c 0.49, CH2Cl2). 
 
Synthesis of (R)-2-hexyl-8-oxo-8-(phenylamino)octanoic acid ((R)-11). To 
a solution of (S)-10 (1.32 g, 3.84 mmol) in DCM (30 mL) was added N-phenylpent-4-
enamide (2.69 g, 15.36 mmol) and Grubbs' second-generation catalyst (261 mg, 8 
mol%). The reaction was heated at 50°C for 12 hours. The solvent was evaporated. 
Flash silica-gel chromatography (1:6 to 1:4 ethyl acetate in hexanes) which yielded 
the alkene intermediate (904 mg, 48%). The intermediate was used in the following 
reaction with no characterization. 
The intermediate alkene (451 mg, 0.92 mmol)  was dissolved in a mixture of 
THF (20 mL) and water (5 mL). Hydrogen peroxide (0.42 mL of 30% solution, 3.68 
mmol) was added at 0°C, followed by lithium hydroxide monohydrate (78 mg, 1.86 
mmol) dissolved in 3 mL water. The reaction was stirred at 0°C for 6 hours, then 
sodium sulfite (1 g) in 7 mL water was added. The reaction was stirred for additional 
15 minutes at room temperature. The reaction was diluted with 10% HCl to pH 2, 
and then extracted with ethyl acetate (2 x 40 mL). The extracts were evaporated and 
the crude product was used in the next reaction. 
The crude product was dissolved in methanol (15 mL), then 20% Pd/C was 
added (22 mg, 10% w/w). Air was replaced with argon (x3) then with hydrogen gas 
(3x). The reaction was left to stir under hydrogen overnight. The reaction was then 




ethyl acetate in hexanes) which yielded the product (R)-11 (212 mg, 69% over 2 
steps). 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.28 (m, 14H), 1.68 (m ,4H), 
2.32 (m, 3H), 7.08 (t, 1H), 7.27 (m, 2H), 7.52 (m, 3H); 13CNMR (100 MHz, CDCl3) δ 
(ppm): 14.06, 22.59, 25.42, 26.98, 27.34, 28.95, 29.20, 31.65, 31.88, 32.31, 37.14, 
45.49, 119.91, 124.22, 128.95, 137.91, 171.66, 182.08. LRMS (LC-SQMS, m/z); 
found: [M+H], 334.16, calculated for C20H32NO3, 334.23, found: [M+Na], 355.99, 
calculated for C20H31NO3Na, 356.22, found: [M-H], 332.22, calculated for C20H30NO3, 
332.23. 
 
Synthesis of (S)-2-hexyl-8-oxo-8-(phenylamino)octanoic acid ((S)-11). 
The procedure for (R)-11 was followed, but yielding 922 mg (43% yield) for the cross 
metathesis reaction from (R)-10 (1.5 g, 4.4 mmol), and then 174 mg (28% over 2 
steps) of (S)-11. 1HNMR (400 MHz, CDCl3)  (ppm): 0.87 (t, 3H), 1.43 (m, 14H), 1.64 
(m ,4H), 2.33 (m, 3H), 7.09 (t, 1H), 7.30 (m, 3H), 7.51 (d, 2H); 13CNMR (100 MHz, 
CDCl3) δ (ppm): 14.06, 22.59, 25.39, 26.97, 27.33, 28.94, 29.19, 31.64, 31.96, 
32.29, 37.55, 45.39, 119.92, 124.22, 128.97, 137.91, 171.47, 181.79. LRMS (LC-
SQMS, m/z); found: [M-H], 332.13, calculated for C20H30NO3, 332.23. 
 
 
Synthesis of (R)-2-hexyl-N1-hydroxy-N8-phenyloctanediamide ((R)-1i). In 




dry DCM (20 mL), followed by the addition of triethyl amine (247 uL, 1.77 mmol), 
HOBt (204 mg, 1.33 mmol) and EDCI HCl (272 mg, 1.42 mmol). The reaction was 
stirred for 1 hour, then triethyl amine (618 uL, 4.43 mmol), hydroxyl amine HCl (308 
mg, 4.43 mmol) and DMF (5 mL) were added. The reaction was stirred overnight. 
The reaction was then concentrated under reduced pressure, diluted with distilled 
deionized water, and extracted with ethyl acetate (2 x 30 mL). The product was 
purified by Flash silica-gel chromatography (2% methanol in DCM, then 1:8 to 1:4 
acetone in DCM) which yielded the product (R)-1i (30 mg, 10%). 1HNMR (400 MHz, 
CD3OD) δ (ppm): 0.89 (t, 3H), 1.35 (m, 14H), 1.67 (m, 4H), 2.02 (m, 1H), 2.35 (t, 
2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H); 13CNMR (100 MHz, CD3OD) δ (ppm): 
13.00, 22.23, 25.34, 26.83, 27.14, 28.75, 28.94, 31.50, 32.28, 32.48, 36.43, 43.58, 
119.84, 123.70, 128.34, 138.46, 173.24, 173.98; HRMS (Waters LCT-MS premier 
TOF, m/z): found [M+Na], 371.2313, calculated for C20H32N2O3Na, 371.2311. []D
23 
= 1.74 (c 0.3, EtOH). Chiral HPLC: 92% ee. 
 
Synthesis of (S)-2-hexyl-N1-hydroxy-N8-phenyloctanediamide ((S)-1i). 
The procedure for (R)-1i was followed, but yielding 30 mg (25% yield) from (S)-11 
(116 mg 0.35 mmol). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.88 (t, 3H), 1.34 (m, 
14H), 1.64 (m, 4H), 2.02 (m, 1H), 2.35 (t, 2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.53 (d, 2H); 
13CNMR (100 MHz, CD3OD) δ (ppm): 13.02, 22.24, 25.35, 26.84, 27.15, 28.76, 
28.95, 31.51, 32.29, 32.49, 36.44, 43.58, 119.85, 123.71,128.35, 138.46, 173.24, 




calculated for C20H32N2O3Na, 371.2311. []D
23 = +1.45 (c 0.9, EtOH). Chiral HPLC: 
95% ee. 
2.7.3. Procedures for biological screening 
2.7.3.1. HeLa cell lysis 
HeLa-S3 cells (purchased from Biovest Inc.) were lysed in lysis buffer (1 x 109 
cells in 10 mL lysis buffer; 50mM Tris-HCl, pH 8.0, 10% glycerol, 150 mM NaCl, 
0.5% Triton X-100) containing Calbiochem protease inhibitor cocktail set V with 
rotation at 4 C for 30 min. Cell debris was removed by centrifugation at 12000 rpm 
at 4 C for 30 min. Protein concentration of the supernatant was determined using 
Bio-Rad protein assay (BioRad, Bradford reagent). 
2.7.3.2. Inhibitors testing with HDAC isoforms 
Screening with HDAC1, 2, 3, and 6 was performed according to the reported 
procedure.93 Briefly, individual wells of a high binding polystyrene 96-well white 
opaque plate (Thermo Scientific) were incubated in binding buffer (100 µL; 0.2M 
carbonate/0.2M bicarbonate buffer, pH 9.4) containing primary HDAC1 antibody 
(Sigma Aldrich, H3284, 100µL of 10µg/mL), primary HDAC2 antibody (Sigma 
Aldrich, H3159, 100µL of 10µg/mL), or primary HDAC6 antibody (Sigma Aldrich, 
SAB1404771, 100µL of 2µg/mL) with rocking (3 rpm) for 1 hr at room temperature, 
or at 4°C overnight with no rocking. For HDAC3 with compounds 1g-i, primary 
HDAC3 antibody (Sigma Aldrich, H3034, 100µL of 25µg/mL) was used following the 
same procedure described above. But in the case of HDAC3 with all other 
compounds, wells of a secondary antibody coated 96-well white opaque plate (G-




100µL of 1µg/mL) in TBST buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.05% 
(v/v) Tween-20) containing 0.1% (w/v) bovine serum albumin (BSA, Jackson 
Immunoresearch) at 4°C overnight without rocking. For all reactions, unbound 
antibody was removed by washing quickly three times with TBST buffer (300 µL), 
followed by a fourth wash with TBST (300 µL) with 5 minutes incubation and rocking 
(3 rpm) at room temperature. In the case of high binding polystyrene plates 
containing HDAC1, 2, 3, or 6 antibodies, the unbound regions of the well were 
blocked with 5% non-fat dry milk in TBST buffer (300 µL) for 1 hr at room 
temperature with rocking (3 rpm). Because the secondary antibody coated plates 
containing HDAC3 were pre-blocked by the manufacturer, no additional blocking 
step was included.  
To affix HDAC enzyme to the plate, HeLa cell lysates (100µL of 100µg/mL for 
HDAC1, 2, and 3 and 100µL of 1 mg/mL for HDAC6 in TBST buffer containing 0.1 % 
(w/v) non-fat dry milk) were added to each well and incubated for 1 h at 4°C without 
rocking, followed by washing with TBST, as described previously. For HDAC3 with 
compounds 1g-i only, HeLa cell lysates (100µL of 1 mg/mL in TBST buffer 
containing 0.1 % (w/v) non-fat dry milk) were used, followed by incubation and 
washing as described earlier. Inhibitors in DMSO (1 µL) were mixed with HDAC-
Glo™ buffer (24 µL), then added to the plate and incubated for 15 min at room 
temperature without rocking. An uninhibited control reaction was also included that 
contained DMSO (1 µL) in HDAC-Glo™ buffer (24 µL). Finally, deacetylase activity 
was measured using the HDAC-Glo™ assay kit (Promega) as per the 




developer (1 µL) were first premixed, then to monitor deacetylase activity, the 
HDAC-Glo™ reagents (25µL) were added to each well (50 µL total volume) and 
incubated for 30-45 min at room temperature without rocking. The deacetylase 
activity was measured as luminescent signal using a GeniosPlus Fluorimeter 
(Tecan) at optimal gain. The concentrations of inhibitors reported in the single dose 
screen and dose-dependent studies are final concentrations after addition of HDAC-
Glo™ reagent. For the single concentration screen, the percent deacetylase activity 
remaining was calculated by dividing the signal with inhibitor by the signal without 
inhibitor (DMSO negative control reaction), and then multiplying by 100.  For dose-
dependent reactions to determine IC50, the luminescent signal was first background 
corrected with the signal from a negative control reaction where the HDAC antibody 
was absent in the initial antibody binding step before the percent deacetylase activity 
was calculated. The mean percent deacetylase activity along with standard error of 
three independent trials is reported. 
Inhibitory activity with HDAC8 with all compounds was measured using the 
following procedure. In a half area 96-well plate, HDAC8 (75 ng, BPS Bioscience) 
was incubated in HDAC-Glo™ buffer (39 μL) with small molecule in DMSO (1 µL), or 
DMSO alone (1 µL) as a control, for 15 minutes at room temperature. HDAC-Glo™ 
reagent (10 μL) was added to each reaction and incubated for 15-30 min at room 
temperature. Luminescent signal was measured at 25-30 minutes after adding the 
substrate reagent using a GeniosPlus Fluorimeter (Tecan) at optimal gain. To 
determine IC50, the luminescent signal was first background corrected with the signal 




IC50 values were calculated by fitting the percent deacetylase activity 
remaining as a function of inhibitor concentration to a sigmoidal dose-response 
curve (y = 100/(1+(x/IC50)
z), where y = percent deacetylase activity and x = inhibitor 
concentration) using non-linear regression with KaleidaGraph 4.1.3 software. 
2.7.3.3. In cellulo target and selectivity validation 
U937 cells were grown in RPMI media supplemented with 10% fetal calf 
serum and 1% penicillin/streptomycin under humidified conditions (37 °C, 5% CO2). 
Cells were added (106 cells/well) to a 12 well flat bottom cell culture plate (Corning™ 
Costar™) in RPMI-1640 (with or with no phenol red) media, supplemented with 10% 
fetal calf serum and 1% penicillin/streptomycin (990 µL final volume). The cells were 
treated with DMSO (10 µL) or the small molecule in DMSO (10 µL), and incubated 
for 18 hours under humidified conditions (37 °C, 5% CO2). The cells were then 
washed once with cold PBS (500 µL) and lysed with lysis buffer (20 µL) containing 
1X protease inhibitor for 30 minutes at 0°C. The total protein concentration in the 
supernatant was then quantified using the Bradford assay kit (Bio-Rad) with BSA as 
the standard.  
2.7.3.4. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
In order to separate proteins, equal quantities of proteins from lysates 
prepared in section 2.7.3.3 were mixed with BME (2-mercapto ethanol, 10% of the 
final volume) and SDS loading buffer (50 mM Tris-Cl [pH 6.8], 100 mM DTT, 2% 
SDS, 0.1% bromophenol blue, and 10% glycerol) before the proteins were 




16% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE gels were 
prepared according to the reported procedure.126 
2.7.3.5. Western blotting and visualization of proteins levels 
To detect and visualize proteins bands, proteins on the SDS-PAGE gel were 
transferred to PVDF membrane (Immobilon P, Millipore). The membrane was 
blocked with 5% (w/v) nonfat milk in TBST buffer at room temperature for 1 h. The 
blocked membrane was incubated with a primary antibody (anti-GAPDH (Cell 
Signaling, 5174P); anti-Acetyl-α-tubulin(Lys40) (Cell Signaling, 5335P), or anti-
Acetyl-histone H3(Lys9) (Cell Signaling, 9649P)) at a 1:1000 dilution in TBST buffer 
at 4 °C overnight. Finally, the membrane was incubated with HRP-conjugated goat 
anti-rabbit secondary antibody (Cell signaling, 7074S; 7:10000 dilution) at room 
temperature for 1 h. HRP activity was detected using an enhanced 
chemiluminescence light-based detection substrate, SuperSignal West Dura 
Extended Duration Substrate (ThermoFisher Scientific, 34075) and Alpha Innotech 
FluorChem imaging system. The western blots were quantified using AlphaView 
FluorChem 3.2.2 program. 
2.7.3.6. In vitro cell growth inhibition 
Jurkat, AML-MOLM-13, or U937 cells were grown in RPMI media supplemented 
with 10% fetal calf serum and 1% penicillin/streptomycin under humidified conditions 
(37°C, 5% CO2). Cells were seeded in 96-well cell culture plates with a density of 
4x104 cells in 99 μL of media composed of RPMI-1640 (no phenol red), 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. The cells 
were treated with 1 µM or 10 µM single concentrations or serial dilution (2-fold) of 




negative control was also included where no cells were added. The plate was 
incubated for 44 hours at 37 °C in humid 5% CO2 atmosphere. A solution of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 10 µL of 5 mg/mL in 
DPBS buffer (HyClone™ Dulbecco's Phosphate Buffered Saline)) was added to 
each well. The cells were incubated for another 4 h at 37 °C in humid 5% CO2 
atmosphere for development to take place. The resulting purple formazan crystals 
were dissolved by addition of DMSO (150 µL), and the absorbance was measured at 
595 nm using a GeniosPlus Fluorimeter (Tecan). For all wells containing inhibitor, 
the signal was background corrected with the signal from a negative control reaction 
(media and MTT only) before the percent viable cells was calculated. The percent 
viable cells was calculated by dividing the absorbance with inhibitor by the 
absorbance without inhibitor (DMSO, cells, and MTT). The assay was performed at 
least three independent times. For the single concentrations experiment, the mean 
percent viable cells along with standard error of three independent trials is reported 
in Figure 2.5. EC50 values were calculated by fitting the percent viable cells as a 
function of inhibitor concentration to a sigmoidal dose-response curve (y = 
100/(1+(x/EC50)
z), where y = percent viable cells and x = inhibitor concentration) 
using non-linear regression with KaleidaGraph 4.1.3 software (Table 2.3). 
2.7.4. Docking procedure 
The AutoDock 4.2 program119, 127 was used to perform the docking calculations. 
The HDAC2 crystal structure was downloaded from the protein data bank (pdb ID: 
3MAX).128 The PyMOL program was used to delete two chains and remove water 
molecules, metal ions (calcium and sodium), and the cocrystallized ligand in the 




grid box of size 60 X 60 X 60 Å3 with a spacing of 0.375 Å and centered at (69.643, 
30.937, -0.989) was used. HDAC6 crystal structure was downloaded from protein 
databank. (pdb: 5EEM).101 PyMOL program was used to manually delete potassium 
and sodium ions, and all water molecules. A grid box of size 42 X 44 X 40 Å3 with a 
spacing of 0.375 Å and centered at (7.000, 17.000, -22.000) was used.  For both 
HDAC2 and HDAC6, AutoDockTools-1.5.4119 was used to add all polar hydrogen 
atoms, compute Gasteiger charges, merge all nonpolar hydrogen, and generate 
pdbqt files. The charge of the zinc atom was manually changed from zero to +2. The 
map type was set by choosing the ligand and then AutoGrid 4.2 was used to pre-
calculate and generate the grid map files required for the docking calculations. All 
the docked compounds were drawn in ChemBioDraw Ultra 12.0, and Chem 3D Pro 
12.0 was used to run MM2 job for energy minimization. Then AutoDockTools-1.5.4 
program was used to choose torsions, compute Gasteiger charges, and generate 
the pdbqt files. All acyclic bonds were made rotatable, except the amide bonds.  The 
generated pdbqt files for the enzymes were set as a rigid macromolecule and the 
genetic algorithm search parameters were set to 100 GA runs for each ligand with a 
population size of 150, a maximum number of 2.5 x 105 energy evaluations, a 
maximum number of 2.7 x 104 generations, a mutation rate of 0.2 and a crossover 
rate of 0.8. The docking parameters were set to default. All output DLG files were 
converted to pdbqt format and the results were visualized in PyMOL.  Among the 
100 docked poses generated, the ones shown in Figures  2.5 and 2.6 displayed 
optimal distances between the hydroxamic acid group of the inhibitor and the 




CHAPTER 3 - SYNTHESIS, BIOLOGICAL EVALUATION AND 
DOCKING OF SAHA DERIVATIVES SUBSTITUTED AT C4 POSITION 
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T. 
and Pflum, M. K. H., The structural requirements of histone deacetylase inhibitors: 
SAHA analogs modified at the C4 position display dual HDAC6/HDAC8 selectivity. 
European Journal of Medicinal Chemistry (Submitted) 
3.1. Rationale for synthesis of C4-modified SAHA analogs 
After we observed a promising dual HDAC6/HDAC8 selectivity with some of 
the C2-modified SAHA analogs, we extended the modifications to the fourth carbon 
of the linker of SAHA in order to explore the effect on both potency and isoform 
selectivity (Figure 3.1). In this chapter, several new SAHA derivatives substituted in 
the linker region at the C4 position were synthesized and screened (Figure 3.1). The 
substituents chosen have different sizes to fit into the active sites of different HDAC 
isoforms (Figure 3.1). Similar to the C2-modified SAHA analogs, several C4-SAHA 
analogs showed substantial improvement in selectivity towards HDAC6 and HDAC8 
over HDAC1, 2, and 3, but with a modest reduction in potency, compared to SAHA. 
Enantioselective syntheses of both enantiomers of the most interesting analog were 
performed and the pure enantiomers were tested for potency and selectivity. 
Docking studies provided a structural rationale for the HDAC6 selectivity. This study 
along with the previous studies discussed in this thesis emphasize that modification 
of the SAHA linker region can enhance isoform selectivity with different effects on 
potency. 
 




3.2. Synthesis of C4-substituted SAHA derivatives 
Synthesis of the C4-SAHA analogs started from a cross metathesis reaction 
of methyl-4-pentenoate 12 with crotonaldehyde 13 using Grubbs' second-generation 
catalyst to afford the α,β-unsaturated aldehyde 14 (Scheme 3.1). Different 
substituents were appended to 14 via 1,4-addition using organolithium cuprates, 
followed by Horner–Wadsworth–Emmons reaction with benzyl phosphonoacetate to 
give the unsaturated benzyl esters 16a-f. Reduction and hydrogenolysis of 16a-f 
gave free acids 17a-f, which were coupled with aniline to afford 18a-f. Intermediates 
18a-f were reacted with hydroxylamine to afford the C4-substituted SAHA 
derivatives 19a-f as racemic mixtures. 





3.3. In vitro screening of C4-modified SAHA analogs 
The analogs were tested for global HDAC inhibition with HeLa cell lysates as 
the source of all HDAC proteins (Table 3.1). HDAC activity was measured using the 
commercially available HDAC-Glo™ I/II substrate (Promega) (see section 2.2). The 
results of the screening showed that all of the synthesized derivatives were less 
potent than SAHA (Table 3.1  and B.1, and Figure B.140). The most potent 
derivative was C4-methyl SAHA (19a), which showed an IC50 value of 3.3 µM. 
Compared to the parent molecule SAHA, C4-methyl SAHA is 18-fold less potent 
than SAHA, while the rest of the analogs showed 78- to 344-fold reduction in 
potency. Because HeLa cell lysates contain all HDAC isoforms, the poor potency of 
the C4-SAHA analogs suggests that they may be selective for some HDAC 
isoforms, similar to prior C2-modified SAHA analogs (see sections 2.1 and 2.2). 









a Mean IC50 value and standard error of at least three independent trials are shown 
(Figure B.140 and Table B.1). 
To assess selectivity, an initial screen was performed with analogs 19a-f and 
the parent molecule SAHA at a single concentration against HDAC1, 2, 3, and 6 
using the recently developed ELISA-based HDAC activity assay (see section 2.2).93  
Compound R IC50 (µM) 
SAHA  0.20 ± 0.02 
19a methyl 3.3 ± 0.1 
19b ethyl 14 ± 1 
 19c n-butyl 53 ± 2 
19d n-hexyl 60 ± 1 
19e phenyl 65 ± 6 




SAHA, as expected, showed no selectivity among HDAC1, 2, 3, and 6, inhibiting 
their activity to a similar extent (Figure 3.2). Interestingly, all C4-SAHA analogs (19a-
f) displayed more potent inhibition against HDAC6 compared to HDAC1, HDAC2, 
and HDAC3 (Figure 3.2 and Table B.2). The analogs that showed the greatest 
difference in potency with HDAC6 versus the other isoforms were C4-n-butyl (19c) 
and C4-benzyl (19f). Among the analogs, the C4-methyl SAHA analog (19a) showed 
the smallest difference in potency comparing HDAC6 to HDAC1 and HDAC3 (Figure 
3.2 and Table B.2). This single concentration screen suggested that C4-modification 
on the SAHA structure results in selectivity for HDAC6. 
 
Figure ‎3.2. In vitro isoform selectivity screening of C4-modified SAHA analogs (19a-
f) against HDAC1, HDAC2, HDAC3, and HDAC6 using the ELISA-based HDAC 
activity assay. Analogs 19a-f were tested at 0.75, 0.75, 2.5, 1.25, 2.5, and 5 µM final 
concentration, respectively. SAHA was tested at 1 µM concentration.93 Mean 
percent deacetylase activities from a minimum of two independent trials with 


















































To further assess selectivity, IC50 values for derivatives 19b-f were 
determined with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms (Table 
3.2). In addition, the non-selective parent molecule SAHA, and the HDAC6-selective 
inhibitor tubastatin, were tested as control compounds (Table 3.2).93 The non-
selective inhibitor SAHA showed similar IC50 values with HDAC1, 2, 3, 6, and 8, 
which is expected for a non-selective inhibitor.93 The HDAC6-selective inhibitor 
tubastatin displayed 87- to 130-fold selectivity for HDAC6 over HDACs 1, 2, and 3, 
and 11-fold selectivity for HDAC6 over HDAC8.93, 112 Interestingly, the analogs 19b-f 
had similar IC50 values compared to SAHA with HDAC6 and HDAC8, which were in 
the 57 to 290 nM range (Tables 3.2 and B.10). Moreover, analogs 19b-f showed 28- 
to 740-fold selectivity for both HDAC6 and HDAC8 over HDAC1, 2, and 3. The C4-
ethyl SAHA (19b) and C4-phenyl SAHA (19e) displayed the lowest selectivity among 
the analogs, with at least 28- and 38-fold selectivities for HDAC6 and 8 over HDAC1, 
2, and 3 (Tables 3.2 and B.10). Modifying SAHA at the C4 position with long alkyl or 
bulky groups (n-butyl, n-hexyl, and benzyl groups in analogs 19c, 19d, and 19f) led 
to substantial enhancement of selectivity with at least 170-fold selectivity for HDAC6 
and 8 over HDAC1, 2, and 3 isoforms (Tables 3.2 and B.10). In addition, the 
modifications in analogs 19c, 19d, and 19f led to modest reductions in HDAC6 
potency (2.5 to 3-fold reduced), but more potent inhibition of HDAC8 (7- to 9.5-fold 
increased) compared to SAHA (Table 3.2).  
In terms of structure-activity relationship (SAR) analysis, modifying SAHA at 
the C4 position with long alkyl substituents led to enhanced selectivity; the C4-hexyl 




480-fold) compared to the C4-butyl 19c analog (170- to 310-fold), which were both 
more selective that the C4-ethyl analog 19b with the smallest alkyl chain (28- and 
46-fold, Tables 3.2 and B.10). The length of the substituent also influenced the 
selectivities of the analogs with aryl groups at the C4 position; the lack of a 
methylene in C4-phenyl analog 19e led to decreased selectivity (38- to 350-fold) 
compared to the C4-benzyl analog 19f (210- to 740-fold).  The reduced selectivity of 
C4-phenyl analog 19e was due to both decreased potency against HDAC8 (290 nM) 
and greater potency with HDAC1 and 2 (11 and 12 µM) compared to C4-benzyl 
analog 19f (57 nM, 29 µM, and 32 µM IC50 values with HDAC1, 2, and 8, Table 
3.2). In total, the SAR analysis indicated that longer substituents at the C4 position 
led to greater HDAC6/8 selectivity. 
Table ‎3.2. IC50 values for SAHA, tubastatin, SAHA analogs 19b-19f, and pure 
enantiomers of the C4-benzyl SAHA (R)-19f and (S)-19f against HDAC1, 2, 3, 6 and 
8.a 
 
a Mean IC50 value and standard error of at least three independent trials are shown 
(Figures B.141-B.147 and Tables B.3-B.9). b Previously reported IC50 values using 






HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
SAHAb 33 ± 1 96 ± 10 20 ± 1 33 ± 3 540 ± 10 
Tubastatinb 2,700 ± 200 3,900 ± 400 2,900 ± 500 31 ± 4 330 ± 10 
19b (ethyl) 4,400 ± 300 4,900 ± 400 6,000 ± 1200 160 ± 10 130 ± 3 
19c (n-butyl) 15,000 ± 1000 18,000 ± 2000 23,000 ± 3000 88 ± 7 74 ± 2 
19d (n-hexyl) 35,000 ± 1000 38,000 ± 3000 30,000 ± 3000 140 ± 10 79 ± 3 
19e (phenyl) 11,000 ± 1000 12,000 ± 1000 23,000 ± 2000 110 ± 10 290 ± 20 
19f (benzyl) 29,000 ± 1000 32,000 ± 2000 42,000 ± 4000 140 ± 10 57 ± 2 
(R)-19f  25,000 ± 2000 36,000 ± 3000 27,000 ± 2000 48 ± 8 27 ± 2 




Compared to previously reported selective inhibitors, the observed HDAC6 
selectivities with the analogs 19c, 19d, and 19f were higher (at least 170-, and 210-
fold) than the selectivity observed with the HDAC6 selective inhibitor tubastatin (at 
least 87-fold) (Table B.10). Moreover,  19c, 19d, and 19f  showed comparable 
selectivities (at least 200-, 380-, and 510-fold) relative to the HDAC8 selective 
inhibitor PCI-34051 (at least 400-fold).87 Interestingly, C4-benzyl analog 19f showed 
higher dual HDAC6/8 selectivity (at least 210- and 510-fold) than the known 
HDAC6/8 dual selective inhibitor BRD-73954 (at least 75-, and 250-fold selectivity to 
HDAC6, and 8 over HDAC1, 2, and 3).89 
3.4. In cellulo selectivity testing 
To further assess the observed HDAC6 selectivity in cellulo, C4-benzyl (19f) 
SAHA analog was tested for selectivity to inhibit HDAC6 over HDAC1, HDAC2, and 
HDAC3 in cells. The inhibition of HDAC6 was monitored by detecting the levels of its 
known substrate acetyl-α-tubulin (AcTub), whereas Class I HDAC proteins (HDAC1, 
2, and 3) inhibition was monitored through the levels of their known substrate acetyl-
histone H3 (AcH3). SAHA or the analogs 19c, 19d, or 19f were incubated with U397 
leukemia cells before lysis and western blot analysis of protein acetylation. As 
expected, SAHA showed an increase in the levels of both acetyl-α-tubulin and 
acetyl-histone H3 (Figure 3.3, lane 2), which is consistent with its non-selective 
inhibition of HDAC1, 2, 3, and 6 isoforms. In contrast, C4-benzyl (19f)  showed a 
dose-dependent selective increase in levels of acetyl-α-tubulin (Figure 3.3, lanes 3-
5, AcTub) over the levels of acetyl histone H3 (Figure 3.3, lanes 3-5, AcH3), 




in cells is consistent with the selectivity observed in the in vitro screening (Table 3.2 
and Figure 3.2). 
 
Figure ‎3.3. Cell based selectivity testing of the C4-benzyl SAHA analog 19f. 
Western blots analysis of acetyl-histone H3 (AcH3) and acetyl-α-tubulin (AcTub) 
after treatment with SAHA or the C4-modified SAHA analogs.  U937 cells were 
treated with DMSO (1%), SAHA (5 µM), or increasing concentrations of C4-benzyl 
SAHA (19f) analog (20-60 µM), before lysis, SDS-PAGE separation, transfer to a 
PVDF membrane, and western analysis with AcH3 or AcTub antibodies. GAPDH 
levels in the samples were also probed as a gel load control. A DMSO control 
sample was included for comparison to inhibitor treated samples. Repetitive trials 
are shown in Figure B.148. 
3.5. In vitro cancer cell growth inhibition 
To assess the cytotoxic effect of the HDAC6/8 selective inhibitors in cancer 
cells, SAHA derivatives 19c, 19d, and 19f were tested with the leukemia cell lines 
U937 and Jurkat due to the prominent role of HDAC6 in leukemia.114 To assess 
cytotoxicity, the EC50 values of SAHA and the three analogs 19c, 19d, and 19f were 
determined with U937 cell line.114 SAHA showed an EC50 value of 0.88 µM (Table 
3.3), which is consistent with the cytotoxicity previously reported.117 The non-
selective inhibition of SAHA to all the HDAC proteins likely contributes to its high 
cytotoxicity. The C4-n-butyl (19c), C4-n-hexyl (19d), and C4-benzyl (19f) SAHA 
analogs displayed 34, 16, and 28 µM EC50 values with the U937 cell line, 
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cytotoxic. To confirm the cytotoxicity study in U937 cells, SAHA and the analogs 
were also tested for cytotoxicity with the Jurkat cell line. The analogs showed 
reduced cytotoxicity compared to SAHA (Figure B.152, Table B.12), consistent with 
the study in U937 cells. The reduced cytotoxicity of the analogs in U937 and Jurkat 
cells compared to SAHA might be due to their selectivity toward HDAC6 and 8.  
Consistent with this hypothesis, similar lower cytotoxicities compared to the non-
selective inhibitor SAHA were also observed with HDAC6 and dual HDAC6/8-
selective inhibitors in previous reports.91, 129-130 
Table ‎3.3. EC50 values of SAHA and C4-butyl, C4-hexyl and C4-benzyl SAHA 





aMean EC50 value and standard error of at least three independent trials are shown. 
Data in table is associated with Figures B.149-B.151 and Table B.11. 
3.6. Enantioselective synthesis and screening of (R)- and (S)-C4-benzyl SAHA 
analog (19f). 
Since all analogs were synthesized and screened as racemic mixtures, 
enantioselective syntheses were performed to test the selectivity of both 
enantiomers of the most selective C4-benzyl SAHA analog (Schemes 3.2-3.4). The 
asymmetric synthesis was carried out utilizing Evan's oxazolidinone chiral auxiliary 
(R)-8 to synthesize both enantiomers.131 To synthesize the (RS)-21 intermediate, 4-
pentenoyl chloride was reacted with the chiral auxiliary (R)-8 using n-butyllithium, 
which yielded pentenoyl oxazolidinone intermediate (R)-20 (Scheme 3.2A). 
Compound EC50 (µM) 
SAHA 0.88 ± 0.13 
19c (n-butyl) 34 ± 2 
19d (n-hexyl) 16 ± 3 




Enantioselective addition of a benzyl group to (R)-20 was achieved via a reaction 
with benzyl bromide, which gave (RS)-21. A similar procedure was employed to 
synthesize (RR)-21 (Scheme 3.2B), but starting with 3-phenylpropanoyl chloride and 
the same chiral auxiliary (R)-8, followed by enantioselective addition of the allyl 
group using allyl bromide that gave (RR)-21. Both diastereomers were obtained in 
high diastereomeric ratios (dr), which were assessed from the 1HNMR spectra of 
both diastereomers (99:1 dr for (RS)-21, and 97:3 dr for (RR)-21 (see Figures B.78 
and B.85). To remove the chiral auxiliary, each diastereomer was subjected to 
lithium aluminum hydride at 0°C, which produced alcohols (S)-22 and (R)-22 from 
(RS)-21 and (RR)-21, respectively (Scheme 3.2). In order to assess the optical purity 
and the enantiomeric excess (ee) of the alcohol intermediates (S)-22 and (R)-22, 
Mosher esters of both alcohols were synthesized by coupling each alcohol with (R)-
(+)-α-Methoxy-α-trifluoromethylphenylacetic acid (R)-MTPA using EDCI and DMAP 
(Scheme B.1).132 Analysis of the 1HNMR spectra (obtained with 600 MHz 
instrument) showed that both Mosher esters were observed in high diastereomeric 
ratios (99:1 dr for (S)-22-(R)-MTPA, and 98:2 dr for (R)-22-(R)-MTPA, Figures B.93, 
B.94, B.99 and B.100), which implies that the alcohol intermediates (S)-22 and (R)-









Scheme ‎3.2. Enantioselective synthesis of intermediate alcohols (S)-22 (Part A) and 
(R)-22 (Part B) 
 
To synthesize the enantiopure C4-benzyl SAHA analogs (R)-19f and (S)-19f, both 
alcohols (S)-22 and (R)-22 were then converted to the methanesulfonate esters, 
followed by substitution with dimethyl malonate to give diesters (R)-24 and (S)-24, 
respectively (Schemes 3.3 and 3.4). Krapcho decarboxylation afforded methyl ester 
intermediates  (S)-25 and (R)-25. Cross metathesis of the methyl esters with N-
phenyl acrylamide 26 using Grubbs' second-generation catalyst afforded ester 
amides  (S)-27 and (R)-27.118 Finally, reduction, followed by substitution with 






Scheme ‎3.3. Synthesis of (R)-C4-benzyl SAHA analog (R)-19f  
 
Scheme ‎3.4. Synthesis of (S)-C4-benzyl SAHA analog (S)-19f  
 
To assess the selectivity of each enantiomer, IC50 values of both the (R)-C4-
benzyl SAHA (R)-19f and the (S)-C4-benzyl SAHA (S)-19f were determined with 
HDAC1, 2, 3, 6, and 8 (Table 3.2). Similar to the racemic mixture, both enantiomers 




potent inhibition against HDAC6 and HDAC8 compared to the (S)-C4-benzyl SAHA 
(S)-19f, with IC50 values of 48 and 27 nM for (R)-19f and 95 and 150 nM for (S)-19f 
(Table 3.2). In addition, (R)-19f showed greater fold preference for HDAC6 and 8 
over HDAC1, 2, and 3 (520- to 1300-fold) compared to the racemic mixture (210- to 
740-fold). In contrast, (S)-19f showed lower fold selectivities (240- to 540-fold) 
compared to both (R)-19f and the racemic mixture (Tables 3.2 and B.10). In vitro 
screening revealed that both (R)-C4-benzyl SAHA and (S)-C4-benzyl SAHA are 
highly selective to HDAC6 and 8 over HDAC1, 2, and 3, with nanomolar potency. 
However (R)-19f was more potent and selective than (S)-19f (Tables 3.2 and B.10). 
3.7. Docking Studies 
Docking studies for both enantiomers of the C4-benzyl SAHA (19f) were 
performed using the AutoDock 4.2 and Autodock tools programs119, 127 in order to 
explain the observed selectivity. The recently reported crystal structures of HDAC6 
(PDB: 5G0H)13 and HDAC3 (PDB: 4A69)100 were used in these studies. SAHA, the 
parent molecule, was docked in both crystal structures as a validation step for the 
docking procedure and for comparison (Figure 3.5). With HDAC6, both enantiomers 
of the C4-benzyl SAHA were positioned similar to SAHA, as expected, with the 
hydroxamic acid moiety near the catalytic metal, the linker region in the 11 Å 
channel, and the anilide group in the solvent exposed region. In addition, the 
hydroxamic acid groups bound within 1.9-2.7 Å of the active site residues (H573, 
H574, and Y745) and the active site catalytic zinc atom (Figures  3.4A and 3.4C), 
similar to that of the parent molecule SAHA (1.7-2.7 Å) (Figure 3.5A). Docking with 
the HDAC6 crystal structure was consistent with the high binding affinity of C4-




showed a similar binding and positioning of the hydroxamic acid moiety (Figures 
3.4E and 3.4G).  
                (S)-C4-benzyl SAHA            (R)-C4-benzyl SAHA 
 
Figure ‎3.4. Docked pose of (S)-C4-benzyl SAHA (A, B, E, F) and (R)-C4-benzyl 
SAHA (C, D, G, H) in the crystal structures of HDAC6 (PDB: 5G0H) and HDAC3 
(PDB: 4A69). Binding distances in HDAC6 (A,C) or HDAC3 (B,D) between the 
hydroxamic acid atoms and active site residues (numbered in figure) or the metal 
are displayed in Angstroms. The atomic radius of the metal (Zn2+) was set at 0.6 Å 
for clarity. Atom color-coding: C4-benzyl SAHA 19f (C=purple/white; O=red; N=blue; 
H=White); amino acids (C=deep teal; O=red, N=blue); Zn2+ metal ion (grey sphere). 
E,G and F,H) Shown is the superimposition of SAHA (yellow) and (S)- or (R)-C4-
benzyl SAHA 19f (red) in the crystal structures of HDAC6 (E, G) and HDAC3 (F, H), 
with the metal ion (Zn2+) represented as a grey sphere (1.39 Å radius). 
 








































Figure ‎3.5. Docking poses of SAHA in the crystal structures of HDAC6 (PDB: 5G0H) 
(A) and HDAC3 (PDB: 4A69) (B). Binding distances between the hydroxamic acid 
atoms and active site residues (numbered in figure) or the metal are displayed in 
Angstroms. The atomic radii of the metals were set at 0.6 Å for clarity. Color-coded 
SAHA (C=green/white; O=red; N=blue; H=White) and amino acid residues (C=deep 
teal; O=red, N=blue); Zn2+ metal ion (grey sphere). 
To explain the observed selectivity, (R)-19f and (S)-19f were also docked into 
the HDAC3 crystal structure. Longer and weaker binding interactions (2.1-5.0 Å) 
were observed with HDAC3 (Figures 3.4B and 3.4D) compared with HDAC6 (1.9-2.7 
Å). Superimposition of both enantiomers with SAHA showed a shift in the position of 
the hydroxamic acid moieties away from the metal binding region compared to 
SAHA (Figure 3.4F and 3.4H). The docking analysis suggests that the presence of a 
bulky substituent on the C4 position weakens binding to HDAC3 due to steric 
clashes with the relatively narrow and long 11Å channel of HDAC3 (Figures 3.6B, 
see white and blue arrows), which placed the hydroxamic acid moiety away from the 
metal binding region (Figures 3.4B, 3.4D and 3.6B). On the other hand, HDAC6 
maintains a wider and shorter V-shaped 11Å channel (Figure 3.6A, see white and 























on binding of the hydroxamic acid group to the metal binding region (Figures 3.4A, 
3.4C and 3.6A). 
 
Figure ‎3.6. Docked poses of (R)-C4-benzyl SAHA (R)-19f in the crystal structures of 
HDAC6 (A) HDAC3 (B). The white arrows show the difference in the width of the 
active site entrances discussed in text (11 Å channel). The blue arrow in part A show 
how the benzyl group can be accommodated in HDAC6 active site with no effect on 
binding of the hydroxamic acid group In part B the benzyl group sterically interact 
with the relatively narrow 11 Å channel, which positioned the hydroxamic acid group 
distant from the metal (see blue arrow). The binding site for both HDAC6 and 
HDAC3 are shown as deep blue mesh. Atom color-coding: (R)-C4-benzyl SAHA 
(C=green/white; O=red; N=blue; H=white). 
Recent studies reporting the HDAC6 crystal structure and prior docking 
studies demonstrated that HDAC6 maintain a wider and shorter 11Å channel 
compared to HDAC1, 2, and 3.13, 86 In previous work, compounds with bulky aryl or 
cyclic groups in the linker region near the hydroxamic acid group had restricted 
access to the active site due to steric clash with the relatively narrower 11Å channel, 
which placed the metal binding group distant from the catalytic metal for weaker or 
no binding of the inhibitor.13  In contrast, HDAC6 active site allowed such inhibitors 
to reach the metal binding region in the active, which led to preferential inhibition of 
HDAC6 over HDAC1, 2, and 3. In other recent reports, the presence of a bicyclic 
 





linker or phenyl linker displayed dual HDAC6 and HDAC8 selectivity.89-91 Moreover, 
valpropylhydroxamic acid with a propyl substituent showed selectivity to HDAC6 and 
8, but with micromolar potency and low fold selectivity (only 9-17-fold selectivity 
against with HDAC1, 2, and 3).88 SAHA analogs with a hexyl or benzyl substituent at 
the C2 linker also demonstrated dual HDAC6 HDAC8 selectivity.112 Based on these 
reports and the docking studies, one possibility that accounts for selectivity is that 
substituting the C4 of SAHA linker with different groups can be accommodated in the 
relatively wider and shorter V-shaped 11Å cavity of HDAC6 active site (Figures 3.4A, 
3.4C, 3.4E, 3.4G, and 3.6A), but not the narrower and relatively longer 11Å cavity of 
HDAC1, HDAC2, and HDAC3 (Figures 3.4B, 3.4D, 3.4F, and 3.4H). In addition, the 
size of the substituent plays a critical role in the selectivity. For example, analogs 
bearing smaller substituents (as methyl or ethyl in 19a or 19b) demonstrated lower 
selectivity compared to analogs comprising bulkier substituents (as butyl, hexyl, 
phenyl, and benzyl 19c-19f) (Figure 3.2 and Table 3.2). In total, the docking results 
confirmed the previously reported structural analyses suggesting that the wider 
HDAC6 active site entrance is the source of selectivity. 
In conclusion, SAHA analogs modified at the C4 position of the linker were 
synthesized and screened. The C4-SAHA analogs showed up to 1300-fold dual 
selectivity for HDAC6 and HDAC8 over HDAC1, HDAC2, and HDAC3. The best 
analogs were C4-n-butyl SAHA (19c) and C4-benzyl SAHA (19f). C4-n-butyl SAHA 
(19c), which showed 170- to 310-fold selectivity for HDAC6 and 8 compared to 
HDAC1, 2, and 3, with 88 and 74 nM IC50 with HDAC6 and HDAC8, respectively. 




selectivity for HDAC6 and 8 compared to HDAC1, 2, and 3, and 140 and 57 nM IC50 
with HDAC6 and HDAC8. Interestingly, the fold selectivity of C4-butyl and C4-benzyl 
SAHA analogs were higher than the recently reported dual HDAC6/8 selective 
inhibitors (at least 23-, 75-, and 79-fold).89-91 Furthermore, in cellulo testing of C4-
benzyl analog showed consistency with the in vitro screening. Enantioselective 
synthesis and screening of both enantiomers of the C4-benzyl SAHA revealed that 
(R)-C4-benzyl SAHA is more potent and selective than the (S) enantiomer, with 48 
and 27 nM IC50 with HDAC6 and HDAC8, and 520- to 1300-fold selectivity for 
HDAC6 and 8 over HDAC1, 2, and 3.  The dual HDAC6/HDAC8 selective C4-SAHA 
analogs reported in this work have the potential to be useful pharmacological tools 
for biomedical research and lead compounds for anti-cancer drug development. 
More generally, these studies with SAHA analogs suggest that modifying current 
drugs can significantly improve their properties. 
3.8. Experimental Procedures 
3.8.1. Materials and instrumentation 
Details were provided in Section 2.7.1 of Chapter 2. Enantiomeric excess 
(ee%) was calculated in this chapter based on the NMR spectra of Mosher's esters 
of intermediate alcohols (Section 3.6). 
3.8.2. Synthesis procedure 
3.8.2.1. Synthesis procedures for 19a-19f 
 
Synthesis of methyl (E)-6-oxohex-4-enoate (14): The compound was 




catalyst.133 Briefly, in a flame dried 2-neck 100 mL flask, purged with argon, 
Grubbs' second generation catalyst (26.65 mg, 0.0314 mmol, 0.5 mol%) was 
dissolved in dry dichloromethane (20 mL). Crotonaldehyde 13 (2.6 mL, 31.38 mmol) 
and methyl pent-4-enoate 12 (0.78 mL, 6.28 mmol) were added, and the reaction 
was stirred with reflux for 3.5 hours under argon. The reaction was then cooled to 
room temperature, concentrated, and purified by silica gel flash chromatography 
(ethyl acetate:hexanes 1:4) to afford aldehyde 14 as an orange oily product (97%). 
The spectral data for the synthesized compound was consistent with the reported 
data in literature.133 
 
Synthesis of 1-benzyl 8-methyl (E)-5-ethyloct-2-enedioate (16b): In a 200 
mL, 2-neck flame dried flask, copper(I)bromide dimethyl sulfide (2.17 g, 10.56 mmol) 
was dissolved in dry THF (20 mL). Air was purged with argon, and then the 
temperature was reduced to -15°C. Ethyllithium (12.35 mL of a 1.7M solution in 
dibutyl ether, 756 mg, 21.0 mmol) was added drop wise with stirring and the 
mixture was allowed to stir for additional 20 minutes at -15°C. The 
temperature was then reduced to -78°, followed by drop wise addition of 
chlorotrimethylsilane (3.44 g, 31.66 mmol) and methyl pent-4-enoate 14 (500 mg, 
3.52 mmol). The reaction was stirred for 5 hours at -78°C. The reaction was then 
quenched by addition of a saturated ammonium chloride:ammonia solution (1:1) 
portion wise until the reaction color turned blue. The organic layer was collected, 




organic layers were dried over anhydrous Na2SO4, filtered, and rotavaped to an oily 
crude product, which was used in the next reaction without purification. 
In a 200 mL 2-neck flame dried flask, air was purged with argon, NaH (169 mg of 
60% NaH in mineral oil, 7.04 mmol) was dissolved in dry THF (20 mL). The reaction 
was then cooled to 0°C and benzyl diethyl phosphonoacetate 15b (1.80 mL, 7.04 
mmol) was added drop wise with stirring. The reaction was allowed to stir for 15 
minutes at 0°C, then the crude product from the previous reaction was added. The 
reaction was stirred for another 30 minutes at 0°C, followed by stirring for 90 
minutes at room temperature. The reaction was quenched with a saturated 
ammonium chloride solution (20 mL). The organic layer was collected, and the 
aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined organic 
layers were dried over anhydrous MgSO4, filtered, and concentrated. The product 
was purified by flash silica gel chromatography (ethyl acetate:hexanes 1:9) to afford 
16b (375 mg, 35% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.86-0.90 
(t, J = 7.2 Hz, 3H), 1.28-1.34 (m, 2H), 1.47 (m, 1H), 1.55-1.61 (m, 2H), 2.18-2.22 (m, 
2H), 2.30-2.34 (t, J = 7.2 Hz, 2H), 3.63 (s, 3H), 5.15 (s, 2H), 5.89-5.93 (d, J = 16 
Hz, 1H), 6.92-6.98 (m, 1H), 7.29-7.35 (m, 4H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 9.69, 25.31, 27.86, 30.79, 35.24, 35.33, 38.07, 50.66, 65.69, 122.02, 127.80 
(2C), 128.15, 136.28, 148.47, 166.31, 174.4. IR: 2957, 2931, 2875, 1723, 1655, 
1437 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C18H24O4H
+, 305.2, found 305.2; 
calculated for [M+Na]+ C18H24O4Na






Synthesis of 1-benzyl 8-methyl (E)-5-ethyloct-2-enedioate (16c): The 
procedure was similar to that of 16b except the following reagents were used: 
copper(I)bromide dimethyl sulfide (4.34 g, 21.10 mmol), n-butyllithium (16.86 ml of a 
2.5 M solution in hexanes, 2.7 g, 42.2 mmol), chlorotrimethylsilane (6.87 g, 63.3 
mmol), methyl pent-4-enoate 14 (1 g, 7.03 mmol), NaH (478 mg of 60% NaH in 
mineral oil, 11.95 mmol) and benzyl diethyl phosphonoacetate 14b (3.42 g, 11.95 
mmol). The reaction was left to stir at room temperature for 10 hours. The product 
was purified by flash silica gel chromatography (5% ethyl acetate in hexanes) to 
afford 16c (602 mg, 26% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.91 
(t, J = 6.8 Hz, 3H), 1.29 (m 7H), 1.58 (m, 3H), 2.22 (t, J = 6.0 Hz, 2H), 2.33 (t, J = 
7.2 Hz, 2H), 3.63 (s, 3H), 5.16 (s, 2H), 5.91 (d, J = 15.2 Hz, 1H), 6.97 (dt, 1H), 7.34 
(m, 4H). 13CNMR (100 MHz, CD3OD) δ (ppm): 12.96, 22.05, 28.35, 28.38, 30.78, 
32.60, 35.77, 36.51, 50.64, 65.68, 122.01, 127.76 (2C), 128.12, 136.29, 148.47, 
166.33, 174.44. IR: 3057, 3033, 2954, 2928, 2860, 1720, 1654, 1456, 1436 cm-1. 
LRMS (ESI, m/z): calculated for [M+Na]+ C20H28O4Na
+, 355.19, found 355.16. 
 
Synthesis of 1-benzyl 8-methyl (E)-5-phenyloct-2-enedioate (16e): The 
procedure was similar to that of 16b except the following reagents were used: 




2M in dibutyl ether, 44.8 mmol), chlorotrimethylsilane (8.53 mL, 76.24 mol), methyl 
pent-4-enoate 14 (1.06 g, 7.49 mmol), NaH (0.51 g of 60% NaH in mineral oil, 12.70 
mmol) and benzyl dimethyl phosphonoacetate 15a (2.67 mL, 12.70 mmol). The 
reaction was heated to reflux for 1 hour 45 minutes. The product was purified by 
column chromatography (diethyl ether:petroleum ether 1:6 to 1:4) to afford 16e as an 
orange yellow oil (1.64 g, 62% over two steps). 1HNMR (400 MHz, CDCl3): 1.87 (m, 
1H), 2.05 (m, 1H), 2.15 (m, 2H), 2.53 (t, J = 7.6 Hz, 2H), 2.67 (m, 1H), 3.61 (s, 3H), 
5.14 (s, 2H), 5.82 (d, J = 15.2 Hz, 1H), 6.88 (dt, J = 15.6 Hz, and 7.2 Hz, 1H), 7.12 
(d, J = 7.6 Hz, 2H), 7.22 (m, 1H), 7.37 (m. 7H). 13CNMR (100 MHz, CDCl3): 30.94, 
31.96, 39.61, 44.50, 51.56, 66.05, 115.33, 120.33, 126.81, 127.53, 128.15, 128.53, 
128.71, 136.04, 142.81, 147.45, 166.19, 173.82. IR: 3063, 3030, 2951, 1718, 1654, 
1495, 1454, 1437 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C22H24O4H
+, 353.2; 
found 353.4; calculated for [M+Na]+ C22H24O4Na
+, 375.2; found 375.3.  
 
Synthesis of 8-methoxy-5-ethyl-8-oxooctanoic acid (17b): In a 50 mL 
flask, 16b (375 mg, 1.2 mmol) was dissolved in MeOH (20 mL), then Pd(OH)2 (87 
mg of 20 wt. % Pd(OH)2 on carbon, 0.12 mmol) was added. The air inside the flask 
was purged with argon (three times), then with hydrogen gas (three times). The 
reaction was stirred under hydrogen for 4 hours. The reaction was filtered through a 
celite plug, and the solvent was evaporated. The product was purified by silica gel 
flash chromatography (ethyl acetate:hexanes 1:1.5) to afford 17b (299 mg, 94%); 




4H), 2.30 (m, 4H), 3.66 (s, 3H) 11.40 (br s, 1H). 13CNMR (100 MHz, CD3OD) δ (ppm): 
10.58, 21.69, 25.28, 28.00, 31.47, 32.11, 34.27, 38.12, 51.55, 174.52, 179.89. IR: 
2956, 2930, 2873, 1738, 1709, 1614, 1459, 1439 cm-1. LRMS (ESI, m/z): calculated 
for [M+Na]+ C11H20O4Na
+, 239.1, found 239.2.  
 
Synthesis of 8-methoxy-8-oxo-5-phenyloctanoic acid (17e): The 
procedure was similar to that of 17b except the following reagents were used: 16e 
(1.40 g, 3.98 mmol), Pd(OH)2 (1.12 g of 20 wt. % Pd(OH)2 on carbon, 1.59 mmol). 
The product was purified by column chromatography (ethyl acetate:petroleum ether 
1:6 then 1:3) to afford 17e (764 mg, 73%); 1HNMR (400 MHz, CD3OD): 1.40 (m, 2H), 
1.63 (m, 2H), 1.80 (m, 1H), 1.98 (m, 1H), 2.10 (m, 2H), 2.20 (m, 2H), 2.54 (m, 1H), 
3.60 (s, 3H), 7.17 (m, 3H), 7.28 (m, 2H); 13CNMR (100 MHz, CDCl3): 22.30, 31.80, 
32.20, 33.95, 35.90, 45.15, 51.80, 126.40, 127.50, 128.30, 143.95, 174.30, 179.90. 
IR: 3028, 2948, 1734, 1705, 1603, 1494, 1453, 1437 cm-1. LRMS (ESI, m/z): 
calculated for [M+H]+ C15H20O4H
+, 265.1; found 265.4; calculated for [M+Na]+ 
C15H20O4Na
+, 287.1; found 287.4. 
 
Synthesis of methyl 4-methyl-8-oxo-8-(phenylamino)octanoate (18a): 
The procedure was similar to 16b except the following: copper(I)bromide dimethyl 




1.6M solution in diethyl ether, 482 mg, 21.9 mmol), chlorotrimethylsilane (3.58 g, 
32.94 mmol), methyl pent-4-enoate 14 (520 mg, 3.66 mmol). NaH (293 mg of 60% 
NaH in mineral oil, 7.32 mmol), dry THF (20 mL),  benzyl diethyl phosphonoacetate 
15b (2.10 g, 7.32 mmol). The reaction was stirred for 3.5 hours. The product was 
used in the next step without purification. 
The procedure was similar to 17b except the following: Crude 16a from prior 
step, MeOH (20 mL) and Pd(OH)2 (413 mg of 20 wt. % Pd(OH)2 on carbon, 0.59 
mmol). The reaction was stirred under hydrogen for 3.5 hours. The reaction was 
filtered through a celite plug, and the solvent was evaporated. The crude product 
was used in the following reaction. 
The crude product 17a was dissolved in acetonitrile (10 mL), followed by 
addition of DIPEA (946 mg, 7.32 mmol) and TBTU (1.76 g, 5.49 mmol), and the 
reaction was left to stir for 20 minutes. Aniline (0.51 g, 5.49 mmol) was added, and 
the reaction was left to stir for 4.5 hours. The reaction was quenched with 10% 
aqueous HCl (20 mL). The aqueous layer was extracted with ethyl acetate (4 x 20 
mL). The combined organic extracts were washed with a saturated NaHCO3 (10 mL) 
and then dried over anhydrous Na2SO4, filtered, and evaporated. The product was 
purified by silica flash chromatography (ethyl acetate:hexanes 1:4) to afford 18a 
(434 mg, 43% over four steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.90 (d, J = 6.4 
Hz, 3H), 1.21 (m, 1H), 1.43 (m, 3H), 1.74 (m, 3H), 2.67 (m, 4H), 3.63 (s, 3H), 7.06 (t, 
J = 7.6 Hz, 1H), 7.28 (t, J = 8.4 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H). 13CNMR (100 MHz, 
CD3OD) δ (ppm): 18.15, 22.90, 31.13, 31.50, 31.98, 35.79, 36.71, 50.61, 119.83, 




1736, 1662, 1600, 1542, 1499, 1442 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ 
C16H23NO3H




Synthesis of methyl 4-ethyl-8-oxo-8-(phenylamino)octanoate (18b): The 
procedure was similar to the last step of 18a except the following reagents were 
used: DIPEA (319 mg, 2.47mmol), TBTU (594 mg, 1.85 mmol) and aniline (172 mg, 
185 mmol). The extraction was done with dichloromethane (4 x 20 mL). The product 
was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:4) to afford 
18b (250 mg, 75%). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.87 (t, J = 7.2 Hz, 3H), 
1.34 (m, 5H), 1.60 (m, 2H), 1.68 (m, 2H), 2.33 (m, 4H), 3.64 (s, 3H), 7.07 (t, 1H), 
7.29 (t, J = 7.2 Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 9.35, 22.23, 24.83, 27.55, 30.56, 31.63, 36.48, 37.83, 50.32, 119.55, 123.40, 
128.06, 138.19, 172.82, 174.49. IR: 3302, 3198, 3137, 3062, 2955, 2930, 2862, 1737, 
1663, 1600, 1542, 1499, 1442 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C17H25O3H
+, 
292.19, found 292.19; calculated for [M+Na]+ CI7H25O3Na
+, 314.17, found 314.17. 
 
Synthesis of methyl 4-butyl-8-oxo-8-(phenylamino)octanoate (18c): The 
procedure was similar to that of 17b except the following reagents were used: 16c 
(1.2 g, 3.6 mmol) Pd(OH)2 (504 mg of 20 wt. % Pd(OH)2 on carbon, 0.72 mmol). 




The procedure was similar to that of 18a except the following reagents were 
used: Crude 17c from prior reaction, DIPEA (464 mg, 3.59 mmol), TBTU (865 mg, 
2.69 mmol) and aniline (250 mg, 2.69 mmol). The product was purified by silica gel 
flash chromatography (ethyl acetate:hexanes 1:6) to afford 18c (250 mg, 44% over 
two steps).  1HNMR (400 MHz, CD3OD) δ (ppm): 0.89 (t, J = 6.4 Hz, 3H), 1.31 (m, 
9H), 1.60 (m, 2H), 1.68 (m, 2H), 2.32 (m, 4H), 2.82 (s, 3H), 7.06 (t, J = 7.2 Hz, 1H), 
7.28 (t, J = 8 Hz, 2H), 7.53 (d, J = 8 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 
13.07, 22.48, 22.66, 28.29, 28.46, 30.84, 32.37, 32.55, 36.56, 36.77, 50.63, 119.84, 
123.69, 128.36, 138.49, 173.10, 174.77. IR: 3302, 3198, 3137, 3041, 2953, 2928, 
2859, 1737, 1661, 1600, 1541, 1499, 1441 cm-1. LRMS (ESI, m/z): calculated for 
[M+H]+ C19H29NO3H
+, 320.22, found 320.21; calculated for [M+Na]+ C19H29NO3Na
+, 
342.20, found 342.17. 
 
Synthesis of methyl 4-hexyl-8-oxo-8-(phenylamino)octanoate (18d): The 
procedure was similar to that of 16b except the following reagents were used: 14 
(460 mg, 3.24 mmol) dry THF (20 mL), copper(I)bromide dimethyl sulfide (2 g, 9.73 
mmol), n-hexyllithium (8.46 ml of a 2.3 M solution in hexanes, 1.792 g, 19.46 mmol), 
chlorotrimethylsilane (3.17 g, 29.19 mmol), NaH (259 mg of 60% NaH in mineral oil, 
6.48 mmol), benzyl diethyl phosphonoacetate 15b (1.85 g, 6.48 mmol). The reaction 
was heated to reflux for 4.5 hours. The product was purified by silica gel flash 





 The procedure was similar to that of 17b except the following reagents were 
used: 16d from prior reaction, Pd(OH)2 (228 mg of 20 wt. % Pd(OH)2 on carbon, 
0.32 mmol). The crude product was used in the following reaction. 
The procedure was similar to that of 18a except the following: 17d from prior 
reaction, acetonitrile (15 mL), DIPEA (838 mg, 6.48 mmol), TBTU (1.56 g, 4.86 
mmol) and aniline (452 mg, 4.86 mmol). The reaction was quenched with 10% 
aqueous HCl (10 mL). The product was purified by silica gel flash chromatography 
(ethyl acetate:hexanes 1:6) to afford 18d (214 mg, 19% over four steps). 1HNMR 
(400 MHz, CD3OD) δ (ppm): 0.88 (t, J = 6.8 Hz, 3H), 1.31 (m, 13H), 1.60 and 1.68 
(overlapped quartet and quintet, J = 7.6 and 7.6 Hz, 4H), 2.32 (m, 4H), 3.64 (s, 3H), 
7.07 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 2H). 13CNMR 
(100 MHz, CD3OD) δ (ppm): 13.02, 22.30, 22.47, 26.14, 28.32, 29.34, 30.85, 31.61, 
32.35, 32.86, 36.57, 36.75, 50.61, 119.86, 123.70, 128.34, 138.47, 173.13, 174.81. 
LRMS (ESI, m/z): calculated for [M+H]+ C21H33NO3H
+, 348.25, found 348.26; 
calculated for [M+Na]+ C21H33NO3Na
+, 370.24, found 370.22. 
 
Synthesis of methyl 8-oxo-4-phenyl-8-(phenylamino)octanoate (18e): 8-
Methoxy-8-oxo-5-phenyloctanoic acid 17e (0.763 g, 2.89 mmol) was dissolved in 
dichloromethane (25 mL), then aniline (0.32 mL, 3.47 mmol) was added, followed by 
4-(dimethylamino)pyridine (0.424 g, 3.47 mmol). The mixture was stirred until 4-
(dimethylamino)pyridine was completely dissolved, then dicyclohexyl carbdiimide 




temperature. The reaction was quenched with 10% aqueous HCl (40 mL), the 
organic layer was washed with a saturated NaHCO3 solution, and then brine, dried 
over anhydrous Na2SO4, concentrated, and purified by column chromatography 
(acetone:petroleum ether 1:6) to give 18e (704 mg, 72%). 1HNMR (400 MHz, 
CD3OD): 1.46 (m, 2H), 1.65 (m, 2H), 1.80 (m, 1H), 1.98 (m, 1H), 2.11 (m, 2H), 2.28 
(m, 2H), 2.53 (m, 1H), 3.55 (s, 3H), 7.05 (t, J = 7.6 Hz, 1H), 7.16 (m, 3H), 7.26 (m, 
4H), 7.52 (d, J = 8.4 Hz, 2H); 13CNMR (100 MHz, CD3OD): 23.59, 31.55, 31.58, 
35.92, 36.50, 45.05, 50.59, 119.83, 123.71, 126.10, 127.41, 128.21, 128.39, 138.48, 
144.07, 172.96, 174.34. IR: 3301, 3197, 3135, 3061, 3027, 2949, 2865, 1734, 1663, 
1600, 1543, 1499, 1442 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C21H25NO3H
+, 
340.2; found 340.2; calculated for [M+Na]+ C21H25O3Na
+, 362.2; found 362.2. 
 
Synthesis of methyl 4-benzyl-8-oxo-8-(phenylamino)octanoate (18f): 
The procedure was similar to that of 16b except the following reagents were 
used: 14 (500 mg, 3.52 mmol), dry THF (20 mL), copper(I)bromide dimethyl sulfide 
(2.17 g, 10.56 mmol), benzylmagnesium chloride (21.11 ml of a 1.0 M solution in 
methyl THF, 3.189 g, 21.12 mmol), chlorotrimethylsilane (3.44 g, 31.68 mmol), NaH 
(282 mg of 60% NaH in mineral oil, 7.04 mmol) and benzyl diethyl phosphonoacetate 
15b (2.02 g, 7.04 mmol). The reaction was heated to reflux for 1 hour 45 minutes. 
The crude product was purified by silica gel flash chromatography (ethyl 




The procedure was similar to that of 17b except the following: 16f from prior 
reaction, Pd(OH)2 (247 mg of 20 wt. % Pd(OH)2 on carbon, 0.35 mmol). The 
reaction was stirred for 4.5 hours under hydrogen, then it was filtered, and the solvent 
was evaporated. The crude product was used in the following reaction. 
The procedure was similar to that of 18a except the following: Crude 17f from 
prior reaction, DIPEA (464 mg, 3.59 mmol), TBTU (865 mg, 3.59 mmol), and aniline 
(250 mg, 2.69 mmol). The reaction was stirred for 4 hours 45 minutes. The combined 
organic extracts were dried over anhydrous Na2CO3. The product was purified by 
silica gel flash chromatography (ethyl acetate:hexanes 1:3) to afford 18f (340 mg, 
27% over four steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.35 (m, 2H), 1.60 and 
1.72 (overlapped m and m, 5H), 2.34 (m, 4H), 2.55 (d, J = 6.8 Hz, 2H), 3.61 (s, 3H), 
7.10 (m, 4H), 7.21 (t, J = 7.6 Hz, 2H), 7.28 (t, J = 7.2 Hz, 2H), 7.51 (d, J = 7.6 Hz, 
2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 22.35, 28.00, 30.84, 31.97, 36.66, 38.87, 
39.61, 50.62, 119.90, 123.71, 125.47, 127.86, 128.34, 128.79, 138.44, 140.65, 
173.04, 174.65. IR: 3302, 3026, 2929, 2863, 1734, 1661, 1599, 1542, 1498, 1441 
cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C22H27NO3H
+, 354.21, found 354.22; 
calculated for [M+Na]+ C22H27NO3Na
+, 376.19, found 376.21.  
 
Synthesis of N1-hydroxy-4-methyl-N8-phenyloctanediamide (19a): In an 
acid washed flask, hydroxylamine HCl (1.09 g, 15.67 mmol) was dissolved in MeOH 
(10 mL). KOH (1.76 g, 31.33 mmol) was added at 0°C and allowed to stir for 20 




added, and the reaction was stirred for 4.5 hours at 0°C. The pH of the reaction 
mixture was adjusted to 6 with concentrated aqueous HCl, followed by dilution with 
distilled de-ionized water (30 mL). The reaction was extracted with ethyl acetate (3 x 
30 mL). The organic extracts were collected together and dried over anhydrous 
Na2SO4. The product was purified by silica gel flash chromatography 
(acetone:dichloromethane 1:3) using iron-free silica gel to afford 19a (312 mg, 72%). 
1HNMR (400 MHz, CD3OD) δ (ppm): 0.92 (d, J = 6.0 Hz, 3H), 1.23 (m, 1H), 1.44 (m, 
3H), 1.72 (m, 3H), 2.15 (m, 2H), 2.35 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H), 
7.28 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 18.19, 22.89, 29.98, 32.01, 32.26, 35.76, 36.64, 119.87, 123.72, 128.35, 
138.45, 171.79, 173.21. IR: 3308, 3138, 3063, 3030, 2954, 2930, 2861, 1737, 1695, 
1663, 1601, 1543, 1500, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C15H22N2O3Na
+, 301.1528, found 301.1520. HPLC analytical purity analysis 98.4%. 
 
Synthesis of 4-ethyl-N1-hydroxy-N8-phenyloctanediamide (19b): The 
procedure was similar to that of 19a except the following: hydroxylamine HCl (597 
mg, 8.59 mmol), KOH (964 mg, 17.18 mmol), and 18b (250 mg, 0.86 mmol). The 
reaction was left to stir for 4 hours at 0°C, then at room temperature overnight. 
The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 
1:4 to 1:3) using iron-free silica gel to afford 19b (116 mg, 46%). 1HNMR (400 MHz, 
CD3OD) δ (ppm): 0.87 (t, J = 6.4 Hz, 3H), 1.32 (m, 5H), 1.59 and 1.67 (overlapped 




1H), 7.28 (t, J = 7.6 Hz, 2H), 7.54 (d, J = 8 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 9.72, 22.52, 25.16, 28.67, 29.82, 31.90, 36.76, 38.14, 119.90, 123.76, 
128.39, 138.45, 171.89, 173.25. IR: 3252, 3199, 3061, 2960, 2932, 2872, 1658, 
1600, 1546, 1500, 1444 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C16H24N2O3Na
+, 315.1685, found 315.1669. HPLC analytical purity analysis 97.5%. 
 
Synthesis of 4-butyl-N1-hydroxy-N8-phenyloctanediamide (19c): The 
procedure was similar to that of 19a except the following: hydroxylamine HCl (538 
mg, 7.74 mmol), KOH (869 mg, 15.49 mmol), and 18c (247 mg, 0.77 mmol). The 
product was purified by silica gel flash chromatography (acetone:dichloromethane 
1:4) using iron-free silica gel to afford 19c (167 mg, 67%) 1HNMR (400 MHz, 
CD3OD) δ (ppm): 0.90 (t, J = 7.6 Hz, 3H), 1.33 (m, 9H), 1.60 and 1.69 (overlapped 
m and quintet, J = 7.2 Hz, 4H), 2.08 (t, J = 7.2 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 7.07 
(t, J = 8.0 Hz, 1H), 7.29 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H). 13CNMR (100 
MHz, CD3OD) δ (ppm): 13.06, 22.45, 22.68, 28.48, 29.11, 29.76, 32.30, 32.62, 36.62, 
36.72, 119.86, 123.73, 128.36, 138.45, 171.87, 173.23. IR: 3288, 2972, 2927, 2872, 
1647, 1600, 1545, 1499, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C18H28N2O3Na
+, 343.1998, found 343.1985. HPLC analytical purity analysis 97.7%. 
 
Synthesis of 4-hexyl-N1-hydroxy-N8-phenyloctanediamide (19d): The 




mg, 8.24 mmol), KOH (925 mg, 16.48 mmol), and 18d (286 mg, 0.82 mmol). The 
reaction was stirred for 2 hours at 0°C, then pre-incubated solution of 
hydroxylamine HCl (573 mg, 8.24 mmol) and KOH (925 mg, 16.48 mmol) was 
added followed by stirring for 1.5 hour at 0°C. The product was purified by 
sequential silica gel flash chromatography (acetone:dichloromethane 1:3 and a 
second purification with acetone:dichloromethane 1:2) using iron-free silica gel. The 
compound was further purified by HPLC on a reverse phase HPLC semi-preparative 
column (YMC America,  250 x 10 mmI.D., 4µm, 8 nm) using a gradient of 60% to 
10% of buffer A over 90 minutes (buffer A = 0.1% HPLC grade TFA in water; buffer 
B = HPLC grade acetonitrile) at a flow rate of 3.0 mL/min at room temperature to 
yield 19d (49 mg, 17%). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.88 (t, J = 6.8 Hz, 
3H), 1.33 (m, 13H), 1.59 (m, 2H), 1.69 (quintet, J = 7.6 Hz, 2H), 2.08 (t, J = 8.0 Hz, 
2H), 2.35 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.6 Hz, 1H), 7.29 (t, J = 7.6 Hz, 2H), 7.52 (d, 
J = 7.6 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 13.01, 22.30, 22.44, 26.20, 
29.14, 29.38, 29.78, 31.63, 32.29, 32.96, 36.66, 36.71, 119.89, 123.71, 128.34, 
138.45, 171.85, 173.21. IR: 3254, 3064, 2957, 2927, 2858, 1660, 1601. 1547, 1500, 
1444 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ C20H32N2O3Na
+, 
371.2311, found 371.2319. HPLC analytical purity analysis 98.2%. 
 
Synthesis of 4-hexyl-N1-hydroxy-N8-phenyloctanediamide (19e): The 
procedure was similar to that of 19a except the following: hydroxylamine HCl (1.38 g, 




mmol). The reaction was stirred overnight. The product was purified by silica gel 
flash chromatography (5% MeOH in dichloromethane) using iron-free silica gel, 
followed by crystallization from MeOH to afford 19e (350 mg, 52%). 1HNMR (400 
MHz, CD3OD): 1.53 (m, 2H), 1.68 (m, 2H), 1.85 (m, 3H), 2.01 (m, 1H), 2.30 (m, 2H), 
2.57 (m, 1H), 7.06 (t, J = 7.6 Hz, 1H), 7.18 (m, 3H), 7.28 (m, 4H), 7.50 (d, J = 7.2 Hz, 
2H). 13CNMR (100 MHz, CD3OD): 23.58, 30.50, 32.22, 35.90, 36.43, 45.14, 119.84, 
123.69, 126.04, 127.40, 128.21, 128.34, 138.42, 144.19, 171.5, 173.02. IR: 3253, 
3199, 3061, 3027, 2929, 2866, 1657, 1600, 1545, 1499, 1444 cm-1. HRMS (ESI-
TOF, m/z): calculated for [M+Na]+ C20H24N2O3Na
+, 363.1685, found 363.1686. HPLC 
analytical purity analysis 98.8%. 
 
Synthesis of 4-benzyl-N1-hydroxy-N8-phenyloctanediamide (19f): The 
procedure was similar to that of 19a except the following: hydroxylamine HCl (600 
mg, 8.64 mmol), KOH (970 mg, 17.28 mmol), and 18f (305 mg, 0.86 mmol). The 
reaction was stirred for 2 hours at 0°C, then another premixed solution of 
hydroxylamine HCl (600 mg, 8.64 mmol) and KOH (970 mg, 17.28 mmol) was 
added followed by stirring for 1.5 hour at 0°C. The product was purified by silica gel 
flash chromatography (acetone:dichloromethane 1:2) using iron-free silica gel to 
afford 19f (158 mg, 51%). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.33 (m, 2H), 1.67 
(m 5H), 2.12 (m, 2H), 2.29 (m, 2H), 2.56 (m, 2H), 7.15 (m, 6H), 7.28 (t, J = 7.6 Hz, 
2H), 7.51 (d, J = 7.6 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 22.28, 28.83, 




138.43, 140.65, 171.70, 173.13. IR: 3253, 3063, 3027, 2972, 2927, 1660, 1600, 
1547, 1499, 1444 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C21H26N2O3Na
+, 377.1841, found 377.1824. HPLC analytical purity analysis 98.9%. 
3.8.2.2. Enantioselective synthesis procedures for (R)-19f and (S)-19f 
 
Synthesis of (R)-4-benzyl-3-(pent-4-enoyl)oxazolidin-2-one ((R)-20). The 
compound was synthesized in a similar way to the reported procedure.134 Briefly, 
(R)-8 (1.0 g, 5.64 mmol) was dissolved in dry THF (25 mL) followed by the addition 
of n-butyl lithium (2.5 mL of 2.5 M solution, 5.64 mmol) drop wise under argon at -
78°C. The reaction was stirred at that temperature for 10 minutes, then 4-pentenoyl 
chloride (0.81 mL, 6.77 mmol) was added drop wise. Stirring was continued for 30 
minutes at -78°C, then the reaction temperature was raised to gradually room 
temperature over 30 minutes. The reaction was diluted with saturated solution of 
ammonium chloride (30 mL) and saturated solution of sodium carbonate (30 mL) 
and stirred for 15 minutes at room temperature. The solution was extracted with 
ethyl acetate (3 x 40 mL). The organic extracts were combined, evaporated and the 
product was purified by Flash silica-gel chromatography (ethyl acetate:hexanes 1:9-
1:3) which yielded the product (R)-20 (954 mg, 65%). 1HNMR (400 MHz, CDCl3)  
(ppm): 2.45 (q, J = 6.8 Hz, 2H), 2.61 (dd, J = 3.6 Hz and 13.2, 1H), 3.04 (m, 2H), 
3.31 (dd, J = 2.8 and 13.2 Hz, 1H), 4.17 (m, 2H), 4.68 (m, 1H), 5.07 (overlapped d 
and d, J = 10.4 and 17.2 Hz, 2H), 5.87 (m, 1H), 7.21 (d, J = 7.2 Hz, 2H), 7.31 (m, 




127.36, 128.96, 129.42, 135.26, 136.69, 153.46, 172.55. LRMS (LC-SQMS, m/z); 
found: [M+H], 260.01, calculated for C15H18NO3, 260.13, found: [M+Na], 281.97, 
calculated for C15H17NO3Na, 282.11. Spectral data were consistent with the reported 
spectra.134 
 
Synthesis of (R)-4-benzyl-3-((S)-2-benzylpent-4-enoyl)oxazolidin-2-one 
((RS)-21). To compound (R)-20 (951 mg, 3.67 mmol) was added dry THF (20 mL) 
followed by reduction of the temperature to -78°C. NaHMDS (2.0 mL of 2 M solution, 
4.04 mmol) was added drop wise under Argon and the reaction was stirred at -78°C 
for 30 minutes. Benzyl bromide (0.86 mL, 7.34 mmol) was then added drop wise, 
and the reaction was stirred at -78°C for 5 hours, then the temperature was 
increased gradually to room temperature overnight. The reaction was then quenched 
with saturated ammonium chloride solution (15 mL) and was left to stir at room 
temperature for 15 minutes. The reaction was extracted with ethyl acetate (2 x 30 
mL). The extracts were combined, evaporated, and the product was purified by 
Flash silica-gel chromatography (ethyl acetate:hexanes 1:15-1:10) which yielded 
(RS)-21 as a white solid (730 mg, 57%). 1HNMR (400 MHz, CDCl3)  (ppm): 2.29 
(m, 1H), 2.47 (m, 2H), 2.83 (dd, J = 6.8 and 13.6 Hz, 1H), 3.03 (overlapped dd and 
dd, J = 3.2, 13.2, 8.4, and 13.6 Hz, 2H), 4.05 (dd, J = 3.2, and 9.2 Hz, 1H), 4.11 (t, J 
= 7.6 Hz, 1H), 4.35 (m, 1H), 4.62 (m, 1H), 5.05 (m, 2H), 5.81 (m, 1H), 7.01 (dd, J = 
2.4, and 8.0 Hz, 2H), 7.20 (m, 1H), 7.25 (m, 3H), 7.28 (m, 4H); 13CNMR (100 MHz, 




128.38, 128.88, 129.37, 129.38, 135.18, 138.90, 153.07, 175.26. LRMS (LC-SQMS, 
m/z); found: [M+H], 349.98, calculated for C22H24NO3, 350.18, found: [M+Na], 
371.95, calculated for C22H23NO3Na, 372.16. []D
23 = -48.40 (c = 1.00, CH2Cl2). 
Spectral data were consistent with the reported spectra.135 Diastereomeric ratio of 
99:1 was calculated from the integration of peaks of both the major and the minor 
diastereomers in the 1HNMR spectrum (See Figure B.78).   
 
Synthesis of (R)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one ((R)-
23). The procedure was similar to that of (R)-20 except the following reagents were 
used: (R)-8 (1.5 g, 8.47 mmol), n-butyl lithium (4.1 mL of 2.5 M solution, 10.16 
mmol), and 3-phenyl propanoyl chloride (1.64 mL, 11 mmol). The reaction gave (R)-
23 in 90% yield (2.36 g). 1HNMR (400 MHz, CDCl3)  (ppm): 2.75 (dd, J = 9.6 Hz 
and 13.2, 1H), 3.03 (m, 2H), 3.29 (m, 3H), 4.16 (m, 2H), 4.67 (m, 1H), 7.22 (m, 3H), 
7.32 (m, 7H); 13CNMR (100 MHz, CDCl3) δ (ppm): 30.26, 37.13, 37.82, 55.11, 66.18, 
126.28, 127.36, 128.48, 128.58, 128.96, 129.42, 135.19, 140.44, 153.41, 172.41. 
LRMS (LC-SQMS, m/z); found: [M+H], 310.31, calculated for C19H20NO3, 310.14, 
found: [M+Na], 332.31, calculated for C19H19NO3Na, 332.13. Spectral data are 
consistent with the reported spectra.136 
 
Synthesis of (R)-4-benzyl-3-((R)-2-benzylpent-4-enoyl)oxazolidin-2-one 




were used: (R)-23 (2.35 g, 7.59 mmol), NaHMDS (4.18 mL of 2 M solution, 8.35 
mmol), and allyl bromide (1.97 mL, 22.8 mmol). The product was purified by Flash 
silica-gel chromatography (ethyl acetate:hexanes 1:15) which yielded (RS)-21 as an 
oily product (1.84 g, 69%). 1HNMR (400 MHz, CDCl3)  (ppm): 2.37 (m, 1H), 2.52-
2.67 (overlapped m and dd,  J = 10.0 and 13.2 Hz, 2H), 2.84 (dd, J = 6.4 and 13.2 
Hz, 1H), 2.96 (dd, J =  8.8 and 13.2 Hz, 1H), 3.23 (dd, J = 3.2, and 13.2 Hz, 1H), 
3.82 (t, J = 8.4 Hz, 1H), 4.01 (d, J = 9.2 Hz, 1H), 4.33 (m, 1H), 4.45 (m, 1H), 5.10 
(m, 2H), 5.86 (m, 1H), 7.17-7.33 (m, 10H); 13CNMR (100 MHz, CDCl3) δ (ppm): 
36.32, 38.03, 38.29, 43.95, 55.49, 65.84, 117.41, 126.41, 127.29, 128.35, 128.90, 
129.11, 129.42, 135.05, 135.36, 138.91, 153.01, 175.30. LRMS (LC-SQMS, m/z); 
found: [M+H], 350.45, calculated for C22H24NO3, 350.18, found: [M+Na], 372.47, 
calculated for C22H23NO3Na, 372.16. []D
23 = -121.5 (c = 1.00, CH2Cl2). Spectral 
data were consistent with the reported spectra.135-136 Diastereomeric ratio of 97:3 
was calculated from the integration of peaks of both the major and the minor 
diastereomers in the 1HNMR spectrum (See Figure B.87). 
 
Synthesis of (S)-2-benzylpent-4-en-1-ol ((S)-22). A solution of (RS)-21 (901 
mg, 2.58 mmol) in dry THF (7 mL) was cooled and stirred at 0°C in ice bath for 15 
minutes. Lithium aluminum hydride (295 mg, 7.77 mmol) was added portion wise 
and the reaction was stirred at 0°C for 2 hours. The reaction was quenched by 
careful drop wise addition of 1M solution of NaOH until no effervescence was 




with ethyl acetate (3 x 40 mL). The organic extracts were combined, evaporated, 
and the product was purified by Flash silica-gel chromatography (ethyl 
acetate:hexanes 1:15-1:10) which afforded (S)-22 (402 mg, 88%). 1HNMR (400 
MHz, CDCl3)  (ppm): 1.38 (br s, 1H), 2.14 (t, J = 7.2 Hz, 2H), 2.64 (m,  2H), 3.55 
(m, 2H), 5.06 (m, 2H), 5.83 (m, 1H), 7.19 (m, 3H), 7.28 (m, 2H); 13CNMR (100 MHz, 
CDCl3) δ (ppm): 35.50, 37.24, 42.37, 64.74, 116.61, 125.97, 128.35, 129.17, 136.83, 
140.48. []D
23 = -13.96 (c =  0.824, CH2Cl2). Compound characterization and specific 
rotation were consistent with literature.137 
 
Synthesis of (R)-2-benzylpent-4-en-1-ol ((R)-22). The procedure was 
similar to that of (S)-22 except the following reagents were used: (RR)-21 (1.83 g, 
5.23 mmol) in dry THF (25 mL), Lithium aluminum hydride (595 mg, 15.68 mmol). 
The reaction afforded (R)-22 in 70% yield (645 mg). 1HNMR (400 MHz, CDCl3)  
(ppm): 42 (t, J = 5.6 Hz, 1H), 1.92 (m, 1H), 2.15 (m, 2H), 2.65 (m,  2H), 3.55 (m, 2H), 
5.07 (m, 2H), 5.83 (m, 1H), 7.21 (m, 3H), 7.28 (m, 2H); 13CNMR (100 MHz, CDCl3) δ 
(ppm): 35.49, 37.24, 42.37, 64.71, 116.62, 125.97, 128.35, 129.18, 136.84, 140.50. 
[]D
23 = +15.80 (c =  1, CH2Cl2). Compound characterization and specific rotation 





3.8.2.3. Synthesis procedure for Mosher's esters of (S)-11-(R)-MTPA and (R)-
11-(R)-MTPA 
 
Synthesis of (S)-2-benzylpent-4-en-1-yl (R)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate ((S)-22-(R)-MTPA). Alcohol (S)-22 (35 mg, 0.2 mmol) was 
dissolved in dry DCM (4 mL) followed by replacement of air with argon. and (R)-(+)-
a-Methoxy-a-trifluoromethylphenylacetic acid ((R)-MTPA) (71 mg, 0.3 mmol), EDCI 
(116 mg, 0.6 mmol), and 4-(dimethylamino)pyridine (73 mg, 0.6 mmol). The reaction 
was stirred overnight at room temperature. Solvent was evaporated and the residue 
was suspended in 1N HCl (5 mL) and then extracted with ethyl acetate (2 x 15 mL). 
The combined extracts were combined, evaporated, and purified by silica gel flash 
chromatography (ethyl acetate:hexanes 1:15) to afford (S)-22-(R)-MTPA (49 mg, 
63%). 1HNMR (600 MHz, CDCl3) δ (ppm): 2.03 (m, 3H), 2.51 (m, 2H), 3.49 (s, 3H), 
4.06-4.13 (overlapped dd and dd, J = 2.8  and 7.2 Hz, 2H), 4.99 (m, 2H), 5.68 (m, 
1H), 6.96 (d, J = 4.8 Hz, 2H), 7.12 (t, J = 5.2 Hz, 1H), 7.18 (d, J = 5.6 Hz, 2H), 7.35 
(m, 3H), 7.46 (m, 2H). 13CNMR (150 MHz, CDCl3) δ (ppm): 35.15, 36.97, 39.26, 
55.46, 67.18, 117.45, 121.99, 124.85, 126.23, 127.38, 128.45, 129.07, 129.67, 
132.31, 135.48, 139.38, 166.57. 19FNMR (400 MHz, CDCl3) δ (ppm): -71.30. LRMS 






Synthesis of (R)-2-benzylpent-4-en-1-yl (R)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate ((R)-22-(R)-MTPA). The procedure was similar to that of (SR)-
18 except the following reagents were used (R)-22 (15.8 mg, 0.09 mmol), (R)-(+)-a-
Methoxy-a-trifluoromethylphenylacetic acid ((R)-MTPA) (46 mg, 0.2 mmol), EDCI 
(35 mg, 0.27 mmol), and 4-(dimethylamino)pyridine (33 mg, 0.27 mmol). The 
reaction was stirred at room temperature for 3 hours. The product was purified by 
silica gel flash chromatography (ethyl acetate:hexanes 1:50) and afforded (R)-22-
(R)-MTPA in 89% yield (32 mg). 1HNMR (600 MHz, CDCl3) δ (ppm): 2.03 (m, 3H), 
2.54 (m, 2H), 3.48 (s, 3H), 4.01 (dd, J = 2.8  and 7.2 Hz, 1H), 4.20 (dd, J = 2.8  and 
7.2 Hz, 1H), 4.97 (m, 2H), 5.66 (m, 1H), 7.01 (d, J = 4.8 Hz, 2H), 7.13 (t, J = 5.2 Hz, 
1H), 7.20 (d, J = 5.6 Hz, 2H), 7.35 (m, 3H), 7.46 (m, 2H). 13CNMR (150 MHz, CDCl3) 
δ (ppm): 34.99, 37.05, 39.15, 55.41, 67.19, 117.48, 121.98, 124.85, 126.26, 127.43, 
128.45, 129.10, 129.67, 132.28, 135.42, 139.34, 166.55. 19FNMR (400 MHz, CDCl3) 
δ (ppm): -71.26. LRMS (LC-SQMS, m/z); found: [M+Na], 415.17, calculated for 
C22H23F3O3Na, 415.15. 
 
Synthesis of dimethyl (R)-2-(2-benzylpent-4-en-1-yl)malonate ((R)-24). A 
solution of (S)-22 (400 mg, 2.27 mmol) in dry DCM (10 mL) was cooled to 0°C in ice 




methanesulfonyl chloride (476 µL, 3.41 mmol) drop wise. The reaction was stirred 
for 10 minutes at 0°C, then for 1 hour at room temperature. The reaction was diluted 
with water (10 mL) followed by concentration at reduced pressure. The aqueous 
layer was extracted with ethyl acetate (3 x 20 mL). The organic extracts were 
combined, dried over anhydrous sodium sulfate, and evaporated. The crude product 
was used in the following reaction with no purification. 
In a 2-neck flame dried flask, air was purged with argon, NaH (273 mg of 
60% NaH in mineral oil, 6.82 mmol) was dissolved in dry THF (20 mL). The reaction 
was then cooled to 0°C and dimethyl malonate (0.78 mL, 6.82 mmol) was added 
drop wise with stirring. The reaction was allowed to stir for 15 minutes at 0°C, then 
the crude product from previous reaction was added (in 10 mL dry THF). The 
reaction was heated under reflux for 20 hours, then another solution of malonate 
anion (prepared in the same way as described above) was added to the reaction 
and reflux was continued for another 20 hours. The reaction was then quenched 
with saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate 
(3 x 30 mL). The extracts were combined, evaporated, and the product was purified 
by Flash silica-gel chromatography (ethyl acetate:hexanes 1:9) which yielded (R)-24 
in 49% yield (269 mg) over two steps. 1HNMR (400 MHz, CDCl3)  (ppm): 1.67 (m, 
1H), 1.83-2.12 (m, 4H), 2.58 (m, 2H), 3.50 (t, J = 7.6 Hz, 1H) 3.69 (s, 3H), 3.73 (s, 
3H), 5.05 (m, 2H), 5.76 (m, 1H), 7.13 (d, J = 7.2 Hz, 2H), 7.19 (m, 1H), 7.24 (m ,2H); 
13CNMR (100 MHz, CDCl3) δ (ppm): 32.47, 37.16, 37.37, 39.85, 49.70, 52.48, 52.50, 




2953, 2924, 2853, 1733, 1651, 1623, 1592, 1575, 1496, 1436 cm-1. LRMS (LC-
SQMS, m/z); found: [M+H], 291.19, calculated for C17H23O4, 291.16, 
 
Synthesis of dimethyl (S)-2-(2-benzylpent-4-en-1-yl)malonate ((S)-24). 
The procedure was similar to that of (R)-24 except the following reagents were used: 
(R)-22 (597 mg, 3.34 mmol), triethyl amine (710 µL, 5.09 mmol), methanesulfonyl 
chloride (394 µL, 5.09 mmol), and the reaction was stirred at room temperature for 3 
hours. For the next reaction, the following reagents were used once only, NaH (407 
mg of 60% NaH in mineral oil, 10.17 mmol), dimethyl malonate (1.16 mL, 10.17 
mmol) and the reaction was refluxed for 20 hours. The reaction afforded (S)-13 in 
66% yield (648 mg) over two steps. 1HNMR (400 MHz, CDCl3)  (ppm): 1.74 (m, 
1H), 1.88-2.08 (m, 4H), 2.56 (m, 2H), 3.50 (t, J = 7.6 Hz, 1H) 3.69 (s, 3H), 3.72 (s, 
3H), 5.05 (m, 2H), 5.75 (m, 1H), 7.13 (d, J = 6.8 Hz, 2H), 7.19 (m, 1H), 7.29 (m ,2H); 
13CNMR (100 MHz, CDCl3) δ (ppm): 32.47, 37.16, 37.37, 39.85, 49.70, 52.48, 52.50, 
117.22, 126.02, 128.30, 129.16, 135.70, 140.16, 169.82, 169.89. IR: 3066, 3028, 
2953, 2924, 1733, 1657, 1638, 1621, 1605, 1497, 1436 cm-1. LRMS (LC-SQMS, 
m/z); found: [M+H], 291.37, calculated for C17H23O4, 291.16, found: [M+Na], 313.38, 








Synthesis of methyl (S)-4-benzylhept-6-enoate ((S)-25). (R)-24 (269 mg, 
0.93 mmol) was dissolved in DMSO (15 mL) followed by addition of LiCl (394 mg, 
9.3 mmol) and water (167 µL, 9.3 mmol). The reaction was heated under reflux (150-
160 °C) overnight. Water (20 mL) was added to the reaction and the product was 
extracted with ethyl acetate (2 x 30 mL). The organic layer was evaporated and the 
product was purified by Flash silica-gel chromatography (ethyl acetate:hexanes 
1:15) which yielded (S)-25 in 75% yield (162 mg). 1HNMR (400 MHz, CDCl3)  
(ppm): 1.64 (m, 2H), 1.77 (m, 1H), 2.04 (m, 2H), 2.33 (m, 2H), 2.57 (m, 2H), 3.65 (s, 
3H), 5.04 (m, 2H), 5.78 (m, 1H), 7.19 (m, 3H), 7.24 (t, J = 7.2 Hz, 2H); 13CNMR (100 
MHz, CDCl3) δ (ppm): 28.14, 31.61, 37.20, 39.07, 39.91, 51.52, 116.76, 125.89, 
128.27, 129.17, 136.29, 140.67, 174.17. IR: 3062, 3027, 2953, 2924, 2855, 1735, 
1658, 1640, 1595, 1574, 1511, 1497, 1445 cm-1. LRMS (LC-SQMS, m/z); found: 
[M+Na], 255.12, calculated for C15H20O2Na, 255.14. 
 
Synthesis of methyl (R)-4-benzylhept-6-enoate ((R)-25). The procedure 
was similar to that of (S)-25 except the following reagents were used (S)-24 (617 mg, 
2.13 mmol), LiCl (270 mg, 6.38 mmol), water (115 µL, 6.38 mmol). The reaction 




2H), 1.77 (m, 1H), 2.05 (m, 2H), 2.33 (m, 2H), 2.56 (m, 2H), 3.65 (s, 3H), 5.04 (m, 
2H), 5.77 (m, 1H), 7.17 (m, 3H), 7.26 (m, 2H); 13CNMR (100 MHz, CDCl3) δ (ppm): 
28.13, 31.61, 37.19, 39.07, 39.91, 51.53, 116.76, 125.89, 128.26, 129.16, 136.29, 
140.67, 174.19. IR: 3063, 3027, 2924, 2856, 1736, 1657, 1640, 1596, 1511, 1497, 
1436 cm-1. LRMS (LC-SQMS, m/z); found: [M+Na], 255.26, calculated for 
C15H20O2Na, 255.14. 
 
Synthesis of N-phenylacrylamide (26). The compound was synthesized 
similar to the reported procedure.139 Briefly, aniline (3.03 mL, 33.15 mmol) and 
triethyl amine (6 mL, 66.29 mmol) were dissolved in dry DCM (30 mL) and the 
temperature of the solution was lowered to 0°C. A solution of acryloyl chloride (2.69 
mL, 33.15 mmol) in dry DCM (10 mL) was added drop wise. The reaction 
temperature was increased gradually from 0°C to room temperature and stirring was 
continued overnight at room temperature. Solvent was evaporated and the residue 
was suspended in 10% HCl (20 mL) and then extracted with DCM (2 x 30 mL). The 
combined organic extracts were washed with saturated solution of sodium carbonate 
(20 mL), dried over anhydrous sodium sulfate and evaporated to give the product 26 
as a yellow solid (4.44 g, 91%). 1HNMR (400 MHz, CDCl3)  (ppm): 5.71 (dd, J = 1.6 
and 10.0 Hz, 1H), 6.30 (dd, J = 10.0 and 16.8 Hz, 1H), 6.41 (dd, J = 1.6 and 16.8 
Hz, 1H), 7.12 (t, J = 7.6, 1H), 7.28 (m, 2H), 7.60 (d, J = 8.0 Hz, 2H), 7.98 (s, 1H); 




137.85, 163.86. The spectral data for the synthesized compound was consistent with 
the reported data in literature.139 
 
Synthesis of methyl (S,E)-4-benzyl-8-oxo-8-(phenylamino)oct-6-enoate 
((S)-27). To a solution of (S)-25 (162 mg, 0.7 mmol) in dry DCM (20 mL) was added 
26 (103 mg, 0.7 mmol), then air was replaced with argon. Grubbs' second-
generation catalyst (35 mg, 5 mol%) was added and the reaction was heated to 50-
60°C for 20 hours. A second addition of Grubbs' second generation catalyst (35 mg, 
5 mol%) was done and the reaction was heated to 50-60°C for 28 hours. The solvent 
was evaporated and the product was purified by Flash silica-gel chromatography 
(ethyl acetate:hexanes 1:15 followed by 1:7-1:3) which yielded (S)-27 in 46% yield 
(112 mg). 1HNMR (400 MHz, CDCl3)  (ppm): 1.67 (m, 2H), 1.88 (m, 1H), 2.18 (m, 
2H), 2.33 (t, J = 8.0 Hz, 2H), 2.51 (dd, J = 7.6 and 13.6 Hz, 1H), 2.63 (dd, J = 6.4 
and 13.6 Hz, 1H), 3.66 (s, 3H), 5.92 (d, J = 15.2 Hz, 1H), 6.91 (m, 1H), 7.12 (m, 3H), 
7.21 (t, J = 7.2 Hz, 1H), 7.31 (m, 4H), 7.36 (s, 1H), 7.57 (dd, J = 7.6 Hz, 2H); 
13CNMR (100 MHz, CDCl3) δ (ppm): 28.45, 31.67, 35.61, 38.93, 40.07, 51.65, 
119.81, 124.27, 126.00, 126.16, 128.41, 129.01, 129.13, 138.02, 140.03, 143.84, 
163.75, 173.97. IR: 3301, 3136, 3062, 3027, 2926, 1733, 1670, 1640, 1600, 1542, 
1497, 1441 cm-1. LRMS (LC-SQMS, m/z); found: [M+H], 352.07, calculated for 





Synthesis of methyl (R,E)-4-benzyl-8-oxo-8-(phenylamino)oct-6-enoate 
((R)-27). A similar to that of (S)-27 was followed except the following reagents were 
used (R)-25 (321 mg, 1.38 mmol), 26 (204 mg, 1.38 mmol), and Grubbs' second-
generation catalyst (59 mg, 5 mol%). The reaction afforded (R)-27 in 48% yield (233 
mg). 1HNMR (400 MHz, CDCl3)  (ppm): 1.66 (m, 2H), 1.87 (m, 1H), 2.17 (m, 2H), 
2.34 (t, J = 8.0 Hz, 2H), 2.52 (dd, J = 7.6 and 13.6 Hz, 1H), 2.62 (dd, J = 6.4 and 
13.6 Hz, 1H), 3.65 (s, 3H), 5.93 (d, J = 15.2 Hz, 1H), 6.91 (m, 1H), 7.11 (m, 3H), 
7.20 (t, J = 7.6 Hz, 1H), 7.30 (m, 4H), 7.51 (s, 1H), 7.58 (d, J = 7.2 Hz, 2H); 13CNMR 
(100 MHz, CDCl3) δ (ppm): 28.43, 31.66, 35.60, 38.92, 40.04, 51.66, 119.85, 
124.26, 126.01, 126.15, 128.41, 129.00, 129.13, 138.06, 140.03, 143.79, 163.83, 
173.00. IR: 3401, 3062, 3026, 2924, 2856, 1736, 1658, 1640, 1597, 1574, 1512, 
1437 cm-1. LRMS (LC-SQMS, m/z); found: [M+H], 352.07, calculated for C22H26NO3, 
352.19, found: [M+Na], 374.02, calculated for C22H25NO3Na, 374.17. 
 
Synthesis of (R)-4-benzyl-N1-hydroxy-N8-phenyloctanediamide ((R)-19f). 
(S)-27 (112 mg, 0.32 mmol) was dissolved in MeOH (15 mL), then Pd (30 mg of 20 
wt.% Pd on carbon) was added to the solution. Air inside the flask was purged with 




under hydrogen overnight. The reaction was filtered, and the solvent was 
evaporated. The crude product was used in the next reaction with no purification. 
In an acid washed flask, hydroxylamine HCl (222 mg, 3.19 mmol) was 
dissolved in MeOH (10 mL). KOH (358 mg, 6.38 mmol) was added at 0°C and 
allowed to stir for 10 minutes. An alcoholic solution of the crude product from the 
previous reaction (in 5 mL MeOH) was added, and the reaction was stirred for 3.5 
hours at 0°C, then another premixed solution of hydroxylamine HCl (222 mg, 3.19 
mmol) and KOH (358 mg, 6.38 mmol) was added followed by stirring for 4 hour at 
0°C. The pH of the reaction mixture was adjusted to 6 with concentrated aqueous 
HCl, followed by dilution with distilled de-ionized water (10 mL). The reaction was 
extracted with ethyl acetate (2 x 20 mL). The product was purified by silica gel flash 
chromatography (acetone:dichloromethane 1:4-1:2) using iron-free silica gel to afford 
(R)-19f (84 mg, 74% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.32 (m, 
2H), 1.69 (m 5H), 2.12 (m, 2H), 2.29 (m, 2H), 2.52 (dd, J = 7.2 and 13.2 Hz, 2H), 
2.61 (dd, J = 6.4 and 13.6 Hz, 2H), 7.05-7.15 (m, 4H), 7.21 (t, J = 7.2 Hz, 2H), 7.28 
(t, J = 7.6 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 
22.28, 28.84, 29.77, 31.72, 36.63, 38.93, 39.57, 119.92, 123.73, 125.46, 127.86, 
128.35, 128.85, 138.43, 140.65, 171.70, 173.13. IR: 3230, 3061, 3026, 2925, 2864, 
1648, 1598, 1543, 1497, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C21H26N2O3Na







Synthesis of (S)-4-benzyl-N1-hydroxy-N8-phenyloctanediamide ((S)-19f). 
similar to that of (R)-19f was followed except the following reagents were used (R)-27 
(283 mg, 0.8 mmol), Pd (58 mg of 20 wt.% Pd on carbon). Hydroxylamine HCl (557 
mg, 8.02 mmol) and KOH (900 mg, 16.03 mmol) were added once only and the 
reaction was stirred for 3 hours at 0°C. The product was purified by silica gel flash 
chromatography (acetone:dichloromethane 1:4-1:2) using iron-free silica gel to afford 
(S)-19f (133 mg, 47% over two steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.33 (m, 
2H), 1.59-1.82 (m 5H), 2.14 (m, 2H), 2.30 (m, 2H), 2.53 (dd, J = 7.2 and 13.6 Hz, 
2H), 2.61 (dd, J = 6.8 and 13.6 Hz, 2H), 7.05-7.16 (m, 4H), 7.21 (t, J = 7.2 Hz, 2H), 
7.28 (t, J = 7.6 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 22.28, 28.83, 29.76, 31.71, 36.62, 38.93, 39.57, 119.91, 123.73, 125.46, 
127.86, 128.34, 128.84, 138.43, 140.65, 171.70, 173.13. IR: 3232, 3026, 2926, 2865, 
1645, 1598, 1543, 1497, 1443 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C21H26N2O3Na
+, 377.1841, found 377.1848. HPLC analytical purity analysis 95.6%. 
3.8.3. Procedures for biological screenings 
3.8.3.1. HeLa cell lysis  
Details were provided in Section 2.7.3.1 of Chapter 2. 
3.8.3.2. Global HDAC inhibition 
To measure global HDAC inhibition, HeLa cell lysates (1 µg total protein) 
were mixed with HDAC-Glo™ buffer (Promega) in polystyrene 96-well half area 




DMSO (0.5 µL) and incubation for 15 min at room temperature without rocking. An 
uninhibited control reaction was also included that contained DMSO (0.5 µL) in 
HDAC-Glo™ buffer (12 µL). Deacetylase activity was measured using the HDAC-
Glo™ assay kit as per the manufacturer’s protocol (Promega). Specifically, the 
HDAC-Glo™ substrate (1 mL) and developer (1 µL) were first premixed to form the 
HDAC-Glo™ reagents. Then, to monitor deacetylase activity, HDAC-Glo™ reagent 
(5µL) and HDAC-Glo™ buffer (7.5 µL) were added to each well (25 µL total volume) 
and incubated for 35 min at room temperature without rocking. The deacetylase 
activity was measured as luminescent signal using a GeniosPlus Fluorimeter 
(Tecan) at optimal gain. The concentrations of inhibitors reported in the dose-
dependent studies are final concentrations after addition of HDAC-Glo™ reagent 
and HDAC-Glo™ buffer. The luminescent signal was first background corrected with 
the signal from a negative control reaction where no lysates was added to that 
reaction.  Percent deacetylase activity was calculated by dividing the background 
corrected signal for each reaction by the background corrected signal of the 
uninhibited control, and then multiplying by 100. IC50 values were calculated by fitting 
the percent deacetylase activity remaining as a function of inhibitor concentration to 
a sigmoidal dose-response curve (y = 100/(1+(x/IC50)
z), where y = percent 
deacetylase activity and x = inhibitor concentration) using non-linear regression with 





3.8.3.3. Inhibitor testing with HDAC isoforms  93 
Details were provided in Section 2.7.3.2 of Chapter 2. Results are reported in 
Figures 3.2 and B.141-B.147, and Tables 4.2 and B.2-B.9. 
3.8.3.4. In cellulo selectivity testing 
Details were provided in Sections 2.7.3.3-2.7.3.5 of Chapter 2. Results are 
reported in Figures 3.3 and B.148. 
3.8.3.5. In vitro cell growth inhibition 
Details were provided in Section 2.7.3.6 of Chapter 2. Results are reported in 
Figures B.149-B.152 and Tables 3.3 B.11-B.12. 
3.8.4. Docking procedure 
The AutoDock 4.2 and Autodock tools programs 119, 127 were used to perform 
the docking studies. HDAC6 catalytic domain 2 (CD2) (PDB: 5G0H)13 and HDAC3 
(PDB: 4A69)100 crystal structures were downloaded from the protein data bank. 
PyMOL program (Schrodinger, LLC) was used to delete the co-crystallized inhibitor 
(S-trichostatin A), ethylene glycol molecules, potassium ions and all water molecules 
in HDAC6 crystal structure. With HDAC3 crystal, chain A, deacetylase-activation-
domain (DAD) (from the SMRT corepressor), glycerol, D-myo-inositol-1,4,5,6-
tetrakisphosphate and glycerol molecules, acetate, potassium and sulfate ions, and 
all water molecules were deleted. Only the zinc atom remained in both crystal 
structures. AutoDockTools-1.5.4 program 119, 127 was used to add all polar hydrogen 
atoms, modify histidine protonation (H573 and H574 residues of HDAC6, and H134 
and H135 of HDAC3) by adding only HD1, compute Gasteiger charges, and merge 
all non polar hydrogen, followed by generation of the pdbqt output file. The charge of 




spacing of 0.375 Å, size of 42 x 40 x 44, and coordinates for the center of the grid 
box (-13.000, -2.000, -5.000) were used. For HDAC3, a grid box of size 58 X 58 X 
54 Å3 with a spacing of 0.375 Å and centered at (8.166, 76.663, 21.318) were used. 
The rest of binding sites preparation procedure and all docking parameters were 





CHAPTER 4 - SYNTHESIS AND BIOLOGICAL EVALUATION OF 
SAHA DERIVATIVES SUBSTITUTED AT C5 POSITION 
Some of the text in this chapter was reprinted or modified from: Negmeldin, A. T. 
and Pflum, M. K. H., The structural requirements of histone deacetylase Inhibitors: 
SAHA analogs modified at the C5 Position Display dual HDAC6/8 Selectivity, 
Bioorganic & medicinal chemistry letters 2017 (Accepted). 
4.1. Rationale for synthesis and screening of C5-modified SAHA analogs 
Guided by the promising modifications of the C4 position in the linker of 
SAHA that led to substantial improvement in selectivity with a modest reduction in 
potency compared to SAHA, we explored the effect of modifications on the C5 
position in the linker (Figure 4.1). Based on the experimental and computational 
studies done for the C4-modified SAHA analogs, we expected that the C5-modified 
SAHA analogs would show similar selectivity to HDAC6 and HDAC8. As discussed 
in the previous two chapters, some of the C2-SAHA analogs showed about 30-fold 
reduction in potency against HDAC6, while some of  the C4-SAHA analogs showed 
only about 2.5-fold reduction in potency against HDAC6 compared to SAHA. The 
question that needed to be answered was to what extent modification of SAHA at 
the C5 position would affect both potency and selectivity. In this chapter, SAHA 
analogs substituted at the C5 of the linker region were synthesized (Figure 4.1 and 
scheme 4.1) and tested for potency and selectivity both in vitro and in cellulo. 
Several analogs showed dual HDAC6/8 selectivity over HDAC1, 2, and 3, with a 
modest reduction in HDAC6 inhibition but enhanced HDAC8 inhibition compared to 
SAHA. This chapter documents that modifying the linker region of SAHA can alter its 





Figure ‎4.1. Chemical structures of C5-modified SAHA analogs (34a-e). 
4.2. Synthesis of C5-substituted SAHA derivatives 
C5-modified SAHA analogs 43a-e were synthesized as shown in Scheme 4.1. 
The synthesis started from a coupling reaction of 4-pentenoic acid 28 with aniline 
using TBTU to obtain amide 92. Intermediate amide 29 was then reacted with 
crotonaldehyde 13 via a cross metathesis reaction using Grubbs' second-generation 
catalyst to afford the α,β-unsaturated aldehyde 43. Aldehyde 43 was substituted with 
different groups through a 1,4-conjugate addition using organolithium or 
organomagnesium cuprates, which yielded intermediates 31a-e. Horner–
Wadsworth–Emmons olefination of 31a-e with trimethyl phosphonoacetate 32 
followed by reduction gave amide esters 33a-e with a saturated linker. Finally, amide 
esters 33a-e were reacted with hydroxylamine to afford the C5-substituted SAHA 











Scheme ‎4.1. Synthesis of C5-SAHA analogs (34a-e)  
 
 
4.3. In vitro screening of C5-modified SAHA derivatives 
As a preliminary screen, the new analogs were tested for their global HDAC 
inhibition with HeLa cell lysates as the source of all HDAC proteins (Table 4.1). 
SAHA was also tested as the parent unsubstituted control molecule. The inhibitory 
activities of the analogs were measured with the HDAC-Glo™ I/II substrate (see 
section 2.2). C5-methyl SAHA analog 34a showed greater potency compared to 
SAHA (100 nM vs. 200 nM IC50 values, Table 4.1). However, all other analogs 
showed weaker potency than SAHA (11- to 33-fold reduction in potency), with IC50 
values from 2.2 to 6.5 µM (Table 4.1). The observed lower potencies of compounds 
34b-34e may be due to selectivity for specific HDAC isoform(s), which lowered the 




here was similar to what was observed with both the C2- and the C4-modified SAHA 
analogs (see sections in 2.2 and 3.3 Chapters 2 and 3).  









a Mean IC50 value and standard error of at least three independent trials are shown 
(Figure C.52 and Table C.1). 
To test isoform selectivity, the parent molecule, SAHA, and all the C5-
modified SAHA analogs were tested at a single concentration using the recently 
developed ELISA-based HDAC activity assay (see section 2.2).93 SAHA, as 
expected, showed no selectivity among HDAC1, 2, 3, and 6 (Figure 4.2).93 
Interestingly, several C5-SAHA analogs displayed more potent inhibition against 
HDAC6 compared to HDAC1, HDAC2, and HDAC3 (Figure 4.2). The analogs that 
showed the greater difference in potency with HDAC6 versus the other isoforms 
were C5-n-butyl (34b), C5-n-hexyl (34c), and C5-benzyl (34e). The C5-methyl SAHA 
(34a) and C5-phenyl SAHA (34d) showed only a small difference in potency 
comparing HDAC6 to the others (Figure 4.2). 
Compound R IC50 (µM) 
SAHA  0.20 ± 0.02 
34a methyl 0.10 ± 0.01 
34b n-butyl 5.0 ± 0.4 
34c n-hexyl 6.5 ± 0.1 
34d Phenyl 2.2 ± 0.1 





Figure ‎4.2. In vitro isoform selectivity screening of C5-modified SAHA analogs (34a-
e) against HDAC1, HDAC2, HDAC3, and HDAC6 using the ELISA-based HDAC 
activity assay. Analogs 34a-e were tested at 0.025, 0.25, 1.25, 0.125, and 1.25 µM 
final concentrations, respectively. SAHA was tested at 1 µM concentration in a 
previous report using the same assay procedure.93 Mean percent deacetylase 
activities from a minimum of two independent trials with standard errors were plotted 
(Table C.2). 
IC50 values for the most selective derivatives 34b, 34c, and 34e were 
determined with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms to 
quantitatively assess the selectivity (Table 4.2). The IC50 values of SAHA as the 
parent compound were included as well (Table 4.2).93 SAHA displayed similar IC50 
values against HDAC1, 2, 3, and 6, with 6- to 27-fold selectivity against HDAC8 
(Tables 4.2 and C.6).93, 112  Both C5-n-butyl (34b) and C5-n-hexyl (34c) SAHA 
analogs displayed the modest selectivity, with 3- to 5-fold and 5- to 7-fold 
selectivities for HDAC6 and HDAC8 over HDAC1, 2, and 3 (Tables 4.2, C.3, C.4 and 















































in HDAC6 potency (IC50 values of 320 nM and 410 nM), but similar potency against 
HDAC8 (430 and 420 nM) compared to SAHA. The most potent and selective 
analog was C5-benzyl SAHA (34e), which displayed 8- to 21-fold selectivity for 
HDAC6 and HDAC8 over HDAC1, 2, and 3 and IC50 values of 270 and 380 nM with 
HDAC6 and HDAC8, respectively (Tables 4.2, C.5 and C.6, and Figure C.55). The 
selectivity was due to a dramatic reduction in potency with HDAC1, 2, and 3 (14- to 
80-fold), but only a modest potency reduction in HDAC6 (8.5- to 12-fold) and similar 
potency with HDAC8 (380 – 540 nM), compared to SAHA. Modification of SAHA at 
the C5 position of the linker region led to selectivity for HDAC6 and 8 over HDAC1, 
2, and 3. 
Table ‎4.2. IC50 values for SAHA and C5-modified SAHA analogs 34c, 34d, and 34e 
against HDAC1, 2, 3, 6 and 8.a 
a Mean IC50 value and standard error of at least three independent trials are shown 
(Figures C.53-C.55 and Tables C.3-C.5). b Previously reported IC50 values using the 
same assay procedure.93 
4.4. In cellulo selectivity testing 
To test the analogs in a more biological context, the C5-benzyl (34e) SAHA 
analog was tested for selectivity in cells. The inhibition of HDAC6 was monitored by 
detecting the levels of its known substrate acetyl-α-tubulin (AcTub), whereas Class I 
HDAC (HDAC1, 2, and 3) inhibition was monitored by observing the known 
substrate, acetyl-histone 3 (AcH3). SAHA or C5-benzyl SAHA 34e were incubated 
Compound 
IC50 values (µM) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
SAHAb 33 ± 1 96 ± 10 20 ± 1 33 ± 3 540 ± 10 
34b (n-butyl) 1,100 ± 100 1,300 ± 100 1,600 ± 100 320 ± 30 430 ± 10 
34c (n-hexyl) 2,100 ± 100 2,500 ± 100 2,900 ± 300 410 ± 60 420 ± 20 




with U937 leukemia cells before lysis and western blot analysis of protein acetylation 
(Figure 4.3). As expected, SAHA increased the levels of both acetyl-α-tubulin and 
acetyl-histone H3 to a similar extent (Figure 4.3, lane 1), which is consistent with its 
non-selective inhibition of HDAC1, 2, 3, and 6 isoforms. On the other hand, C5-
benzyl SAHA analog 34e showed a dose-dependent selective increase in levels of 
acetyl-α-tubulin (Figure 4.3, lanes 3-5, AcTub), which was greater than the increased 
levels of acetyl histone H3 (Figure 4.3, lanes 3-5, AcH3) compared to the DMSO 
control (Figure 4.3, lane 2). The observed HDAC6 selectivity of the C5-benzyl SAHA 
34e in cells is consistent with the selectivity observed in the in vitro screening (Table 
4.2 and Figure 4.3).  
 
Figure ‎4.3. Cell based selectivity assessment of the C5-benzyl SAHA analog. 
Western blot analysis of acetyl-lysine 9 of histone H3 (AcH3), and acetyl-lysine 40 of 
α-tubulin (AcTub) after treatment with SAHA or C5-benzyl SAHA 34e.  U937 cells 
were treated with DMSO (1%), SAHA (5 µM), or increasing concentrations of C5-
benzyl SAHA (34e) analog (10-40 µM), before lysis, SDS-PAGE separation, transfer 
to a PVDF membrane, and western analysis with AcH3 or AcTub antibodies. 
GAPDH levels in the samples were also probed as a gel load control. A DMSO 
control sample was included for comparison to inhibitor-treated samples. Repetitive 
trials are shown in Figure C.56. 
4.5. In vitro cancer cell growth inhibition 
To evaluate the ability of the C5-modified SAHA analogs to influence cell 
growth, the most selective analogs were tested. C5-n-butyl (34b), C5-n-hexyl (34c), 
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MTT assay with T-cell lymphoma derived cancer Jurkat cell line (Figure 4.4). The 
tested analogs displayed cytotoxicity against the cell line, with 39%, 24%, and 50% 
cell viability with C5-n-butyl SAHA (34b), C5-n-hexyl SAHA (34c),  and C5-benzyl 
SAHA (34e) at 10 µM concentrations, respectively (Figure 4.4 and Table C.7). On 
the other hand, SAHA demonstrated higher cytotoxicity than the C5-modified SAHA 
analogs, with 49% cell viability at 1 µM. The reduced cytotoxicity of the analogs 
compared to SAHA can be due to their lower potency (8- to 12-fold reduction in IC50 
values with HDAC6 compared to SAHA, Table 4.2). In addition, the nonselective 
inhibition of most HDAC isoforms by SAHA might contribute to its higher cytotoxicity 
(Table 4.2 and Figure 4.4). 
 
Figure ‎4.4. Cytotoxicity screening of SAHA and C5-modified SAHA analogs 34b, 
34c, and 34e with the Jurkat cells. Compounds were tested at 1 and 10 µM 
concentrations using MTT assay. Mean percent cell viability from a minimum of 
three independent trials with standard errors were plotted (Table C.7). 
In conclusion, C5-modified SAHA analogs displayed dual HDAC6/8 
selectivity. The best compound was C5-benzyl SAHA (34e), which showed up to 21-
fold selectivity for HDAC6 and 8 compared to HDAC1, 2, and 3, and IC50 values of 




































SAHA analogs 34b-e exhibited 8- to 12-fold reduction in potency towards HDAC6, 
while similar IC50 values with HDAC8 were observed. C5-benzyl SAHA (34e) was 
tested for isoform selectivity in cells and showed selectivity consistent to what was 
observed in vitro. The fold selectivities observed with the C5-modified SAHA analogs 
were reduced compared to previously reported HDAC6/8-selective C2-modified 
SAHA analogs (49- to 300- fold selective for HDAC6 and 8 over HDAC1, 2, and 3 for 
the C2-hexyl SAHA).112 On the other hand, the C5-modified SAHA analogs were 
more potent against HDAC6 and 8 (270 to 430 nM IC50 values) compared to C2-
modifed SAHA analogs (600 to 2,000 nM IC50 values for C2-hexyl SAHA). Moreover, 
by comparing the effect of modifications on the C5 position of the linker region of 
SAHA to the C4 analogs mentioned in Chapter 3, we can conclude that modifying 
the C4 position led to more potent inhibition of both HDAC6 and HDAC8 compared 
to the C5 analogs (57 to 140 nM vs. 270 to 430 nM IC50 values for HDAC6 and 8) 
(Tables 3.2 and 4.2). In addition, the fold selectivities of the C4-SAHA analogs to 
HDAC6 and HDAC8 over HDAC1, 2, and 3 were higher compared to C5-SAHA 
analogs with the same modifications (171- to 740-fold vs. 3- to 21-fold for C4- and 
C5- butyl, hexyl, and benzyl)(Tables 3.2, 4.2, B.10 and C.6). The position of the 
modification in the linker region of SAHA is critical and can greatly affect both 
potency and selectivity of the analogs. In general, this study, along with chapters 2, 
3, and previous reports104-105, 112, indicate that modifying SAHA in the linker region 
can alter the selectivity of HDAC inhibitors. In particular, the reduced potency of 
SAHA against HDAC8 was switched in the C5-modified analogs to poor potency 




selective inhibitors can be used as biological tools to study both HDAC6 and 
HDAC8-related cancer biology, and as leads for development of more effective anti-
cancer agents targeting both HDAC6 and HDAC8. 
4.6. Experimental Procedures 
4.6.1. Materials and instrumentation 
Details were provided in Section 2.7.1 of Chapter 2. 
4.6.2. Synthesis procedure 
 
Synthesis of N-phenylpent-4-enamide (29): TBTU (614 mg, 1.91 mmol) 
was dissolved in dry dichloromethane (10 mL), followed by addition of pent-4-enoic 
acid 28 (127 mg, 1.27 mmol), DIPEA (329 mg, 2.55 mmol), and aniline (178 mg, 
1.91 mmol). The reaction was stirred for 4.5 hours. The reaction was quenched with 
1M HCl (20 mL) and extracted with dichloromethane (3X30 mL). The organic extract 
was dried over anhydrous Na2SO4 and concentrated. The product was purified by 
silica-gel flash chromatography (ethyl acetate/hexanes 1:4) to afford 29 (162 mg, 
73%). 1HNMR (400 MHz, CDCl3) δ (ppm): 2.38 (m, 4H), 4.96 (d, J = 9.6 Hz, 1H), 
5.02 (d, J = 16.4 Hz, 1H), 5.80 (m, 1H), 7.01 (t, J = 7.2 Hz, 1H), 7.22 (t, J = 8.0 Hz, 
2H), 7.43 (d, J = 8.4 Hz, 2H), 7.57 (br s, 1H). 13CNMR (100 MHz, CDCl3) δ (ppm): 
29.48, 36.74, 115.88, 119.99, 124.27, 128.95, 136.85, 137.90, 170.84. The spectral 






Synthesis of (E)-6-oxo-N-phenylhex-4-enamide (30): In a flame dried 2-
neck 100 mL flask and condenser, air was replaced with argon and Grubbs' 
second-generation catalyst (58.2 mg, 0.068 mmol, 1.5 mol%) was dissolved in dry 
dichloromethane (20 mL), followed by the addition of crotonaldehyde 13 (3.20 g, 45.68 
mmol) and 29 (800 mg, 4.57 mmol). The reaction was heated with reflux for 11 hours 
under argon. The reaction was cooled to room temperature, concentrated, and 
purified by silica-gel flash chromatography (ethyl acetate /Hexanes 1:1.5) to afford 30 
(845 mg, 91%). 1HNMR (400 MHz, CDCl3) δ (ppm): 2.56 (t, J = 7.2 Hz, 2H), 2.74 (q, 
J = 6.8 Hz, 2H), 6.14 (dd, J = 7.6 Hz, 1H), 6.91 (dt, J = 15.6 and 6.4 Hz, 1H), 7.11 (t, 
J = 7.2 Hz, 1H), 7.31 (t, J = 7.6 Hz, 2H), 7.50 (d, J = 7.6 Hz, 2H), 7.68 (br s, 1H), 
9.49 (d, J = 7.6 Hz, 1H). 13CNMR (100 MHz, CDCl3) δ (ppm): 27.95, 34.94, 119.95, 
124.53, 129.04, 133.22, 137.64, 156.71, 169.37, 194.03. IR: 3313, 3064, 2971, 2928, 
1668, 1598, 1545, 1498, 757, 694 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ 





Synthesis of methyl 5-methyl-8-oxo-8-(phenylamino)octanoate (33a): In 
a 200 mL 2-neck dry flask, Copper(I)bromide dimethyl sulfide complex (1.52 g, 7.39 
mmol) was dissolved in dry THF (20 mL). Air was replaced with argon, and then 




321 mg, 14.78 mmol) was added drop wise with stirring, and the mixture was 
allowed to stir for additional 20 minutes at -15°C. The temperature was then 
reduced to -78°C followed by the addition of chlorotrimethylsilane (2.40 g, 
22.17 mmol) drop wise, and then 30 (500 mg, 2.46 mmol). The reaction was 
allowed to stir for 3.5 hours at -78°C. The reaction was quenched with a solution 
of saturated ammonium chloride in ammonia (1:1) portion wise until the reaction 
color turned blue. The organic layer was collected and the aqueous layer was 
extracted with ethyl acetate (3X30 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and rotavaped to an oily crude product 31a, which 
was used in the next reaction. 
In a 200 mL 2-neck flame dried flask, air was replaced with argon, NaH (168 
mg of 60% NaH, 4.19 mmol) dissolved in dry THF (25 mL) was added, and the 
reaction was cooled to 0°C. Trimethyl phosphonoacetate (763 mg, 4.19 mmol) was 
added dropwise with stirring. The reaction was allowed to stir for 15 minutes at 
0°C, and then the crude product 31a from the previous reaction dissolved in dry 
THF (8 mL) was added. The reaction was stirred for another 30 minutes at 0°C, 
followed by stirring for 90 minutes at room temperature. The reaction was 
quenched with a saturated aqueous ammonium chloride solution (15 mL) and 
the organic layer was collected. The aqueous layer was extracted with ethyl acetate 
(3 times with 30 mL) and the combined organic layers were dried over anhydrous 
MgSO4, filtered, and concentrated. The crude product was used in the following 




In a 50 mL flask the crude product from the previous reaction was dissolved 
in MeOH (20 mL), and then Pd(OH)2 (173 mg of 20 wt.% Pd(OH)2 on carbon, 0.25 
mmol) was added. Air inside the flask was replaced with argon (3 times), and then 
with hydrogen gas (three times). The reaction was allowed to stir under hydrogen 
for 3.5 hours at room temperature. The reaction was filtered through a celite plug 
and the solvent was evaporated. The product was purified by silica-gel flash 
chromatography (ethyl acetate/hexanes 1:4) to afford 33a (295 mg, 43% over three 
steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.94 (d, J = 5.6 Hz, 3H), 1.19 (m, 1H), 
1.35 (m, 1H), 1.50 (m, 2H), 1.70 (m, 3H), 2.36 (m, 4H), 3.64 (s, 3H), 7.07 (t, J = 7.6 
Hz, 1H), 7.28 (t, J = 8.4 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H). 13CNMR (100 MHz, 
CD3OD) δ (ppm): 18.25, 22.04, 32.17, 32.38, 33.53, 34.27, 35.74, 50.58, 119.82, 
123.69, 128.35, 138.51, 173.40, 174.52. IR: 3302, 2953, 2930, 2870, 1736, 1719, 
1661, 1599, 1543, 1499, 1441, 754, 692 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ 





Synthesis of methyl 5-(3-oxo-3-(phenylamino)propyl)nonanoate (33b): 
The procedure was similar to 33a except n-butyllithium (5.9 mL of 2.5 M solution, 
0.95 g, 14.78 mmol) was used in place of methyllithium. The product was purified by 
silica-gel flash chromatography (ethyl acetate/hexanes 1:5) to afford 33b (493 mg, 
63% over three steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.91 (t, J = 6.80 Hz, 




7.29 (t, J = 7.2 Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 13.05, 21.63, 22.70, 28.47, 29.17, 32.37, 32.64, 33.59, 33.95, 36.79, 50.57, 
119.82, 123.67, 128.34, 138.51, 173.40, 174.52. IR: 3302, 3138, 3062, 2955, 2928, 
2860, 1737, 1721, 1663, 1600, 1543, 1499, 1442, 754, 692 cm-1. LRMS (ESI, m/z): 
calculated for [M+H]+ C19H30NO3, 320.22, found 320.26; calculated for [M+Na]
+ 
C19H29NO3Na
+, 342.20, found 342.26. 
 
Synthesis of methyl 5-(3-oxo-3-(phenylamino)propyl)undecanoate (33c): 
The procedure was similar to 33a except the following reagents were used: 
Copper(I)bromide dimethyl sulfide complex (1.37 g, 6.65 mmol), n-hexyllithium 
(5.78 mL of 2.3 M solution, 1.23 g, 13.30 mmol), chlorotrimethylsilane (2.16 g, 19.95 
mmol), 30 (450 mg, 2.22 mmol), NaH (151 mg of 60% NaH, 3.77 mmol), trimethyl 
phosphonoacetate (686 mg, 3.77 mmol), and Pd(OH)2 (156 mg of 20% Pd(OH)2/C, 
0.22 mmol). The product was purified by silica-gel flash chromatography (ethyl 
acetate/hexanes 1:6 to 1:5) to afford 33c (577 mg, 75% over three steps). 1HNMR 
(400 MHz, CD3OD) δ (ppm): 0.89 (t, J = 7.2 Hz, 3H), 1.33 (m, 13H), 1.63 (m, 4H), 
2.33 (m, 4H), 3.64 (s, 3H), 7.06 (t, J = 7.6 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.54 (d, J 
= 7.2 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 13.10, 21.63, 22.36, 26.19, 
29.18, 29.42, 31.65, 32.38, 32.95, 33.61, 33.99, 36.79, 50.60, 119.81, 123.66, 
128.35, 138.54, 173.40, 174.49. IR: 3302, 3138, 3061, 2953, 2926, 2856, 1737, 1661, 









Synthesis of methyl 8-oxo-5-phenyl-8-(phenylamino)octanoate (33d):The 
procedure was similar to 33a except the following reagents were used: phenyllithium 
(7.38 mL of 2 M solution, 1.24 g, 14.78 mmol) and Pd(OH)2 (692 mg of 20% 
Pd(OH)2/C, 0.99 mmol). The product was purified by silica-gel flash chromatography 
(ethyl acetate/hexanes 1:3) to afford 33d (539 mg, 64% over three steps). 1HNMR 
(500 MHz, CD3OD) δ (ppm): 1.46 (m, 2H), 1.63 (m, 2H), 1.89 (m, 1H), 2.15 (m, 5H), 
2.58 (m, 1H), 3.59 (s, 3H), 7.05 (t, 1H), 7.18 (d, J = 7.2 Hz, 3H), 7.27 (m, 4H), 7.48 
(d, J = 8.0 Hz, 2H). 13CNMR (125 MHz, CD3OD) δ (ppm): 22.68, 32.22, 33.27, 34.61, 
35.84, 45.24, 50.54, 119.81, 123.63, 126.06, 127.44, 128.21, 128.31, 138.46, 144.25, 
172.85, 174.35. IR: 3303, 3137, 3028, 2928, 2859, 1737, 1663, 1600, 1545, 1500, 
756, 693 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C21H26NO3, 340.19, found 
340.14; calculated for [M+Na]+ C21H25NO3Na
+, 362.17, found 362.12. 
 
Synthesis of methyl 5-benzyl-8-oxo-8-(phenylamino)octanoate (33e):The 
procedure was similar to 33a except benzylmagnesium chloride (14.78 mL of 1 M 




purified by silica-gel flash chromatography (ethyl acetate/hexanes 1:3) to afford 33e 
(274 mg, 32% over three steps). 1HNMR (400 MHz, CD3OD) δ (ppm): 1.31 (q, J = 
5.6 Hz, 2H), 1.67 (m, 5H), 2.26 (t, J = 7.2 Hz , 2H), 2.39 (m, 2H), 2.60 (m, 2H), 3.61 
(s, 3H), 7.07 (t, J = 7.2 Hz, 1H), 7.15 (m, 3H), 7.26 (m, 4H), 7.51 (d, J = 8.4 Hz, 2H). 
13CNMR (100 MHz, CD3OD) δ (ppm): 21.50, 28.93, 31.87, 33.50, 33.94, 39.08, 
39.69, 50.54, 119.88, 123.70, 125.47, 127.86, 128.34, 128.81, 138.47, 140.74, 
173.24, 174.47. IR: 3302, 3027, 2927, 2866, 1734, 1661, 1599, 1542, 1498, 1442, 755, 
694 cm-1. LRMS (ESI, m/z): calculated for [M+H]+ C22H28NO3, 354.21, found 354.20; 
calculated for [M+Na]+ C22H27NO3Na
+, 376.19, found 376.19. 
 
Synthesis of N8-hydroxy-4-methyl-N1-phenyloctanediamide (34a): In an 
acid-washed flask, hydroxylamine HCl (877 mg, 12.60 mmol) was dissolved in 
MeOH (10 mL). KOH (1.42 g, 25.24 mmol) was added at 0°C and left to stir for 
20 minutes. An alcoholic solution of 33a (350 mg, 1.26 mmol, in 10 mL methanol) 
was added and the reaction was left to stir for 2.5 hours at 0°C. The pH of the 
reaction mixture was adjusted to 6.0 with concentrated aqueous HCl, followed by 
dilution with distilled de-ionized water (30 mL). The reaction was extracted with ethyl 
acetate (3X30 mL). The organic extracts were collected together and dried over 
anhydrous Na2SO4. The product was purified with acid-washed silica-gel flash 
chromatography (acetone/DCM 1:3) to afford 34a (214 mg, 61%). 1HNMR (400 MHz, 
CD3OD) δ (ppm): 0.94 (d, J = 6.4 Hz, 3H), 1.21 (m ,1H), 1.39 (m, 1H), 1.48-1.78 (m, 




Hz, 2H), 7.52 (d, J = 7.6 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 18.26, 22.75, 
32.09, 32.37, 32.50, 34.24, 35.68, 119.87, 123.69, 128.33, 138.50, 171.54, 173.43. 
IR: 3291, 2955, 2928, 2871, 1736, 1660, 1600, 1546, 1500, 1444, 756, 693 cm-1. 
HRMS (ESI-TOF, m/z): calculated for [M+Na]+ C15H22N2O3Na
+, 301.1528, found 
301.1540.  HPLC analytical purity analysis 97.1%. 
 
Synthesis of 4-butyl-N8-hydroxy-N1-phenyloctanediamide (34b): The 
procedure was similar to 34a except for the following: MeOH (15 mL), hydroxylamine 
HCl (1.0 g, 14.46 mmol), KOH (1.62 g, 28.92 mmol), 33b (462 mg, 1.45 mmol). 
The reaction was stirred for 2 hours at 0°C. The product was purified with acid-
washed silica-gel flash chromatography (acetone/DCM 1:4) to afford 34b (363 mg, 
78%). 1HNMR (400 MHz, CD3OD) δ (ppm): 0.91 (t, J = 6.8 Hz, 3H), 1.34 (m, 9H), 
1.65 (m, 4H), 2.08 (t J = 7.6 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H), 
7.29 (t, J = 7.2 Hz,  2H), 7.53 (d, J = 8.0 Hz,  2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 13.06, 22.34, 22.70, 28.49, 29.18, 32.31, 32.57, 32.70, 33.92, 36.73, 119.85, 
123.70, 128.35, 138.51, 171.56, 173.50. IR: 3242, 2955, 2926, 2858, 1645, 1599, 
1543, 1499, 1443, 1047, 754, 691 cm-1. HRMS (ESI-TOF, m/z): calculated for 
[M+Na]+ C18H28N2O3Na







Synthesis of 4-hexyl-N8-hydroxy-N1-phenyloctanediamide (34c): The 
procedure was similar to 34a except for the following: hydroxylamine HCl (1.06 g, 
15.20 mmol), KOH (1.71 g, 30.40 mmol), 33c (529 mg, 1.52 mmol). The reaction 
was stirred for 3 hours at 0°C. The product was purified with acid-washed silica-gel 
flash chromatography (acetone/DCM 1:4) to afford 34c (326 mg, 61%). 1HNMR (400 
MHz, CD3OD) δ (ppm): 0.88 (t, J = 6.8 Hz, 3H), 1.35 (m, 13 H), 1.64 (m, 4H), 2.08 (t, 
J = 7.2 Hz, 2H), 2.35 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 8.0 Hz, 
2H), 7.53 (d, J = 8.0 Hz, 2H). 13CNMR (100 MHz, CD3OD) δ (ppm): 13.04, 22.33, 
22.36, 26.22, 29.19, 29.40, 31.63, 32.36, 32.58, 33.04, 33.95, 36.75, 119.89, 123.70, 
128.34, 138.50, 171.56, 173.49. IR: 3243, 3199, 3061, 2953, 2925, 2856, 1651, 1600, 
1545, 1499, 1443, 755, 692 cm-1. HRMS (ESI-TOF, m/z): calculated for [M+Na]+ 
C20H32N2O3Na
+, 371.2311, found 371.2311. HPLC analytical purity analysis 96.7%. 
 
Synthesis of N8-hydroxy-N1,4-diphenyloctanediamide (34d): The 
procedure was similar to 34a except for the following: hydroxylamine HCl (1.08 g, 
15.50 mmol), KOH (0.87 g, 15.50 mmol), 33d (526 mg, 1.55 mmol). The reaction 
was stirred overnight at room temperature, then another 820 mg KOH was added 
and left to stir for 7 hours. The product was purified with acid-washed silica-gel 




MHz, CD3OD) δ (ppm): 1.35 (m, 2H), 1.57 (m, 2H), 1.81 (m, 1H), 2.02 (m 5H), 2.49 
(m, 1H), 6.95 (t, J = 7.5 Hz, 1H), 7.08 (m, 3H), 7.18 (m, 4H) 7.38 (d, J = 8.5 Hz, 2H).  
13CNMR (125 MHz, CD3OD) δ (ppm): 23.47, 32.14, 32.28, 34.59, 35.92, 45.20, 
119.84, 123.66, 126.06, 127.45, 128.22, 128.31, 138.44, 144.26, 171.40, 172.91. IR: 
3255, 3065, 3022, 2906, 2847,1683, 1600, 1541, 1499, 1442, 552, 686 cm-1. HRMS 
(ESI-TOF, m/z): calculated for [M+Na]+ C20H24N2O3Na
+, 363.1685, found 363.1680. 
HPLC analytical purity analysis 96.0%. 
 
Synthesis of 4-benzyl-N8-hydroxy-N1-phenyloctanediamide (34e): The 
procedure was similar to 34a except for the following: hydroxylamine HCl (522 mg, 
7.50 mmol), KOH (842 mg, 15.00 mmol), 33e (265 mg, 0.75 mmol). The reaction 
was stirred for 2 hours at 0°C, followed by the second addition of hydroxylamine 
HCl (522 mg, 7.50 mmol), KOH (842 mg, 15.00 mmol) and stirring for additional 
3.5 hours at 0°C. The product was purified with acid-washed silica-gel flash 
chromatography (acetone/DCM 1:3) to afford 34e (183 mg, 69%). 1HNMR (400 MHz, 
CD3OD) δ (ppm): 1.32 (q, J = 8.0 Hz, 2H), 1.69 (m, 5H), 2.02 (m, 2H), 2.39 (m, 2H), 
2.59 (m, 2H), 7.07 (t, J = 7.6 Hz, 1H), 7.14 (m, 3H), 7.23 and 7.28 (overlapped t and 
t, J = 7.2 and 7.6 Hz, 4H), 7.51 (d, J = 7.6 Hz,  2H). 13CNMR (100 MHz, CD3OD) δ 
(ppm): 22.19, 28.91, 31.86, 32.50, 33.90, 39.00, 39.70, 119.89, 123.72, 125.48, 
127.89, 128.35, 128.82, 138.46, 140.72, 171.46, 173.29. IR: 3244, 3061, 3026, 2923, 





+, 377.1841, found 377.1831. HPLC analytical purity 
analysis 98.7%. 
4.6.3. Procedures for biological screenings 
4.6.3.1. HeLa cell lysis 
Details were provided in Section 2.7.3.1 of Chapter 2. 
4.6.3.2. Global HDAC inhibition 
Details were provided in Section 3.6.3.2 of Chapter 3. Results are reported in 
Figures 4.2 and C.52, and Tables 4.2 and C.1. 
4.6.3.3. Inhibitor testing with HDAC isoforms 93 
Details were provided in Section 2.7.3.2 of Chapter 2. Results are reported in 
Figures 4.2 and C.53-C.55, and Tables 4.2 and C.2-C.5. 
4.6.3.4. In cellulo selectivity testing 
Details were provided in Section 2.7.3.3-2.7.3.5 of Chapter 2. Results are 
reported in Figures 4.3 and C.56. 
4.6.3.5. In vitro cell growth inhibition 
Details were provided in Section 2.7.3.6 of Chapter 2. Results are reported in 










CHAPTER 5 - DOCKING STUDY OF N-SUBSTITUTED SAHA 
ANALOGS  102 
Some of the text in this chapter was reprinted or modified from: Bieliauskas, A. V.; 
Weerasinghe, S. V. W.; Negmeldin, A. T.; Pflum, M. K. H., Structural Requirements 
of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid, 
Archiv der Pharmazie (Weinheim, Ger.) 2016, 349, 373-382. 
5.1. Rationale for synthesis, screening, and docking of N-substituted SAHA 
analogs  (35 a-e) 
Towards creating isoform selective inhibitors, the three structural regions of 
HDAC inhibitors (Figure 5.1) have been modified, focusing primarily on the capping 
region and metal binding moiety.12 The high sequence similarity within the active 
sites of the isoforms makes inhibitor design problematic.12 Recently, the structures of 
HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7 and HDAC8 were reported, 13-21 
along with homology models of the other HDAC isoforms.22-23 According to structural 
analysis, a 14Å internal cavity exists deep within the HDAC active site near the 
catalytic metal atom, which functions as an exit channel for release of the acetate 
byproduct after acetyl-lysine deacetylation (see section 1.4 in Chapter 1).98, 142-143 
Important for inhibitor development, several compounds have been designed to 
target the internal cavity by appending large aromatic groups to the metal binding 
moiety.19, 144-145 For example, Cpd-60 (Figure 5.1) displays selectivity for HDAC1 
and HDAC2 compared to HDAC3-8 (Table 1.1) .84, 92 Docking studies of Cpd-60 into 
the HDAC1 and HDAC3 homology models suggested that selectivity was due to 
differential interactions of the aryl group on the metal binding group with residues in 
the 14Å internal cavity.84  A significant conclusion of these studies is that the metal 





Figure ‎5.1. Structures of select HDAC inhibitors with the structural regions indicated 
at the top. 
To further exploit the 14 Å internal cavity for selective inhibitor design, we 
created SAHA analogs functionalized on the amine of the hydroxamic acid metal 
binding moiety. Like the benzamide of Cpd-60 19, crystallographic and modeling 
analyses indicate that the hydroxamic acid is positioned at the base of the active site 
channel adjacent to the internal cavity.15-16, 19-23, 25, 99-100 Given the HDAC1/2 
selectivity of Cpd-60 84, we hypothesized that alkyl or aryl groups attached to the 
hydroxamic acid of SAHA would also impart selectivity. 
In this work, N-substituted SAHA analogs (Figure 5.1) were synthesized by 
Dr. Anton Bieliauskas and screened by Dr. Sujith Weerasinghe to explore the effect 
of hydroxamic acid substitution on the activity and selectivity of SAHA.102 The N-
substituted SAHA analogs displayed reduced potency and solubility, but greater 
selectivity, compared to SAHA. 
To assess selectivity, the analogs were screened by Dr. Sujith Weerasinghe 
against three individual HDAC isoforms, HDAC 1, HDAC3, and HDAC6.102 HDAC1 






in prior work.84, 92 HDAC6 was also tested to assess class II selectivity. The analogs 
were initially screened against the isoforms at a single concentration of 125 M 
(Figure 5.2). The compounds containing aliphatic substituents (35a, methyl, and 
35b, pentyl) displayed little to no isoform selectivity, similar to SAHA.78  Likewise, the 
N-homobenzyl analog 35d also showed roughly similar potency against the 
isoforms.  In contrast, the N-benzyl 35c and N-biphenyl 35e variants displayed some 
degree of HDAC1 selective inhibition, similar to Cpd-60.  Among these two analogs, 
N-biphenyl SAHA 35e demonstrated the most selectivity, with 58 ± 2% activity 
remaining with HDAC1, but statistically insignificant inhibition observed with both 
HDAC3 and HDAC6.  The single concentration selectivity screen points to N-
biphenyl 35e as an HDAC1 selective inhibitor, similar to compound Cpd-60. 
Based on the observation that the benzyl 35c and biphenyl 35e variants 
displayed some level of HDAC1 selectivity at 125 M concentration, IC50 values 
were determined by Dr. Sujith Weerasinghe (Table 5.1).102  As expected,78 the pan-
inhibitor SAHA displayed less than a 1.5-fold preference for any HDAC isoform 
tested.104 The benzyl variant 35c displayed slightly greater selectivity for HDAC1 
versus HDAC3 (2.5-fold).  Interestingly, the N-biphenyl variant 35e displayed 
preferential inhibition for HDAC1 with an IC50 for HDAC1 of 233 ± 40 M. 
Unfortunately, due to solubility issues at high concentrations, IC50 values for HDAC3 
and HDAC6 could not be determined.  However, at the highest concentration 
possible (250 µM), no inhibitory activity was observed with either HDAC3 or HDAC6 




Docking studies discussed here were done to account for the lower potency 
and the enhanced selectivity observed with the N-substituted SAHA analogs. 
Docking studies showed that the N-substituent accesses the 14 Å internal cavity to 
impart preferential inhibition of HDAC1. These studies with N-substituted SAHA 
analogs are consistent with the strategy exploiting the 14Å internal cavity of HDAC 
proteins to create HDAC1/2 selective inhibitors. 
 
Figure ‎5.2. HDAC inhibitory activities of the N-modified SAHA analogs were 
measured at 125 μM against HDAC1, HDAC3 and HDAC6. Data provided by Dr. 
Sujith Weerasinghe).102 
Table ‎5.1. IC50 values for SAHA, N-benzyl 35c, and N-biphenyl 35e against HDAC1, 
HDAC3, and HDAC6.a 
aValues are the means of at least three independent trials with standard error.           
bDeacetylase activity remaining at 250 µM concentration of inhibitor is shown 
because solubility issues prevented IC50 value determination. Data provided by Dr. 
Sujith Weerasinghe.102 
 HDAC1 HDAC3 HDAC6 
SAHA 96 ± 16 nM 146 ± 12 nM 74 ± 9 nM 
35c 177 ± 21 µM 440 ± 23 µM 287 ± 9 µM 




5.2. Docking studies with HDAC1 and HDAC3 crystal structures 
Docking studies were performed to rationalize the lower potency and HDAC1 
selectivity of the N-modified SAHA analogs. SAHA, along with the N-pentyl 35b and 
N-biphenyl 35e analogs, were docked into the HDAC1 crystal structure.99 SAHA 
maintained five interactions (1.1 to 3.8 Å distances) with the bound Zn2+ metal and 
nearby amino acids (H140, H141, and Y303, Figure 5.3A, see residues in blue).  In 
contrast, the N-pentyl 35b variant maintained only three of these interactions (with 
Zn2+, H141, and Y303, Figure 5.3B), while the N-biphenyl 2e analog displayed only 
two (with Zn2+ and Y303, Figure 5.3C). The loss of hydrogen binding capability of the 
hydroxamic acid amine likely accounts for the fewer stabilizing interactions with the 
analogs. In addition, the orientation of the hydroxamic acid is also altered by the N-
modification. Specifically, SAHA positions the carbonyl adjacent to Y303, the amine 
near H141, and the hydroxyl next to H140.  Due to the N-modification, the hydroxyl 
amine orientation is flipped, with N-pentyl 35b positioning the hydroxyl near H141. 
Likewise, the N-biphenyl analog adopts an alternative pose with the carbonyl 
interacting with Zn2+ and the hydroxyl interacting with Y303. The docking 
experiments point towards fewer interactions between the hydroxamic acid and the 
active site, likely due to flipping of the N-modification into the 14Å cavity and loss of 






Figure ‎5.3. Docking of SAHA (A), N-pentyl SAHA 35b (B), and N-biphenyl SAHA 
35e (C) into the HDAC1 crystal structure (PBD 4BKX). The HDAC structure is 
represented as blue mesh, the Zn2+ metal as a blue orb, and the inhibitor and amino 
acids as ball and sticks. The atoms of the inhibitor are color-coded (C= green/white; 
O = red; N = blue, H = white). 
In addition to the loss of bonding interactions, another significant observation 
from the docking studies is the positioning of the N-modification within the 14Å 
internal cavity. The narrowest section of the cavity is created by M30, R34, and L139 
(Figure 5.3A and Figure 5.4A, see resides in purple). While the pentyl group of 35b 
is positioned up to this constricted point in the cavity (Figure 5.3B), the biphenyl 
group of 35e extends beyond the narrow opening (Figure 5.3C). Therefore, the 
reduced potency of N-biphenyl SAHA 35e may also be due to the narrowing of the 
cavity near M30, R34 and L139 to constrict binding (Figure 5.4A). Consistent with 
the extent and orientation of interactions, the energies of the inhibitor/HDAC1 
complexes for SAHA, N-pentyl SAHA 35b, and N-biphenyl SAHA 35e were -5.46, -
4.25, and -3.28 kcal/mole, respectively. The energies are consistent with the 
experimental data indicating that SAHA is the most potent compound, whereas the 








































HDAC1                                                        HDAC3 
 
Figure ‎5.4. Docking of N-biphenyl SAHA 35e into the crystal structures of HDAC1 
and HDAC3. (A) This image is identical to that in Figure 5.3C, except that SAHA, 
M30, R34, and L139 are shown as space filling models. (B) This image is identical to 
that in Figure 5.5C, except that SAHA, M24, R28, and L133 are shown as space 
filling models. The HDAC structure is represented as blue mesh, while amino acids 
interacting with the hydroxamic acid in HDAC1 are shown as blue ball and sticks.  
The atoms on the inhibitor are color-coded (C= green/white; O = red; N = blue, H = 
white).  
The docking studies were further analyzed to explain the enhanced 
preference of 35e compared to SAHA and 35b (Table 5.2).  Prior docking analysis 
with Cpd-60 suggested that selectivity for HDAC1 compared to HDAC3 was a result 
of congestion in the 14 Å cavity due to a tyrosine in HDAC3; HDAC1 contains serine 
at the same position, which allows the cavity to accommodate bulky aromatic 
groups.84 Docking of SAHA into the HDAC3 structure revealed that Y107 is 
positioned relatively distant to the 14Å cavity (Figure 5.5A).100 Likewise, S113 in the 
HDAC1 crystal structure is also located adjacent to the cavity (Figure 5.6). In 
addition, previous mutagenesis studies indicated that S113 is only partially 




















Figure ‎5.5. Docking of SAHA (A), N-pentyl SAHA 35b (B), and N-biphenyl SAHA 
35e (C) into the HDAC3 crystal structure (PBD 4A69). The HDAC structure is 
represented as blue mesh, the Zn2+ metal as a grey orb, and the inhibitor and amino 
acids as ball and sticks. The atoms of the inhibitor are color-coded (C= green/white; 
O = red; N = blue, H = white). 
 
Figure ‎5.6. Docking of N-biphenyl 35e into the HDAC1 crystal structure (PBD 4BKX). 
The HDAC structure is represented as blue mesh, the Zn
2+
 metal as a grey orb, and the 
inhibitor and amino acids as ball and sticks. The atoms on the inhibitor are color-coded 
(C= green/white; O = red; N = blue, H = white). This image is identical to that in Figure 
5.3C, except that S113 is shown here. 
An alternative hypothesis explaining the HDAC1 preference of Cpd-60 and 
HDAC1 preference of N-biphenyl SAHA 35e emerges when considering the 



































maintains a considerably more constricted 14Å internal cavity than HDAC1 
(compare Figures 5.3A to Figure 5.5A and 54.A to 5.4B). The residues M24, R28, 
and L133 of HDAC3 appear to block the cavity and may restrict access to bulky N-
modified inhibitors. Docking of N-biphenyl 35e into the HDAC3 crystal structure 
produced no poses that were consistent with the expected metal/hydroxamic binding 
interaction. Instead, the biphenyl group was positioned up to the narrowest section 
of the cavity, near M24, R28, and L133 of HDAC3 (Figure 5.4B and Figure 5.5C). In 
this case, the biphenyl group is unable to extend beyond the constricted region to 
access the 14 Å internal cavity of HDAC3, as was seen with HDAC1 (Figure 5.3C 
and Figure 5.4A). As a result of the blocked cavity, the hydroxamic acid is positioned 
at the outside edge of the active site channel, unable to interact with the metal ion.  
Therefore, docking suggests that the poor potency observed with 35e and HDAC3 is 
due to restricted access of the N-biphenyl to the 14Å internal cavity, which prevents 
favorable metal/hydroxamic acid interactions. In contrast, the straight chain N-pentyl 
analog 35b is positioned up to the constriction point (Figure 5.5B), similar to HDAC1 
(Figure 5.3B), which allows effective binding and better potency. In total, the docking 
studies are consistent with accessibility of the 14Å cavity to large aromatic groups as 
a significant factor leading to the HDAC1 preference of inhibitors bearing 
substituents on the metal binding group, including Cpd-60 and N-biphenyl SAHA 
35e. 
In conclusion, N-modified SAHA analogs (35a-e) displayed significantly 
reduced potency compared to the parent SAHA. Interestingly, the benzyl and pentyl 




analogs. Docking studies are consistent with the pentyl groups accessing the 14Å 
internal cavities of HDAC1 and HDAC3 (Figure 5.3B and 5.5B). However, the 
additional interactions in the cavity were unable to overcome the lost hydrogen 
bonding due to the presence of the N-modification. The results suggest that any 
group, regardless of size, incorporated directly on the hydroxamic acid will result in 
decreased inhibitory activity compared to the unsubstituted analog. These studies 
are consistent with prior work reporting reduced potencies of HDAC inhibitors as a 
result of N-methylation of the hydroxamic acid group.146-147 
While the N-modified SAHA analogs showed reduced potency compared to 
SAHA, one compound displayed selectivity. The N-biphenyl variant 35e showed 
preference for HDAC1 over HDAC3 and HDAC6. Docking analysis with the HDAC1 
and HDAC3 crystal structures suggests that that accessibility to the 14Å internal 
cavity is differentially restricted, leading to preferential binding to HDAC1 over 
HDAC3. Therefore, the combined experimental and computation analysis of N-
modified SAHA analogs further validates the concept of creating isoform-selective 
HDAC inhibitors by positioning aromatic substituents in the 14Å internal cavity.  
These studies guide future inhibitor design by suggesting that additional substituted 
metal binding groups can be created to take advantage of the altered cavity 
accessibility of the HDAC isoforms. 
5.3. Experimental procedure 
5.3.1. Docking procedure 
Crystal structures for HDAC1 and HDAC3 were downloaded from the RCSB 
protein data bank (HDAC1: 4BKX and HDAC3: 4A69). PyMOL (Schrodinger, LLC) 




in HDAC1 crystal structure.  In the case of the HDAC3 crystal structure, the water 
molecules, chain A, deacetylase-activation-domain (DAD) (from the SMRT 
corepressor), glycerol, D-myo-inositol-1,4,5,6-tetrakisphosphate molecules, acetate, 
potassium and sulfate ions were deleted. AutoDockTools-1.5.4 program 119, 127 was 
used to add all hydrogen atoms, modify histidine protonation (H140 and H141 
residues for HDAC1, His134 His135 for HDAC3) by adding only HD1, compute 
Gasteiger charges, and merge all non polar hydrogen, followed by generation of the 
pdbqt output file. The charge of the zinc atom was manually changed from zero to 
+2. A grid box with a spacing of 0.375 Å, size of 56 x 42 x 38, and coordinates for 
the center of the grid box (-48.000, 18.000, -3.750) were used for HDAC1, while the 
values for HDAC3 were 58 x 58 x 54 and (8.166, 76.663, 21.318). All docking 







CHAPTER 6 - SYNTHESIS AND SCREENING OF BIARYL INDOLYL 
BENZAMIDE HDAC INHIBITORS 
6.1. Rationale for design, synthesis and screening of biaryl indolyl benzamide 
HDAC inhibitors 
The objective of this project was to generate HDAC1-selective inhibitors to 
study HDAC1-related cancer biology. No selective inhibitor for HDAC1 has been 
identified to date. Rational design of HDAC1-selective inhibitors is a challenge due 
to the high sequence similarity and active site similarity between HDAC1 and 
HDAC2.12 In addition to studying HDAC1-related cancer biology, creating HDAC1-
selective inhibitors will be a step forward in the development of HDAC1-selective 
anticancer drugs, which can lead to more effective cancer treatment compared to 
non-selective inhibitors or inhibitors that are selective for more than one HDAC 
isoform.  
Several HDAC1/HDAC2 selective inhibitors have been reported.84, 92 Most of 
the HDAC1/2 selective inhibitor are benzamide derivatives, where the metal binding 
group is a 1,2-diamino benzamide chelating group (such as Cpd-60, an HDAC1/2 
selective inhibitors (Figure 6.1)). According to literature, the selectivity of the 
HDAC1/2 benzamide inhibitors came from the use of bulky aromatic rings (Figure 
6.1, red rings in Cpd-60), which will not fit in the 14 Å channel of HDAC3 protein.84, 
102 The presence of the biaryl group can impart selectivity to HDAC1 and 2 over 
HDAC3, and can be used  to develop an HDAC1-selective inhibitor. 
In 2012, several hydroxamic acid derivatives were reported to be 
HDAC1/HDAC3 dual selective inhibitors.117 The study showed that the selectivity 




with the solvent exposed region of the active sites of HDAC1 and HDAC3 over 
HDAC2.  The capping group that imparted selectivity against HDAC2 can 
successfully be used to generate an HDAC1-selective inhibitor.         
 
 
Figure ‎6.1. Structures of HDAC1/3 selective inhibitor 36, HDAC1/2 selective 
inhibitor Cpd-60, and the biaryl indolyl benzamide HDAC inhibitors Bnz-1, Bnz-2, 
and Bnz-3. 
In this work we combined both the functional groups from the HDAC1/2 
selective inhibitors and HDAC1/3 selective inhibitor in order to generate HDAC1 




part of Cpd-60) which discriminated against HDAC3, with the capping group of the 
HDAC1/3 selective inhibitors (Figure 6.1, blue part of 36) which discriminated 
against HDAC2. By combining these two fragments we designed three potential 
HDAC1-selective inhibitor (Figure 6.1, Bnz-1, Bnz-2, and Bnz-3). 
6.2.   Docking studies of Cpd-60 with HDAC1, 2, 3, and 7 
To validate the design of the HDAC1-selective inhibitors, and to understand 
the binding of selective inhibitors to HDAC1, Cpd-60 was docked in the crystal 
structures of class I HDAC1 (PDB: 4BKX), HDAC2 (PDB: 3MAX), and HDAC3 (PDB: 
4A69), and class II HDAC7 (PDB: 3C0Z) using Autodock program119. The docking 
studies revealed the amino acids that are critical for the selectivity, and more 
importantly, showed the preference of Cpd-60 binding to HDAC1 and HDAC2 
(Figure 6.2). For both HDAC1 and HDAC2, Cpd-60 showed the expected binding, 
with the metal binding group of Cpd-60 (Figure 6.1) well positioned in the metal 
binding region of the active site and the biaryl ring system positioned in the 14 Å 
channel (Figures 6.1, 6.2A and B). It's worth mentioning that the crystal structures of 
both HDAC1 and HDAC2 showed a difference in the width of the 14 Å channel 
(Figure 6.2A and B). HDAC2 displayed a wider channel than HDAC1, with a slight 
constriction in HDAC1 crystal structure 14 Å channel created by M30, R34, and 
L139 (gold mesh in Figure 6.2A). But the compound still bound well to both active 
sites. On the other hand, in HDAC3 Cpd-60 didn't fit in the active site due to the 
presence of a constriction created by M30, R34, and L139 blocking the 14 Å channel 
(Figure 6.2, see arrow), similar to the N-library docking results (section 5.4 in 
Chapter 5).102 The constriction in the 14 Å cavity of HDAC3 prevented the biaryl ring 




compound away from the metal binding region in HDAC3 active site (gold mesh in 
Figure 6.2C). In HDAC7, a similar disfavored binding or no binding was observed 
due to the absence or blocking of the 14 Å channel (gold mesh in Figure 6.2D).   
    
   
Figure ‎6.2. Docking of Cpd-60 into the crystal structures of (A) HDAC1, (B) HDAC2, 
(C) HDAC3 and (D) HDAC7. The Zn2+ metal is represented as a grey orb, the 
inhibitor as ball and sticks, and the HDAC structure as color-coded mesh (gold = 14 
Å cavity constriction point; green = base of the 14 Å cavity; blue = all other regions). 
Residues differing in their position at the cavity surface in HDAC2 versus 1, 3, or 7 
are shown in red. 
6.3. Synthesis of the biaryl indolyl benzamide HDAC inhibitors 
The biaryl indolyl benzamide inhibitors were synthesized according to 
Schemes 6.1-6.4. First, synthesis of intermediates 44a and 44b commenced with 
reduction of (tert-butoxycarbonyl)-L-tryptophan 37 with LiAlH4, which afforded the 




by BOC protection of methyl L-tryptophanate HCl salt 38, then reduction with LiAlH4 
(Scheme 6.1). The coupling partner esters 42a and 42b were synthesized from their 
corresponding carboxylic acids, (E)-3-(4-hydroxyphenyl)acrylic acid 41a or 4-
hydroxy benzoic acid 41b, by esterification with methanol. Mitsunobu coupling of 40 
with 42a or 42b gave 43a or 43b, respectively. Deprotection of 43a or 43b with 
HCl/EtOAc, and coupling with benzoic acid using TBTU and DIPEA afforded 44a or 
44b intermediates.  
Scheme ‎6.1. Synthesis of intermediates 44a and 44b 
 
 
The biaryl fragment of the molecules (biaryl amine 49) was synthesized by 
BOC protection of 4-bromo-2-nitro aniline 46 using di-tert-butyl dicarbonate and a 




Compound 47 was then subjected to Suzuki coupling using phenyl boronic acid, 
potassium carbonate, and bis triphenylphosphine palladium dichloride to give 48, 
which was then reduced by Pd/C and hydrogen gas to afford 49 (Scheme 6.2).  
Scheme ‎6.2. Synthesis of the biaryl amine 49 
 
Synthesis of Bnz-1 and Bnz-3 was done according to Scheme 6.3. Hydrolysis 
of 44a and 44b with NaOH gave the free carboxylic acids 45a and 45b. Coupling of 
45a or 45b with the BOC-protected biaryl amine 49 was achieved with PyBOP and 
afforded the BOC-protected 50a and 50b. The final products Bnz-1 and Bnz-3 were 
obtained by BOC deprotection of with 50% TFA/DCM. Bnz-2 was synthesized by 
reduction of 45a, followed by coupling with the biaryl amine 49 and finally BOC 













Scheme ‎6.4. Synthesis of Bnz-2  
 
6.4. In vitro screening of biaryl indolyl benzamide HDAC inhibitors 
To assess isoform selectivity, the three new compounds were screened 
against recombinant HDAC1 and HDAC2 using the HDAC-Glo assay (Figure 6.3). 
Bnz-3 was further tested with HDAC3 and HDAC6. Cpd-60, as a HDAC1/2 selective 
inhibitor, and SAHA, as a non-selective compound, were tested as well with 
recombinant HDAC1, 2, 3, and 6. As expected, SAHA showed almost the same 
inhibitory activity with HDAC1, 2, 3, and 6 (Figure 6.3). The HDAC1/2 selective 
inhibitor Cpd-60 demonstrated selectivity for HDAC1 and 2 over HDAC3 and 6. The 
new analogs showed several interesting results. First, Bnz-3 displayed the highest 
inhibitory activity among the three analogs, with about ten- to 100-fold higher 




activity at 2 µM for Bnz-3 to 20 and 200µM for Bnz-2 and Bnz-1, or at 0.2 µM for 
Bnz-3 to 2 and 20 µM for Bnz-2 and Bnz-1) (Figure 6.3). Second, all the analogs 
showed selectivity for HDAC1 over HDAC2, with the best selectivity observed for 
HDAC1 with Bnz-3 at 2 µM (Figure 6.3). The presence of the saturated linker in 
Bnz-2 led to about 10-fold improvement in potency compared to the unsaturated 
linker in Bnz-1 (Figures 6.1 and 6.3). Interestingly, removing the linker in Bnz-3 led 
to another 10-fold enhancement in the activity compared to Bnz-2, and about 100-
fold compared to Bnz-1 (Figures 6.1 and 6.3). 
 
Figure ‎6.3. In vitro isoform selectivity screening of SAHA, Cpd-60, Bnz-1, Bnz-2, 
and Bnz-3 against HDAC1, HDAC2, HDAC3, and HDAC6. The concentrations 
shown for each compound are final concentrations. Mean percent deacetylase 
activities from a minimum of two independent trials with standard errors were plotted 
(Table D.1). 
To further assess the selectivity of Bnz-3 as the best analog, IC50 values were 
determined for both Bnz-3 and Cpd-60 using recombinant HDAC1 and HDAC2 
(Table 6.1). Cpd-60 showed about 7.3-fold selectivity for HDAC1 over HDAC2, with 































      SAHA Cpd-60  ------Bnz1------   ------Bnz2------   ------Bnz3------  
      20nM   28nM   200µM   20µM    20µM    2µM       2µM    0.2µM  




selectivity for HDAC1 over HDAC2, with an IC50 value of 548 nM with HDAC1. The 
IC50 values show that the potency of Bnz-3 was about 53-fold less potent than Cpd-
60 in inhibiting HDAC1, while the selectivity for HDAC1 was modestly enhanced to 
10.6-fold compared to 7.3-fold with Cpd-60 (Table 6.1).  
In conclusion, several biaryl indolyl benzamide inhibitors were designed, 
synthesized, and screened for isoform selectivity. The design was based on 
combining two different fragments to discriminate against HDAC2 and HDAC3, to 
get a potential HDAC1-selective inhibitor. Bnz-3 was the best analog in terms of 
potency and selectivity. Bnz-3 displayed about 10-fold higher potency than Bnz-2, 
and about 100-fold higher potency than Bnz-1. Bnz-3 exhibited a modest inhibitory 
potency with HDAC1 (548 nM). In terms of selectivity, Bnz-3 showed HDAC1 
preference, but the observed fold selectivity to HDAC1 over HDAC2 (7.3-fold) was 
far less than what we expected (30- to 50-fold) when we designed these inhibitors.    
Table ‎6.1. IC50 values and fold selectivity for Cpd-60 and Bnz-3 against HDAC1 and 






a Mean IC50 value and standard error of at least three independent trials are shown 
(Figures D.24 and D.25 and Tables D.2 and D.3). 
6.5. Experimental Procedures 
6.5.1. Materials and instrumentation 
Details were provided in Section 2.7.1 of Chapter 2. 
Compound 




Cpd-60 10.4 ± 0.7 75.9 ± 7.9 7.3 




6.5.2. Docking procedure 
Crystal structures of HDAC1 and HDAC3 were prepared in a similar way as 
mentioned previously and all box sizes dimensions were the same (Chapter 5, 
section 5.5.1). For HDAC2, a similar preparation procedure, box dimensions and 
position to Chapter 2, section 2.7.4 were followed. for HDAC7, the crystal structure 
was downloaded from the protein data bank (pdb ID: 3C0Z)21, a grid box of size 26 X 
26 X 26 Å3 with a spacing of 0.375 Å and centered at (-32.876, -29.000, -19.000) 
was used. The PyMOL program was used to delete all water molecules, metal ions 
(potassium), ethanol, and glycerol molecules and the cocrystallized ligand in the 
active site from the crystal structure; only the zinc atoms remained. All docking 
procedure and parameters were similar to what mentioned in Chapter 2, Section 
2.7.4. 
6.5.3. Synthesis procedure 
 
Synthesis of tert-butyl (S)-(1-hydroxy-3-(1H-indol-3-yl)propan-2-
yl)carbamate (40):  Method A: In a 50 mL flask, (tert-butoxycarbonyl)-L-tryptophan 
37 (1 g, 3.29 mmol) was dissolved in dry THF (15 mL). LiAlH4 (499 mg, 13.14 mmol) 
was added at 0ºC portion wise, and then the temperature was increased to room 
temperature and the reaction was left to stir for 5 hours under argon. The reaction 
was quenched with careful dropwise addition of a citric acid solution (10 mL of 1M 
solution in water). The organic layer was separated, and the aqueous layer was 




over anhydrous Na2SO4, and evaporated. The product was purified by silica-gel flash 
chromatography (acetone/petroleum ether 1:3) to afford 40 (655 mg, 83%). Melting 
point: 117-120 ºC (reported 118-120 ºC)148. 1HNMR (400 MHz, DMSO-d6) δ (ppm): 
1.34 (s, 9H), 2.70 (dd, J = 7.2 and 14.4 Hz, 1H), 2.87 (dd, J = 6.4 and 14.4 Hz, 1H), 
3.33 (m, 2H), 3.66 (m, 1H), 4.60 (t, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.95 (t, 
J = 8.0 Hz, 1H), 7.04 and 7.07 (overlapped t and s, J = 7.4 Hz, 2H), 7.30 (d, J = 8.0 
Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 10.75 (br s, 1H). Spectral data for the synthesized 
compound was consistent with the reported data in literature.149 
Method B: The compound was synthesized similar to the reported 
procedure.149 In a 50 mL flask, methyl L-tryptophanate HCl salt 38 (1g, 3.93 mmol) 
was dissolved in dry DCM (10 mL), followed by the addition of triethyl amine (874 
mg, 8.64 mmol) and di-tert-butyl dicarbonate (943 mg, 4.32 mmol). The reaction was 
stirred overnight, washed with citric acid (2x5mL of 1M solution in water) AND then 
brine (10 mL), dried over anhydrous Na2SO4, and evaporated to give 39. Without 
purification, 39 was dissolved in dry THF (20 mL), followed by the addition of  LiAlH4 
(571 mg, 15.04 mmol) portion wise at 0ºC. The same procedure as method A was 
followed. The product was purified by silica-gel flash chromatography (ethyl 
acetate/hexanes 1/2) to afford 40 (850 mg, 72% over two steps). Melting point: 118-
119 ºC (reported 118-120 ºC)148. 
 
Synthesis of methyl (E)-3-(4-hydroxyphenyl)acrylate (42a): The 




hydroxyphenyl)acrylic acid 41a (4 g, 24.37 mmol) was dissolved in methanol (40 
mL). p-Toluenesulfonic acid (927 mg, 4.87 mmol) was added and the reaction was 
heated at reflux for 19 hours. The solvent was evaporated, and the residue was 
dissolved in ethyl acetate (40 mL), washed with saturated NaHCO3 solution (30 mL), 
dried over anhydrous Na2SO4, and evaporated to afford 42a (4.14 g, 95%). Melting 
point: 134-137 ºC. 1HNMR (400 MHz, CDCl3) δ (ppm): 3.80 (s, 3H), 6.30 (d, J = 16 
Hz, 1H), 6.85 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 16 Hz, 1H). 
Spectral data for the synthesized compound was consistent with the reported data in 
literature.150 
 
Synthesis of methyl 4-hydroxy benzoate (42b): The compound was 
synthesized similar to the reported procedure.151 4-hydroxybenzoic acid 41b (4 g, 
24.37 mmol) was dissolved in methanol (100 mL), sulfuric acid (0.5 mL) was added, 
and the reaction was heated to reflux for 6 hours. The solvent was evaporated, and 
the residue was dissolved in ethyl acetate (40 mL), washed with saturated NaHCO3 
solution (30 mL), dried over anhydrous Na2SO4, and evaporated to afford 42b (4.14 
g, 94%). 1HNMR (400 MHz, CDCl3) δ (ppm): 3.90 (s, 3H), 6.28 (br s, 1H) 6.88 (dd, J 
= 2, 4.8 Hz, 2H), 7.95 (dd, J = 2, 4.8 Hz, 2H). Spectral data for the synthesized 





Synthesis of methyl (S,E)-3-(4-(2-benzamido-3-(1H-indol-3-
yl)propoxy)phenyl)acrylate (44a): The compound was synthesized according to 
the reported procedure.117 In dry THF (10 mL), 40 (850 mg , 2.89 mmol), 42a (567 
mg, 3.18 mmol) and triphenyl phosphine (834 mg, 3.18 mmol) were dissolved, 
followed by the addition of diethyl azodicarboxylate (554 mg, 3.18 mmol) drop wise 
at 0 ºC. The reaction was stirred at room temperature for 4 hours. The solvent was 
evaporated, and the product was purified by silica-gel flash chromatography 
(EtOAc/Hexanes 1:3) to afford 43a. 
Compound 43a was dissolved in EtOAc (10 mL), then EtOAc saturated with 
HCl (10 mL) was added. The reaction was left to stir at RT for 8.5 hours. The solvent 
was evaporated and the crude product was used in the following reaction directly 
with no further purification. 
Benzoic acid (493 mg, 4.04 mmol) was dissolved in dry DCM (15 mL), then 
DIPEA (1.05 mL, 6.05 mmol) was added, followed by TBTU (1.94 gm, 6.05 mmol). 
The reaction was left to stir at room temperature for 30 min, followed by the addition 
of  the intermediate from previous step and another portion of DIPEA (1.05 mL, 6.03 
mmol). The reaction was left to stir for 3.5 hours. The solvent was evaporated and 
the product was purified by flash silica-gel chromatography (EtOAc/Hexanes 1:2-




3.08 (d, J = 7.2 Hz, 2H), 3.68 (s, 3H), 4.09 (m, 1H), 4.18 (m, 1H), 4.57 (m, 1H), 6.44 
(d, J = 16 , 1H), 6.94 (m ,3H), 7.04 (t,  J = 7.2 , 1H), 7.16 (s, 1H), 7.30 (d, J = 8, 1H), 
7.43 (t, J = 7.2, 2H), 7.50 (t, J = 6.8, 1H), 7.62 (m, 3H), 7.81 (d, J = 7.6, 2H), 8.47 (d, 
J = 7.6 , 1H), 8.96 (br s, 1H), 10.78 (br s, 1H). Spectral data for the synthesized 
compound was consistent with the reported data in literature.117 
 
Synthesis of methyl (S)-4-(2-benzamido-3-(1H-indol-3-
yl)propoxy)benzoate (44b): The compound was synthesized similar to 44a except 
the following, 40 (1.88 g , 6.47 mmol), 42b (1.08 g, 7.12 mmol), triphenyl phosphine 
(1.87 g, 7.12 mmol), diethyl azodicarboxylate (1.13 mL, 6.47 mmol), benzoic acid 
(210 mg, 1.72 mmol), DIPEA (449 uL, 2.58 mmol), TBTU (828 mg, 2.58 mmol),  43b 
(620 mg, 1.72 mmol) and DIPEA (449 uL, 2.58 mmol). The product was purified by 
flash silica-gel chromatography (EtOAc/Hexanes 1:2-1:1.5) to afford 44b (44% over 
three steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 3.10 (d, J = 6.8 Hz, 2H), 3.78 
(s, 3H), 4.12 (m, 1H), 4.21 (m, 1H), 4.59 (m, 1H), 6.95 (t, J = 7.2 Hz, 1H), 7.04 (t,  J 
= 8.8 , 3H), 7.18 (s, 1H), 7.31 (d, J = 8, 1H), 7.43-7.50 (t and t, J = 6.8, and 7.2 3H), 
7.62 (d, J = 8, 1H), 7.83 (m, 4H), 8.52 (d, J = 8, 1H), 10.82 (br s, 1H). 
 
Synthesis of tert-butyl (4-bromo-2-nitrophenyl)carbamate (47): The 




nitroaniline 46 (2g, 9.2 mmol) was dissolved in dry DCM (20 mL), followed by 
addition of DMAP (113 mg, 0.09 mmol). A solution of di-tert-butyl dicarbonate (2.2 g, 
10.13 mmol) in dry DCM (20 mL) was added drop wise over 1 hour. The reaction 
was left to stir at room temperature for 3 hours. The solvent was evaporated and the 
reaction was purified by flash silica-gel chromatography (EtOAc/Hexanes 1:20) to 
afford 47 (1.7 g, 58%). 1HNMR (400 MHz, CDCl3) δ (ppm): 1.54 (s, 9H), 7.67 (dd, J 
= 2.3, 9.2 Hz, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.50 (d, J = 9.2 Hz, 1H), 9.60 (br s, 1H). 
Spectral data for the synthesized compound was consistent with the reported data in 
literature.152 
 
Synthesis of tert-butyl (3-nitro-[1,1'-biphenyl]-4-yl)carbamate (48): The 
compound was synthesized similar to the reported procedure.152  Compound 47 (1.7 
g, 5.36 mmol) was dissolved in dry THF (20 mL), followed by degassing with argon 
gas for 30 minutes. Phenyl boronic acid (1.05 g, 8.58 mmol), potassium carbonate 
(2.37 g, 17.16 mmol), and Pd[PPh3]2Cl2 (85 mg, 5% w/w) were added. The reaction 
was heated under reflux for 23 hours, then the solvent was evaporated. The residue 
was suspended in diethyl ether (30 mL), filtered, and the solvent was evaporated. 
The residue was purified by flash silica-gel chromatography (EtOAc:Hexanes 1:20) 
and recrystallization of the impure column fractions from EtOH afforded 48 (1.23 g, 
76%). 1HNMR (400 MHz, CDCl3) δ (ppm): 1.56 (s, 9H), 7.37 (m, 1H), 7.48 (m, 2H), 




Hz, 1H), 9.67 (br s, 1H). Spectral data for the synthesized compound was consistent 
with the reported data in literature.152 
 
Synthesis of tert-butyl (3-amino-[1,1'-biphenyl]-4-yl)carbamate (49): The 
compound was synthesized similar to the reported procedure.152 Compound 48 
(1.21 g, 4.26 mmol) was suspended in EtOH (80 mL), and Pd/C (121 mg, 10% w/w) 
was added. The air inside the flask was replaced with argon (X3) then with 
hydrogen gas (X3). The reaction was allowed to stir under hydrogen overnight at 
room temperature. The reaction was filtered and concentrated to afford 49 (1.08 g, 
99%). 1HNMR (400 MHz, CDCl3) δ (ppm): 1.51 (s, 9H), 5.28 (br s, 2H), 6.60 (br s, 
1H), 7.11 (m, 1H), 7.18 (s, 1H), 7.36 (m, 4H), 7.51 (d, J = 8.4 Hz, 2H). Spectral data 
for the synthesized compound was consistent with the reported data in literature.152 
 
Synthesis of (S,E)-N-(1-(4-(3-((4-amino-[1,1'-biphenyl]-3-yl)amino)-3-
oxoprop-1-en-1-yl)phenoxy)-3-(1H-indol-3-yl)propan-2-yl)benzamide (Bnz-1):  
44a (1.82 g, 4 mmol) was dissolved in MeOH (50 mL), followed by the addition of 
NaOH (1.6 g, 40 mmol) in water (10 mL). The reaction was left to stir at room 
temperature for 18 hours. Then the reaction was concentrated under vacuum. HCl 




diluted with water and extracted with ethyl acetate (3X50 mL), dried over MgSO4, 
evaporated to give 45a. 
Crude product 45a was dissolved in dry DMF (8 mL) followed by the addition 
on triethyl amine (0.195 mL, 1.5 mmol). PyBOP (729 mg, 1.5 mmol) was dissolved in 
dry DCM (5 mL) and added to the reaction, followed by the biaryl amine 49 (362 mg, 
1.36 mmol) in dry DCM (5 mL). The reaction was left to stir for 19 hours at room 
temperature, and then was concentrated under reduced pressure, diluted with water 
(15 mL), and extracted with ethyl acetate (3x30 mL). The reaction was purified by 
flash silica-gel chromatography (EtOAc/Hexanes 1:2-1:1) to afford 50a. 
Compound 50a (175 mg, 0.25 mmol) was dissolved in dry DCM (4mL), then 
TFA (4 mL) was added. The reaction was left to stir at room temperature for 4 hours. 
The reaction was then concentrated under vacuum and a saturated solution of 
NaHCO3 was added dropwise until no effervescence was observed. The product 
was extracted with EtOAc (3x15mL) and purified by flash silica-gel chromatography 
(EtOAc/Hexanes 1:1.5-1:1) to afford Bnz-1 (150 mg, 11% over three steps). 1HNMR 
(400 MHz, DMSO-d6) δ (ppm): 3.10 (d, J = 7.2 Hz, 2H), 4.09 (m, 1H), 4.20 (m, 1H), 
4.59 (m, 1H), 5.12 (br s, 2H), 6.76 (d, J = 15.6, 1H), 6.82 (d, J = 8.4, 1H),   6.96 (m, 
4H), 7.22 (m, 3H), 7.31 (d, J = 8, 1H), 7.37 (t, J = 7.6, 2H), 7.49 (overlapped m, 8H), 
7.62 (d, J = 7.6, 1H), 7.71 (br s, 1H), 7.83 (d, J = 8.4 , 2H), 8.50 (d, J = 7.6, 1H), 9.36 
(br s, 1H), 10.80 (br s, 1H); 13CNMR (100 MHz, CD3OD) δ (ppm): 27.16, 50.29, 
69.45, 111.20, 111.86, 115.53, 116.78, 118.78, 120.28, 121.39, 123.21, 123.88, 
124.37, 125.99, 126.46, 127.78, 128.01, 128.64, 129.24, 129.73, 131.62, 134.98, 




calculated for [M+H]+ C39H34N4O3H
+, 607.2709, found 607.2736. HPLC analytical 
purity analysis 94.9%. 
 
Synthesis of (S)-N-(4-amino-[1,1'-biphenyl]-3-yl)-4-(2-benzamido-3-(1H-
indol-3-yl) propoxybenzamide (Bnz-3): Compound 44b (630 mg, 1.47 mmol) was 
dissolved in MeOH (25 mL), followed by the addition of NaOH (588 mg, 14.7 mmol) 
in H2O (5 mL). The reaction was left to stir at room temperature for 18 hours. Then 
the reaction was concentrated under vacuum. HCl (10 N) was added drop wise until 
the pH was 6. The reaction was diluted with water (10 mL) and extracted with EtOAc 
(3X30 mL), dried over MgSO4, and evaporated to give 45b. 
Crude product 45b was dissolved in dry DMF (5 mL), followed by the addition 
on triethyl amine (0.22 mL, 1.57 mmol). PyBOP (446 mg, 1.57 mmol) was dissolved 
in dry DCM (5 mL) and added to the reaction, followed by the biaryl amine 49 (817 
mg, 1.57 mmol) in dry DCM (5 mL). The reaction was left to stir for 21 hours. The 
reaction was then concentrated under reduced pressure, diluted with water (10 mL), 
and extracted with ethyl acetate (3x30mL). The reaction was purified by flash silica-
gel chromatography (EtOAc:Hexanes 1:2-1:1) to afford 50b, which was used in the 
next reaction with no characterization.  
Compound 50b was dissolved in dry DCM (4mL), then TFA (4 mL) was 




was then concentrated under vacuum and a saturated solution of NaHCO3 was 
added till no effervescence was observed. The product was extracted with EtOAc 
(3x20mL), purified by flash silica-gel chromatography  (EtOAc:Hexanes 1:1.5-1:1) 
and afforded Bnz-3 (18% over three steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 
3.11 (d, J = 6.0 Hz, 2H), 4.12 (m, 1H), 4.23 (m, 1H), 4.61 (m, 1H), 5.06 (br s, 2H), 
6.84 (d, J = 8.8, 1H), 6.97 (t, J = 7.2, 1H), 7.05 (m, 3H), 7.20 (m, 2H), 7.29-7.39 
(overlapped t and t, J = 8, 4H), 7.44-7.53 (m, 6H), 7.63 (d, J = 8, 1H), 7.84 (d, J = 
7.2, 2H), 7.95 (d, J = 8.4 , 2H), 8.53 (d, J = 8.4, 1H), 9.61 (br s, 1H), 10.82 (br s, 1H); 
13CNMR (100 MHz, CD3OD) δ (ppm): 27.17, 50.24, 69.52, 111.18, 111.87, 114.54, 
116.98, 118.79, 121.40, 123.90, 125.24, 125.95, 126.45, 127.24, 127.79, 127.86, 
128.58, 128.66, 129.25, 130.17, 131.65, 134.96, 136.62, 140.66, 143.25, 161.54, 
166.79; HRMS (ESI-TOF, m/z): calculated for [M+H]+ C37H32N4O3H
+, 581.2553, 
found 581.2573. HPLC analytical purity analysis 94.9%. 
 
Synthesis of (S)-N-(1-(4-(3-((4-amino-[1,1'-biphenyl]-3-yl)amino)-3-
oxopropyl)phenoxy) -3-(1H-indol-3-yl)propan-2-yl)benzamide (Bnz-2): 
Compound 45a (600 mg, 1.36 mmol) was dissolved in MeOH (15 mL), followed by 
the addition of Pd/C (60 mg, 10% w/w). Air was replaced with argon (3X), then 




temperature. The reaction was then filtered, evaporated and the crude product was 
used in the next reaction. 
The crude product 30 was dissolved in dry DMF (10 mL), followed by the 
addition of triethyl amine (0.244 mL, 1.75 mmol). PyBOP (911 mg, 1.75 mmol) was 
dissolved in dry DCM (5 mL) and added to the reaction, followed by amine 49 (451 
mg, 1.59 mmol) in dry DCM (5 mL). The reaction was left to stir overnight at room 
temperature. The reaction was then concentrated under reduced pressure, diluted 
with water (15 mL), and extracted with ethyl acetate (3x20mL). The reaction was 
purified by flash silica-gel chromatography (EtOAc:Hexanes 1:2-1:1) and the product 
was used in the next reaction with no characterization. 
The crude product from previous reaction was dissolved in dry DCM (4 mL), 
then TFA (4 mL, 52 mmol) was added. The reaction was left to stir at room 
temperature for 2 hours. The reaction was then concentrated under vacuum and a 
saturated solution of NaHCO3 was added until no effervescence was observed. The 
product was extracted with ethyl acetate (3x15mL), purified by flash silica-gel 
chromatography  (EtOAc:Hexanes 2:1-3:1), and afforded Bnz-2 (11% over three 
steps). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 2.59 (t, J = 8.0 Hz, 2H), 2.84 (t, J = 
7.2 Hz, 2H), 3.08 (d, J = 4.8 Hz, 2H), 3.95 (m, 1H), 4.10 (m, 1H), 4.56 (m, 1H), 4.95 
(br s, 2H), 6.76 (d, J = 8.0, 1H), 6.86 (d, J = 8.4, 1H), 6.94 (t, J = 7.2, 1H), 7.03 (t, J = 
7.2, 1H), 7.14-7.23 (m, 5H), 7.29-7.48 (m, 9H), 7.61 (d, J = 7.6, 1H), 7.82 (d, J = 7.2, 
2H), 8.47 (d, J = 7.6, 1H), 9.18 (br s, 1H), 10.79 (br s, 1H); 13CNMR (100 MHz, 
CD3OD) δ (ppm): 27.20, 30.73. 38.21, 50.34, 69.36, 111.30, 111.83, 114.91, 116.54, 




128.42, 128.63, 129.23, 129.73, 131.59, 133.76, 135.00, 136.62, 142.03, 157.29, 
166.74, 171.06; HRMS (ESI-TOF, m/z): calculated for [M+H]+ C39H36N4O3H
+, 
609.2866, found 607.2854. HPLC analytical purity analysis 94.3%.  
6.5.4. Procedures for biological screenings 
6.4.3.1. Inhibitor testing with HDAC isoforms 
To measure HDAC isoforms inhibition, individual baclovirus-expressed 
HDAC isoform (50 ng for HDAC1 (Enzo Life), 3 ng HDAC1 (BPS Bioscience), 0.5 
ng for HDAC2 (BPS Bioscience), 6 ng for HDAC3 (Enzo Life), and 65 ng for 
HDAC6 (Enzo Life)) was mixed with HDAC-Glo™ buffer (Promega) in polystyrene 
96-well half area white plate (Corning). Inhibitor in DMSO (1 µL) was then added 
to a final volume of 25 µL, and pre-incubation for 2 hours at room temperature 
without rocking. An uninhibited control reaction was also included that contained 
DMSO (1 µL) with each HDAC enzyme in HDAC-Glo™ buffer (24 µL). 
Deacetylase activity was measured using the HDAC-Glo™ assay kit as per the 
manufacturer’s protocol (Promega). Specifically, the HDAC-Glo™ substrate (1 
mL) and developer (1 µL) were first premixed to form the HDAC-Glo™ reagent. 
Then, to monitor deacetylase activity, HDAC-Glo™ reagent (5 µL) diluted in 
HDAC-Glo™ buffer (20 µL) was added to each well (50 µL total volume) and 
incubated for 30-45 minutes at room temperature without rocking. The 
deacetylase activity was measured as luminescent signal using a GeniosPlus 
Fluorimeter (Tecan) at optimal gain. The concentrations of inhibitors reported in 
the dose-dependent studies are final concentrations after addition of HDAC-Glo™ 
reagent and HDAC-Glo™ buffer. Percent deacetylase activity was calculated by 




then multiplying by 100. IC50 values were calculated by fitting the percent 
deacetylase activity remaining as a function of inhibitor concentration to a 
sigmoidal dose-response curve (y = 100/(1+(x/IC50)
z), where y = percent 
deacetylase activity and x = inhibitor concentration) using non-linear regression 
with KaleidaGraph 4.1.3 software. Results are reported in Figures 6.3, D.24 and 





CHAPTER 7 - CONCLUSION 
In this thesis, several HDAC inhibitors have been designed, synthesized, and 
screened for biological activity. Several SAHA (Vorinostat) analogs were modified at 
different positions in the linker region of SAHA. C2-modififed SAHA analogs were 
generated by Dr. Anton Bieliauskas. Herein, isoforms selectivity assessment, and in 
cellulo testing of the C2-SAHA analogs were performed. Several of the C2-modified 
SAHA analogs displayed selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3. 
C2-n-hexyl SAHA analog 1i, showed the highest selectivity with 49- to 300-fold 
selectivity for HDAC6 and 8 over HDAC1, 2, and 3. Enantioselective syntheses of 
both the (R) and (S) enantiomers of C2-n-hexyl SAHA were performed, and both 
enantiomers exhibited similar potency and selectivity to the racemic C2-n-hexyl 
SAHA 1i.  
In addition, several other SAHA derivatives substituted at the C4 and C5 
positions of the linker region were synthesized and screened. The C4-SAHA analogs 
showed up to 1300-fold dual selectivity for HDAC6 and HDAC8 over HDAC1, 
HDAC2, and HDAC3. C4-benzyl SAHA 19f, was the best analogs, which showed 
the highest fold selectivity with 210- to 740-fold selectivity for HDAC6 and 8 
compared to HDAC1, 2, and 3, and 140 and 57 nM IC50 with HDAC6 and HDAC8. In 
cellulo testing of the C4-benzyl SAHA analog showed consistent isoform selectivity 
with the in vitro screening. Both enantiomers of the C4-benzyl SAHA were 
synthesized via enantioselective syntheses. In vitro screening of the pure 
enantiomers revealed that (R)-C4-benzyl SAHA is more potent and selective than 




1300-fold selectivity for HDAC6 and 8 over HDAC1, 2, and 3. In addition, C5-
modified SAHA analogs also displayed dual HDAC6/8 selectivity. The best analog, 
C5-benzyl SAHA, showed much lower selectivity  (8- to 21-fold selectivity) compared 
to the C4-benzyl SAHA. The potency (IC50 values of 270 and 380 nM with HDAC6 
and 8, respectively) was also lower compared to the C4-benzyl SAHA.  
In terms of structure activity relationship (SAR), the position of the 
modification is critical and can greatly affect both potency and selectivity of the 
inhibitors. In the C2-modified SAHA analogs, high fold selectivities were observed 
(up to 300-fold) to HDAC6 and 8, but with micromolar to submicromolar IC50 values 
(0.6 to 2 µM). Modifications at the C4 position of the linker gave analogs with higher 
fold selectivity (up to 1300-fold) to HDAC6 and 8, and the potency was enhanced as 
well (48 and 27 nM IC50 values with HDAC6 and 8, respectively) compared to the 
C2-modified SAHA analogs. On the other hand, moving the same modification 
farther to the C5- position of the linker (C5-benzyl SAHA) resulted in reduction in 
both selectivity (8- to 12-fold only), and potency (270 and 380 nM IC50 values with 
HDAC6 and 8) compared to the C4-benzyl SAHA. 
Docking studies were done for the (R)- and (S)-C2-n-hexyl SAHA, and (R)- 
and (S)-C4-benzyl SAHA, and showed that the presence of the hexyl or benzyl 
groups at the C2 or C4 positions in the linker region led to the dual HDAC6/HDAC8 
selectivity over HDAC1, 2, and 3 due to steric clash between the substituents and 
the active site entrances of HDAC1, 2, and 3.  
In another project, several biaryl indolyl benzamide derivatives were 




showed the highest potency compared to Bnz-1 and Bnz-2. Bnz-3 displayed about 
10-fold higher potency than Bnz-2, and about 100-fold higher potency than Bnz-1. 
Bnz-3 exhibited a modest inhibitory potency with HDAC1 (548 nM), but only 7.3-fold 
selectivity for HDAC1 over HDAC2. 
This thesis, along with previous reports103-105, indicate that modifying SAHA in 
the linker region can alter the selectivity of HDAC inhibitors, and suggest that 
modifying current drugs can significantly improve their properties. The dual 
HDAC6/8 selective inhibitors reported in this work can be used as biological tools to 
study both HDAC6 and HDAC8-related cancer biology, and as leads for 
development of more effective anti-cancer agents targeting both HDAC6 and 
HDAC8. 
The first future direction in this work is to test the (R)-C4-benzyl SAHA analog (R)-
19f in mouse studies in a collaboration work with Dr. Ge at Karmanos Cancer 
institute. A second future direction is based on the unique dual HDAC6/8 selectivity 
that was observed upon substituting the C4 in the linker of SAHA, in which HDAC 
substrate bearing the benzyl group in its linker region will be synthesized and tested 
for isoform selectivity. Isoform selective HDAC substrate can be used for PET 
imaging, to monitor levels of HDAC isoforms in different types of tumors (like brain 
tumors) in order to monitor treatment effectiveness and disease progression in a 
collaboration with Dr. Gelovani at college of engineering, Wayne State University. 
Finally, to develop highly selective HDAC1 selective inhibitors, several analogs of 
Cpd-60 and other HDAC1/2 selective inhibitors will be designed and synthesized 




structures of the HDAC1/2 selective inhibitors and then docking of the modified 
structures in the crystal structures of HDAC1 and HDAC2 using LeadIt program. The 
best hits that show selectivity to HDAC1 over HDAC2 will be synthesized and 





APPENDIX A  
A.1. Compound characterization data of (R) and (S)-C2-n-hexyl SAHA (1i) 
 
Figure ‎A.1. 1H NMR spectrum of (S)-9. 
 





Figure ‎A.3. Low resolution mass spectrum of (S)-9.   
 





Figure ‎A.5. 13C NMR spectrum of (R)-9. 
 





Figure ‎A.7. 1H NMR spectrum of (S)-10. 
 
 






Figure ‎A.9. Low resolution mass spectrum of (S)-10. 
 





Figure ‎A.11. 13C NMR spectrum of (R)-10. 
 





Figure ‎A.13. 1H NMR spectrum of (R)-11. 
 





Figure ‎A.15. Low resolution mass spectrum of (R)-11. 
 






Figure ‎A.17. 1H NMR spectrum of (S)-11. 
 





Figure ‎A.19. Low resolution mass spectrum of (S)-11. 
 





Figure ‎A.21. 13C NMR spectrum of R-C2-n-hexyl SAHA (R)-1i. 
 






Figure ‎A.23. 1H NMR spectrum of (S)-C2-n-hexyl SAHA (S)-1i. 
 
 





Figure ‎A.25. High resolution mass spectrum of (S)-C2-n-hexyl SAHA (S)-1i.  
 
 
Figure ‎A.26. Chiral HPLC spectrum taken at 254 nm of the C2-n-hexyl SAHA (1i) as 
a racemic mixture. The spectrum shows peaks for both the R and the S 
enantiomers. The calculated area and height under each peak, along with % area, is 





Figure ‎A.27. Chiral HPLC spectrum taken at 254 nm of the (R)-C2-n-hexyl SAHA 
(R)-1i. The major peak (at 36.5 min) represents the R enantiomer, while the minor 
peak (at 30.2 min) represents the S enantiomer. The calculated area and height 
under each peak, along with % area, is shown in the table below the spectrum. 
 
 
Figure ‎A.28. Chiral HPLC spectrum taken at 254 nm of the (S)-C2-n-hexyl SAHA 
(S-1i). The major peak (at 29.3 min) represents the S enantiomer, while the minor 
peak (at 38.6 min) represents the R enantiomer. The calculated area and height 




A.2. In vitro HDAC activity screening data 
Table ‎A.1. Percent remaining deacetylase activity after incubation of a single 
concentration of SAHA and each C2-modified SAHA analog with HDAC1, HDAC2, 
HDAC3, and HDAC6 using the ELISA-based activity assay.a  
a The means and standard errors for a minimum of three independent trials are 
shown. All analogs were used at 5M final concentration, except SAHA and C2-butyl 
(1d) which were tested at 1µM and 10µM respectively. This data is associated with 
Figure 2.3. 
 
 Deacetylase activity (%) 
compound HDAC1 HDAC2 HDAC3 HDAC6 
SAHA93 8.9±0.1 8.3±0.2 14±3 7.9±1.6 
1a (methyl) 62±8 78±3 96±4 55±6 
1b (ethyl) 76±5 65±6 88±5 52±6 
1c (propyl) 75±4 69±1 86±7 49±5 
1d (butyl) 69±8 82±4 78±6 39±4 
1e (allyl) 83±6 78±3 90±3 52±7 
1f (propargyl) 90±7 91±2 99±3 62±7 
1g (benzyl) 92±4 99±1 92±8 30±6 
1h (pentyl) 89±1 99±2 95±4 21±5 






Figure ‎A.29. Dose dependent curve of SAHA with HDAC8 isoform with error bars 
depicting the standard error of at three independent trials. In some cases, the error 
bars are smaller than the size of the filled circle.  IC50 values associated with Table 
2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 
(Synergy Software) (Table A.2). 
 











a Means and standard errors of at three independent trials with the SAHA 
concentrations shown.  Data is associated with Figure A.29 and Table 2.2. 
 
 
Concentration (M) Deacetylase activity (%) 
3.2 x 10-6 111 
1.6 x 10-6 231 
8.0 x 10-7 382 
4.0 x 10-7 603 
2.0 x 10-7 742 





Figure ‎A.30. Dose dependent curve of tubastatin with HDAC8 isoform with error 
bars depicting the standard error of at three independent trials. In some cases, the 
error bars are smaller than the size of the filled circle. IC50 values associated with 
Table 2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table A.3). 
 











a Means and standard errors of at three independent trials with the tubastatin 
concentrations shown. Data is associated with Figure A.30 and Table 2.2. 
 
Concentration (M) Deacetylase activity (%) 
2.0 x 10-6 152 
1.0 x 10-6 252 
5.0 x 10-7 402 
2.5 x 10-7 581 
1.25 x 10-7 733 





Figure ‎A.31. Dose dependent curves of C2-benzyl SAHA analog (1g) with HDAC1, 
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the 
standard error of at least two independent trials. IC50 values associated with Table 
2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 
(Synergy Software) (Table A.4). 
Table ‎A.4. Percentage remaining deacetylase activity after incubation of C2-benzyl 
SAHA (1g) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
a Means and standard errors of at least two independent trials with the C2-benzyl 




Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
4.0 x 10-4 131 171 112   
2.0 x 10-4 312 302 273   
1.0 x 10-4 416 551 502   
5.0 x 10-5 661 741 682   
2.5 x 10-5 813 843 827   
4.0 x 10-6    217 252 
2.0 x 10-6    503 373 
1.0 x 10-6    646 544 
5.0 x 10-7    731 696 





Figure ‎A.32. Dose dependent curves of C2-n-pentyl SAHA analog (1h) with 
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting 
the standard error of at least two independent trials. IC50 values associated with 
Table 2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table A.5). 
Table ‎A.5. Percentage remaining deacetylase activity after incubation of C2-n-pentyl 
SAHA (1h) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
Concentration 
(M) 
Deacetylase Activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-4 211 261 193   
8.0 x 10-5 381 441 362   
4.0 x 10-5 564 593 503   
2.0 x 10-5 711 741 714   
1.0 x 10-5 833 841 836   
8.0 x 10-6     172 
4.0 x 10-6    185 261 
2.0 x 10-6    314 413 
1.0 x 10-6    424 552 
5.0 x 10-7    646 711 
2.5 x 10-7    781  
a Means and standard errors of at least two independent trials with the C2-n-pentyl 






Figure ‎A.33. Dose dependent curves of C2-n-hexyl SAHA derivative (1i) with 
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting 
the standard error of at least two independent trials.  IC50 values associated with 
Table 2.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table A.6). 
Table ‎A.6. Percentage of remaining HDAC deacetylase activity after incubation of 
C2-n-hexyl SAHA derivative (1i) HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
Concentration 
(M) 
Deacetylase Activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
6.4 x 10-4 322 353 285   
3.2 x 10-4 398 431 383   
1.6 x 10-4 523 555 435   
8.0 x 10-5 603 612 505   
4.0 x 10-5 774 617 632   
8.0 x 10-6     181 
4.0 x 10-6    153 302 
2.0 x 10-6    283 511 
1.0 x 10-6    441 704 
5.0 x 10-7    502 844 
2.5 x 10-7    676  
a Means and standard errors of at least two independent trials are shown. Data is 





Figure ‎A.34. Dose dependent curves of (S)-C2-n-hexyl SAHA ((S)-1i) with HDAC1, 
HDAC2, HDAC3, and HDAC8 isoforms with error bars depicting the standard error 
of at least two independent trials. IC50 values associated with Table 2.2 were 
determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 (Synergy 
Software) (Table A.7). 
Table ‎A.7. Percentage of remaining HDAC deacetylase activity after incubation of 
(S)-C2-n-hexyl SAHA ((S)-1i) HDAC1, HDAC2, HDAC3, and HDAC8.a 
Concentration 
(M) 
Deacetylase Activity (%) 
HDAC1 HDAC2 HDAC3 HDAC8 
1.28 x 10-3 205 241 304  
6.4 x 10-4 321 492 385  
3.2 x 10-4 561 683 684  
1.6 x 10-4 675 862 822  
8.0 x 10-5 752 911 9010  
1.6 x 10-5    154 
8.0 x 10-6    262 
4.0 x 10-6    434 
2.0 x 10-6    602 
1.0 x 10-6    786 
a Means and standard errors of at least two independent trials are shown. Data is 





Figure ‎A.35. Dose dependent curves of (R)-C2-n-hexyl SAHA derivative ((S)-1i) 
with HDAC8 isoform with error bars depicting the standard error of at least two 
independent trials.  IC50 values associated with Table 2.2 were determined by fitting 
data to a sigmoidal curve using KaleidaGraph 4.1.3 (Synergy Software) (Table A.8). 
Table ‎A.8. Percentage of remaining HDAC deacetylase activity after incubation of 
(R)-C2-n-hexyl SAHA and HDAC8.a 
Concentration 
(M) 
Deacetylase Activity (%) 
HDAC8 
8.0 x 10-6 3.73.5 
4.0 x 10-6 114 
2.0 x 10-6 241 
1.0 x 10-6 506 
5.0 x 10-7 635 
2.5 x 10-7 728 
1.25 x 10-7 7612 
a Means and standard errors of at least two independent trials are shown. Data is 






A.3. In cellulo selectivity data 






Figure ‎A.36. Representative cell-based selectivity trials with SAHA, tubastatin and 
SAHA analogs. U937 cells were treated with DMSO (1%), SAHA, C2-benzyl SAHA 
(1g), C2-n-pentyl SAHA (1h), C2-n-hexyl SAHA (1i). After lysis and SDS-PAGE 
separation of the proteins in the lysates, western blots analysis of acetyl-histone H3 
(AcH3) and acetyl-α-tubulin (AcTub) was performed.  GAPDH was used as a loading 
control. DMSO was used as the no inhibitor control.  These three trials (parts A-C) 
are associated with the fourth trial shown in Figure 2.4a. 
Table ‎A.9. Fold increase in acetyl-histone H3 and acetyl-tubulin at 30 µM of SAHA 
analogs 1g, 1i, and 1h, compared to DMSO treated cells for the western blots 
images in figures 2.4a and A.36.a 
Compound 









1g (benzyl) 0.99 0.32 5.0 0.80 
1i (pentyl) 1.6 0.84 7.5 3.2 
1h (hexyl) 1.3 0.44 3.9 0.53 
a Means and standard errors of four independent trials are shown. Data is 
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Figure ‎A.37. Repetitive cell-based selectivity trials with C2-n-hexyl SAHA analog 
(1i). U937 cells were treated with increasing concentrations of C2-n-hexyl SAHA 
analog (1i, 10-60 µM or 5-50 µM). After lysis and SDS-PAGE separation of the 
proteins in the lysates, western blot analysis of acetyl-histone H3 (AcH3) and acetyl-
α-tubulin (AcTub) was performed.  GAPDH was used as a loading control. DMSO 
was used as the no inhibitor control. These two trials (parts a and b) are associated 
with the third trial shown in Figure 2.4b. 
A.4. Cell growth inhibition data 
Table ‎A.10. Percentage of viable cells after treatment of Jurkat cell line with of C2-
benzyl SAHA 1g, C2-pentyl SAHA 1h, C2-hexyl SAHA 1i, and SAHA.a 
 Viable cells (%) 
Compound 1 µM 10 µM 
1g (benzyl) 100 ± 8 83 ± 2 
1h (pentyl) 80 ± 13 92 ± 8 
1i (hexyl) 88 ± 11 47 ± 9 
SAHA 49 ± 6 5 ± 3 
a Means and standard errors for a minimum of three independent trials are shown. 
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Figure ‎A.38. Dose dependent cell viability of SAHA with Jurkat, AML MOLM-13, and 
U937 cell lines, with error bars depicting the standard error of at least three 
independent trials. EC50 values associated with Table 2.3 were determined by fitting 
data to a sigmoidal curve using KaleidaGraph 4.1.3  (Synergy Software) (Table 
A.11). 
 
Table ‎A.11. Percentage of viable cells after treatment of different cell lines with 











a Standard errors of at least three independent trials are shown. Data is associated 







Viable cells (%) 
Jurkat AML-MOL13 U937 
4.0 x 10-6 12  1 9  1 22  3 
2.0 x 10-6 18  4 24  2 24  6 
1.0 x 10-6 53  5 60  6 43  23 
5.0 x 10-7 59  9 88  3 75  11 
2.5 x 10-7 70  11 103  10 76  4 






Figure ‎A.39. Dose dependent cell viability of C2-n-hexyl SAHA (1i) with Jurkat, AML 
MOLM-13, and U937 cell lines, with error bars depicting the standard error of more 
than three independent trials. EC50 values associated with Table 2.3 were 
determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3  (Synergy 
Software) (Table A.12). 
Table ‎A.12. Percentage of viable cells after treatment of different cell lines with of 
C2-n-hexyl SAHA (1i) at the specified concentrations.a 
a Means and standard errors of at least three independent trials are shown. Data is 
associated with Figure A.39 and Table 2.3. 
Concentration (M) 
Viable cells (%) 
Jurkat AML-MOL13 U937 
6.4 x 10-5   14  3 
3.2 x 10-5 30  2 11  1 19  3 
1.6 x 10-5 41  2 54  3 30  1 
8.0 x 10-6 52  6 64  5 98  10 
4.0 x 10-6 83  10 64  4 94  20 
2.0 x 10-6 83  5 84  3 98  10 




APPENDIX B  
B.1. Compound characterization of the C4-modified SAHA analogs 
  
Figure ‎B.1. 1HNMR spectrum of 16b in CD3OD.  
 















Figure ‎B.5. 1HNMR spectrum of 16c in CD3OD.   
  





Figure ‎B.7. IR spectrum of 16c using a Perkin Elmer Spectrum Two ATR-FTIR.  
  
 





Figure ‎B.9. 1HNMR spectrum of 16e in CDCl3.   
 






Figure ‎B.11. IR spectrum of 16e using a Perkin Elmer Spectrum Two ATR-FTIR.  
 
  





Figure ‎B.13. 1HNMR spectrum of 17b in CDCl3.  
  







Figure ‎B.15. IR spectrum of 17b using a Perkin Elmer Spectrum Two ATR-FTIR.  
 
   





Figure ‎B.17. 1HNMR spectrum of 17e in CD3OD. 
   
 







Figure ‎B.19. IR spectrum of 17e using a Perkin Elmer Spectrum Two ATR-FTIR.  
  
  






Figure ‎B.21. 1HNMR spectrum of 18a in CD3OD. 
 
  






Figure ‎B.23. IR spectrum of 18a using a Perkin Elmer Spectrum Two ATR-FTIR.  
  





Figure ‎B.25. 1HNMR spectrum of 18b in CD3OD. 
 





Figure ‎B.27. IR spectrum of 18b using a Perkin Elmer Spectrum Two ATR-FTIR.  
 
  





Figure ‎B.29. 1HNMR spectrum of 18c in CD3OD. 
 
  






Figure ‎B.31. IR spectrum of 18c using a Perkin Elmer Spectrum Two ATR-FTIR.  
   
 





Figure ‎B.33. 1HNMR spectrum of 18d in CD3OD. 
 





Figure ‎B.35. Low resolution mass spectrum of 18d. 
 
 









Figure ‎B.37. 13CNMR spectrum of 18e in CD3OD. 
 
  




   
  
Figure ‎B.39. Low resolution mass spectrum of 18e. 
   
 





Figure ‎B.41. 13CNMR spectrum of 18f in CD3OD. 
 
 





Figure ‎B.43. Low resolution mass spectrum of 18f. 
  






Figure ‎B.45. 13CNMR spectrum of 19a in CD3OD. 
 





Figure ‎B.47. High resolution mass spectrum of 19a. 
 
 
Figure ‎B.48. HPLC spectrum taken at 254 nm of C4-methyl SAHA (19a).  The peak 
at 13.676 is C4-methyl SAHA.  The calculated area and height under each peak, 





Figure ‎B.49. 1HNMR spectrum of 19b in CD3OD. 
 





Figure ‎B.51. IR spectrum of 19b using a Perkin Elmer Spectrum Two ATR-FTIR.   
 






Figure ‎B.53. HPLC spectrum taken at 254 nm of C4-ethyl SAHA (19b). The peak at 
16.388 is C4-ethyl SAHA. The calculated area and height under each peak, along 
with % area, is shown in the table below the spectrum. 
 






Figure ‎B.55. 13CNMR spectrum of 19c in CD3OD. 
 
 





Figure ‎B.57. High resolution mass spectrum of 19c. 
 
 
Figure ‎B.58. HPLC spectrum taken at 254 nm of C4-n-butyl SAHA (19c).  The peak 
at 20.128 is C4-n-butyl SAHA. The calculated area and height under each peak, 





Figure ‎B.59. 1HNMR spectrum of 19d in CD3OD. 
 





Figure ‎B.61. IR spectrum of 19d using a Perkin Elmer Spectrum Two ATR-FTIR.  
 






Figure ‎B.63. HPLC spectrum taken at 254 nm of C4-n-hexyl SAHA (19d).  The peak 
at 22.624 is C4-n-hexyl SAHA. The calculated area and height under each peak, 
along with % area, is shown in the table below the spectrum. 
 






Figure ‎B.65. 13CNMR spectrum of 19e in CD3OD. 
 
 






Figure ‎B.67. High resolution mass spectrum of 19e. 
 
 
Figure ‎B.68. HPLC spectrum taken at 254 nm of C4-phenyl SAHA (19e). The peak 
at 19.398 is C4-phenyl SAHA. The calculated area and height under each peak, 





Figure ‎B.69. 1HNMR spectrum of 19f in CD3OD. 
 
 







Figure ‎B.71. IR spectrum of 19f using a Perkin Elmer Spectrum Two ATR-FTIR.  
 






Figure ‎B.73. HPLC spectrum taken at 254 nm of C4-benzyl SAHA (19f). The peak 
at 18.119 is C4-benzyl SAHA. The calculated area and height under each peak, 
along with % area, is shown in the table below the spectrum. 
 





Figure ‎B.75. 13CNMR spectrum of (R)-20 in CDCl3. 
 





Figure ‎B.77. 1HNMR spectrum of (RS)-21 in CDCl3. 
 
Figure ‎B.78. Enlarged 1HNMR spectrum of (RS)-21 showing a peak of the major 
diastereomer at 4.05 (overlapping with another peak) and a peak of the minor 
diastereomer (RR)-21 at 3.82. Integration of these two peaks (2.00 and 0.02) was 





Figure ‎B.79. 13CNMR spectrum of (RS)-21 in CDCl3. 
  





Figure ‎B.81. 1HNMR spectrum of (R)-23 in CDCl3. 
 





Figure ‎B.83. Low resolution mass spectrum of (R)-23. 
 





Figure ‎B.85. Enlarged 1HNMR spectrum of (RR)-21 showing a peak of the major 
diastereomer at 4.45 and a peak of the minor diastereomer (RS)-21 at 4.63. 
Integration of these two peaks (0.99 and 0.03) was used to calculate the 
diastereomeric ratio (dr) discussed in the text (97:3 dr). 
 





Figure ‎B.87. Low resolution mass spectrum of (RR)-21. 
 





Figure ‎B.89. 13CNMR spectrum of (S)-22 in CDCl3. 
 
 





Figure ‎B.91. 13CNMR spectrum of (R)-22 in CDCl3. 
B.2. Synthesis scheme for Mosher's esters 
Scheme B.1: Synthesis of Mosher's esters (S)-22-(R)-MTPA and (R)-22-(R)-MTPA 







Figure ‎B.92. 1HNMR spectrum of (S)-22-(R)-MTPA in CDCl3. 
 
Figure ‎B.93. Enlarged 1HNMR spectrum of (S)-22-(R)-MTPA showing a singlet peak 
of the major diastereomer at 3.491, and another singlet peak of the minor 
diastereomer (R)-22-(R)-MTPA at 3.481. Integration of these two peaks (100.00 and 






Figure ‎B.94. Enlarged 1HNMR spectrum of (S)-22-(R)-MTPA showing a doublet 
peak of the major diastereomer at 6.961 and 6.973, and another doublet peak of the 
minor diastereomer (R)-22-(R)-MTPA at  7.003 and 7.015. Integration of these two 
peaks (100.00 and 1.14) was used to calculate the diastereomeric ratio (dr) 
discussed in the text (99:1 dr). 
 





Figure ‎B.96. 19FNMR spectrum of (S)-22-(R)-MTPA in CDCl3. 
 





Figure ‎B.98. 1HNMR spectrum of (R)-22-(R)-MTPA in CDCl3. 
 
Figure ‎B.99. Enlarged 1HNMR spectrum of (R)-22-(R)-MTPA showing a doublet 
doublet peaks of the major diastereomer at 4.004-4.029 and another doublet doublet 
peak of the minor diastereomer (S)-22-(R)-MTPA at 4.107-4.133. Integration of 
these two peaks (100.06 and 2.07) was used to calculate the diastereomeric ratio 





Figure ‎B.100. Enlarged 1HNMR spectrum of (R)-22-(R)-MTPA showing a doublet 
peak of the major diastereomer at 7.004 and 7.016, and another doublet peak of the 
minor diastereomer (S)-22-(R)-MTPA at 6.962 and 6.974. Integration of these two 
peaks (100.00 and 2.53) was used to calculate the diastereomeric ratio (dr) 
discussed in the text (98:2 dr). 
 





Figure ‎B.102. 19FNMR spectrum of (R)-22-(R)-MTPA in CDCl3. 
 





Figure ‎B.104. 1HNMR spectrum of (R)-24 in CDCl3. 
 





Figure ‎B.106. IR spectrum of (R)-24. 
 





Figure ‎B.108. 1HNMR spectrum of (S)-24 in CDCl3. 
 





Figure ‎B.110. IR spectrum of (S)-24. 
 





Figure ‎B.112. 1HNMR spectrum of (S)-25 in CDCl3. 
 





Figure ‎B.114. IR spectrum of (S)-25. 
 





Figure ‎B.116. 1HNMR spectrum of (R)-25 in CDCl3. 
 





Figure ‎B.118. IR spectrum of (R)-25. 
 





Figure ‎B.120. 1HNMR spectrum of 26 in CDCl3. 
 





Figure ‎B.122. 1HNMR spectrum of (S)-27 in CDCl3. 
 





Figure ‎B.124. IR spectrum of (S)-27. 
 





Figure ‎B.126. 1HNMR spectrum of (R)-27 in CDCl3. 
 





Figure ‎B.128. IR spectrum of (R)-27. 
 





Figure ‎B.130. 1HNMR spectrum of (R)-19f in CD3OD. 
 






Figure ‎B.132. IR spectrum of (R)-1f. 
  





Figure ‎B.134. HPLC spectrum taken at 254 nm of R-C4-benzyl SAHA ((R)-19f). The 
peak at 18.465 is R-C4-benzyl SAHA. The calculated area and height under each 
peak, along with % area, is shown in the table below the spectrum. 
 





Figure ‎B.136. 13CNMR spectrum of (S)-19f in CD3OD. 
 





Figure ‎B.138. High resolution mass spectrum of (S)-19f. 
 
 
Figure ‎B.139. HPLC spectrum taken at 254 nm of R-C4-benzyl SAHA ((S)-19f). The 
peak at 18.240 is R-C4-benzyl SAHA. The calculated area and height under each 




B.3. In vitro screening with HDAC isoforms tables and figures 
 
Figure ‎B.140. Dose response curve of SAHA and C4-SAHA analogs 19a-f tested 
using the HDAC activity in HeLa cells lysates from three independent trials with error 
bars indicating standard error (see Table S1). In some cases, the error bar is smaller 
than the marker size. Data were fit to the sigmoidal curve using KaleidaGraph 4.1.3 



















Table ‎B.1. Percent remaining HDAC activity after incubation of SAHA or C4-SAHA 
analogs 19a-f with HeLa Lysates 
 Deacetylase activity (%) 
Concentration 
(M) 
SAHA 19a 19b 19c 19d 19e 19f 
2.0 x 10-4     21±3 15±1 19±2 
1.0 x 10-4     35±3 32±1 35±5 
1.2 x 10-4    24±1    
6.0 x 10-5    44±4    
5.0 x 10-5     56±2 57±2 58±4 
4.8 x 10-5   12±1     
3.0 x 10-5    69±2    
2.5 x 10-5     73±2 88±1 74±5 
2.4 x 10-5   31±2     
1.5 x 10-5    88±1    
1.25 x 10-5     87±1 104±1 88±4 
1.2 x 10-5   53±3     
1.0 x 10-5  17±2      
7.5 x 10-6    97±2    
6.0 x 10-6   82±7     
5.0 x 10-6  38±4      
3.0 x 10-6   92±1     
2.5 x 10-6  60±3      
1.25 x 10-6  79±3      
6.25 x 10-6  91±2      
2.0 x 10-7 49±1       
1.0 x 10-7 78±4       
5.0 x 10-8 86±4       
2.5 x 10-8 97±1       
a Mean percentage deacetylase activity and standard error of three trials are shown. 











Table ‎B.2. Percent remaining deacetylase activity after incubation of a single 
concentration of each C4-modified SAHA analog with HDAC1, HDAC2, HDAC3, and 
HDAC6 using the ELISA-based activity assay.a  
 Deacetylase activity (%) 
Compound HDAC1 HDAC2 HDAC3 HDAC6 
SAHA93 1 µM  8.9±0.1 8.3±0.2 14±3 7.9±1.6 
19a (methyl) 0.75 µM 75±2 90±7 78±4 26±5 
19b (ethyl) 0.75 µM 91±2 87±1 71±10 18±6 
19c (butyl) 2.5 µM 88±2 87±1 85±2 5±3 
19d (hexyl) 1.25 µM 97±3 101±2 100±6 21±2 
19e (phenyl) 2.5 µM 86±1 85±3 85±5 17±7 
19f (benzyl) 5 µM 87±4 92±4 90±3 2.9±0.5 
a The means and standard errors for a minimum of two independent trials are 





























Figure ‎B.141. Dose dependent curves of C4-ethyl SAHA analog (19b) with HDAC1, 
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the 
standard error of at least three independent trials. IC50 values associated with Table 
3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 
(Synergy Software) (Table B.3). 
Table ‎B.3. Percentage remaining deacetylase activity after incubation of C4-ethyl 















a Means and standard errors of at least three independent trials with the C4-ethyl 





Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-5 191 232 178   
8.0 x 10-6 324 347 526   
4.0 x 10-6 581 592 642   
2.0 x 10-6 685 691 714   
1.0 x 10-6 813 862 837   
4.0 x 10-7    333 251 
2.0 x 10-7    435 391 
1.0 x 10-7    616 552 
5.0 x 10-8    747 732 





Figure ‎B.142. Dose dependent curves of C4-butyl SAHA analog (19c) with HDAC1, 
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the 
standard error of at least three independent trials. IC50 values associated with Table 
3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 
(Synergy Software) (Table B.4). 
Table ‎B.4. Percentage remaining deacetylase activity after incubation of C4-butyl 
SAHA analog (19c) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
a Means and standard errors of at least three independent trials with the C4-butyl 
SAHA (19c) concentrations shown. Data is associated with Figure B.133 and Table 
3.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
5.6 x 10-5 191 1810 255   
2.8 x 10-5 351 432 485   
1.4 x 10-5 533 571 642   
7.0 x 10-6 672 712 793   
3.5 x 10-6 811 815 793   
4.0 x 10-7    233  
2.0 x 10-7    395 284 
1.0 x 10-7    469 415 
5.0 x 10-8    616 617 
2.5 x 10-8    706 743 





Figure ‎B.143. Dose dependent curves of C4-n-hexyl SAHA analog (19d) HDAC1, 
HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting the 
standard error of at least three independent trials. IC50 values associated with Table 
3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 4.1.3 
(Synergy Software) (Table B.5). 
Table ‎B.5. Percentage remaining deacetylase activity after incubation of C4-n-hexyl 
SAHA analog (19d) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
a Means and standard errors of at least three independent trials with the C4-n-hexyl 
SAHA (19d) concentrations shown.  Data is associated with Figure B.134 and Table 
3.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-4 131 161 53   
8.0 x 10-5 262 312 251   
4.0 x 10-5 461 466 425   
2.0 x 10-5 674 732 564   
1.0 x 10-5 834 796 882   
4.0 x 10-7    272  
2.0 x 10-7    424 272 
1.0 x 10-7    564 424 
5.0 x 10-8    756 634 
2.5 x 10-8    779 786 





Figure ‎B.144. Dose dependent curves of C4-phenyl SAHA analog (19e) with 
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table B.6). 
Table ‎B.6. Percentage remaining deacetylase activity after incubation of C4-phenyl 
SAHA analog (19e) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
a Means and standard errors of at least three independent trials with the C4-phenyl 
SAHA (19e) concentrations shown.  Data is associated with Figure B.135 and Table 
3.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
4.8 x 10-5 191 222 302   
2.4 x 10-5 341 336 533   
1.2 x 10-5 532 531 643   
6.0 x 10-6 635 682 745   
3.0 x 10-6 742 723 884   
8.0 x 10-7     291 
4.0 x 10-7    327 487 
2.0 x 10-7    402 572 
1.0 x 10-7    525 693 
5.0 x 10-8    647 802 





Figure ‎B.145. Dose dependent curves of C4-benzyl SAHA analog (19f) with 
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table B.7). 
Table ‎B.7. Percentage remaining deacetylase activity after incubation of C4-benzyl 
SAHA analog (19f) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
 
a Means and standard errors of at least three independent trials with the C4-beznyl 
SAHA (19f) concentrations shown.  Data is associated with Figure B.136 and Table 
3.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-4 161 201 192   
8.0 x 10-5 272 275 332   
4.0 x 10-5 442 471 553   
2.0 x 10-5 585 601 635   
1.0 x 10-5 755 744 874   
4.0 x 10-7    184  
2.0 x 10-7    455 211 
1.0 x 10-7    604 342 
5.0 x 10-8    765 511 
2.5 x 10-8    907 732 





Figure ‎B.146. Dose dependent curves of (R)-C4-benzyl SAHA analog ((R)-19f) with 
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table B.8). 
Table ‎B.8. Percentage remaining deacetylase activity after incubation of C4-benzyl 
SAHA analog ((R)-19f) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
 
a Means and standard errors of at least three independent trials with the (S)-C4-
beznyl SAHA ((R)-19f) concentrations shown.  Data is associated with Figure B.137 
and Table 3.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
8.0 x 10-5 242 291 252   
4.0 x 10-5 383 435 392   
2.0 x 10-5 536 714 544   
1.0 x 10-5 723 835 772   
5.0 x 10-6 884 961 892   
2.0 x 10-7    264 161 
1.0 x 10-7    376 221 
5.0 x 10-8    575 373 
2.5 x 10-8    598 564 





Figure ‎B.147. Dose dependent curves of (S)-C4-benzyl SAHA analog ((S)-19f) with 
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 isoforms with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 3.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table B.9). 
Table ‎B.9. Percentage remaining deacetylase activity after incubation of C4-benzyl 
SAHA analog ((S)-19f) with HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8.a 
 
a Means and standard errors of at least three independent trials with the (S)-C4-
beznyl SAHA ((S)-19f) concentrations shown.  Data is associated with Figure B.138 
and Table 3.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-4 171 222 152   
8.0 x 10-5 322 376 334   
4.0 x 10-5 503 563 482   
2.0 x 10-5 683 743 674   
1.0 x 10-5 847 875 765   
8.0 x 10-7    166 191 
4.0 x 10-7    176 281 
2.0 x 10-7    377 422 
1.0 x 10-7    487 613 




Table ‎B.10. Fold selectivity of SAHA, tubastatin, and C4-SAHA analogs 19b-19f for 
HDAC6 and HDAC8 over HDAC1, 2, and 3.a 
Compound 
HDAC6 fold selectivity HDAC8 fold selectivity 
HDAC1 HDAC2 HDAC3 HDAC1 HDAC2 HDAC3 
SAHA 1 3 0.6 b 0.06 c 0.2 c 0.04 c 
Tubastatin 87 130 94 8.2 12 8.8 
C4-ethyl SAHA 19b 28 31 38 34 38 46 
C4-butyl SAHA 19c 170 200 260 200 240 310 
C4-hexyl SAHA 19d 250 270 210 440 480 380 
C4-phenyl SAHA 19e 100 350 210 38 130 79 
C4-benzyl SAHA 19f 210 270 300 510 670 740 
(S)-C4-benzyl SAHA 
(S)-19f 
520 750 560 930 1300 1000 
(R)-C4-benzyl SAHA 
(R)-19f 
420 540 390 260 330 240 
a Fold selectivities were calculated from the IC50 values in tables 2 and 3. 
b SAHA 
displayed 1.65-fold preference for HDAC3 versus HDAC6. c SAHA displayed 16-fold, 
6-fold, and 27-fold preference for HDAC1, 2, and 3, respectively, over HDAC8 
B.4. In cellulo selectivity testing figure 
A)             B) 
     
Figure ‎B.148. Repetitive cell-based selectivity trials of the western blots analysis of 
acetyl-α-tubulin (AcTub) after treatment with SAHA or the SAHA analogs. U937 cells 
were treated with SAHA (5 µM), DMSO (1%),  C4-benzyl SAHA (19f) analog before 
lysis, SDS-PAGE separation, transfer to a PVDF membrane, and western blotted 
with AcTub antibody. GAPDH levels in the samples were also probed as a gel load 
control. A DMSO control sample was included for comparison to inhibitor  treated 
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B.5. In vitro cancer cell growth inhibition tables and figures 
 
 
Figure ‎B.149. Dose dependent cell viability of C4-n-butyl SAHA (19c) with U937 cell 
line, with error bars depicting the standard error of more than three independent 
trials. EC50 values associated with Table 3.2 were determined by fitting data to a 
sigmoidal curve using KaleidaGraph 4.1.3  (Synergy Software) (Table B.11). 
 
Figure ‎B.150. Dose dependent cell viability of C4-n-hexyl SAHA (19d) with U937 
cell line, with error bars depicting the standard error of six independent trials. EC50 
values associated with Table 3.2 were determined by fitting data to a sigmoidal 
curve using KaleidaGraph 4.1.3  (Synergy Software) (Table B.11). 
 






Figure ‎B.151. Dose dependent cell viability of C4-benzyl SAHA (19f) with U937 cell 
line, with error bars depicting the standard error of more than three independent 
trials. EC50 values associated with Table 3.2 were determined by fitting data to a 
sigmoidal curve using KaleidaGraph 4.1.3  (Synergy Software) (Table B.11). 
Table ‎B.11. Percentage of viable cells after treatment of U937 cell line with C4-butyl 










a Means and standard errors of at least three independent trials are shown. Data is 
associated with Figures B.140-B.142 and Table 3.3. 
 
Concentration (M) 
Viable cells (%) 
19c (butyl) 19d (hexyl) 19f (benzyl) 
6.4 x 10-5 24  1 24  4 26  2 
3.2 x 10-5 54  2 28  6 49  3 
1.6 x 10-5 80  4 37  7 69  8 
8.0 x 10-6 87  6 102  7 80  2 
4.0 x 10-6 100  9 108  9 74  4 





Figure ‎B.152. Cytotoxicity screening of SAHA, and C4-SAHA analogs 19c, 19d, and 
19f, at 1 and 10 µM concentrations using an MTT assay with Jurkat cell line.  Mean 
percent cell viability from a minimum of three independent trials with standard errors 
were plotted (Table B.12). 
Table ‎B.12. Percentage of viable cells after treatment of Jurkat cell line with of C4-
butyl SAHA 19c, C4-hexyl SAHA 19d, C4-benzyl SAHA 19f, and SAHA.a 
 Viable cells (%) 
Compound 1 µM 10 µM 
19c (butyl) 98  6 62  16 
19d (hexyl) 69  4 39  6 
19f (benzyl) 89  20 97  4 
SAHA 49  6 5  3 
a Means and standard errors for a minimum of four independent trials are shown. All 








APPENDIX C  
C.1. Compound characterization of the C5-modified SAHA analogs 
 
Figure ‎C.1. 1HNMR spectrum of 29. 
 





Figure ‎C.3. 1HNMR spectrum of 30. 
 





Figure ‎C.5. Low resolution mass spectrum of 30 using a Waters ZQ LC-SQMS 
instrument. 
 





Figure ‎C.7. 1HNMR spectrum of 33a. 
 





Figure ‎C.9. Low resolution mass spectrum of 33a using a Waters ZQ LC-SQMS 
instrument. 
 






Figure ‎C.11. 1HNMR spectrum of 33b. 
 





Figure ‎C.13. Low resolution mass spectrum of 33b using a Waters ZQ LC-SQMS 
instrument. 
 





Figure ‎C.15. 1HNMR spectrum of 33c. 
 





Figure ‎C.17. Low resolution mass spectrum of 33c using a Waters ZQ LC-SQMS 
instrument. 
 






Figure ‎C.19. 1HNMR spectrum of 33d. 
 





Figure ‎C.21. Low resolution mass spectrum of 33d using a Waters ZQ LC-SQMS 
instrument. 
 






Figure ‎C.23. 1HNMR spectrum of 33e. 
 





Figure ‎C.25. Low resolution mass spectrum of 33e using a Waters ZQ LC-SQMS 
instrument. 
 





Figure ‎C.27. 1HNMR spectrum of 34a in CD3OD in the presence of trace amounts of 
acetone (2.15 ppm).124 
 






Figure ‎C.29. High resolution mass spectrum of 34a using a Waters LCT-MS premier 
TOF instrument.   
 






Figure ‎C.31. HPLC spectrum taken at 254 nm of C5-methyl SAHA (34a). The peak 
at 13.760 is C5-methyl SAHA. The calculated area and height under each peak, 
along with % area, is shown in the table below the spectrum. 
 





Figure ‎C.33. 13CNMR spectrum of 34b. 
 






Figure ‎C.35. IR spectrum of 34b using a Perkin Elmer Spectrum Two ATR-FTIR. 
 
 
Figure ‎C.36. HPLC spectrum taken at 254 nm of C5-butyl SAHA (34b). The peak at 
20.969 is C5-butyl SAHA. The calculated area and height under each peak, along 





Figure ‎C.37. 1HNMR spectrum of 34c. 
 
 





Figure ‎C.39. High resolution mass spectrum of 34c using a Waters LCT-MS premier 
TOF instrument. 
 





Figure ‎C.41. HPLC spectrum taken at 254 nm of C5-hexyl SAHA (34c). The peak at 
22.847 is C5-hexyl SAHA. The calculated area and height under each peak, along 
with % area, is shown in the table below the spectrum. 
 





Figure ‎C.43. 13CNMR spectrum of 34d. 
 






Figure ‎C.45. IR spectrum of 34d using a Perkin Elmer Spectrum Two ATR-FTIR. 
 
 
Figure ‎C.46. HPLC spectrum taken at 254 nm of C5-phenyl SAHA (34d). The peak 
at 17.693 is C5-phenyl SAHA. The calculated area and height under each peak, 





Figure ‎C.47. 1HNMR spectrum of 34e. 
 





Figure ‎C.49. High resolution mass spectrum of 34e using a Waters LCT-MS premier 
TOF instrument. 
 






Figure ‎C.51. HPLC spectrum taken at 254 nm of C5-benzyl SAHA (34e). The peak 
at 18.748 is C5-benzyl SAHA. The calculated area and height under each peak, 










C.2. In vitro screening with HeLa cell lysates and HDAC isoforms 
 
Figure ‎C.52. Dose response curve of C5-modified SAHA analogs 34a-e tested 
using the HDAC activity in HeLa cells lysates from three independent trials with error 
bars indicating standard error (see Table C.1). In some cases, the error bar is 
smaller than the marker size. Data were fit to the sigmoidal curve using 
KaleidaGraph 4.1.3 (Synergy Software) to determine the IC50. The data are reported 











Table ‎C.1. Percent remaining HDAC activity after incubation of SAHA or C5-
modified SAHA analogs 34a-e with HeLa Lysates.a 














2.0 x 10-5    15±2  17±1 
1.2 x 10-5   23±3    
1.0 x 10-5    35±2  33±3 
8.0 x 10-6     15±2  
6.0 x 10-6   42±3    
5.0 x 10-6    58±2  56±4 
4.0 x 10-6     31±4  
3.0 x 10-6   66±6    
2.5 x 10-6    83±1  78±3 
2.0 x 10-6     53±3  
1.5 x 10-6   88±4    
1.0 x 10-6     74±3  
1.25 x 10-6    92±2  93±4 
7.5 x 10-7   101±4    
5.0 x 10-7  14±1   94±3  
2.5 x 10-7  15±2     
2.0 x 10-7 49±1      
1.25 x 10-7  44±2     
1.0 x 10-7 78±4      
6.25 x 10-8  68±4     
5.0 x 10-8 86±4      
3.13 x 10-8  85±2     
2.5 x 10-8 97±1      
a Mean percentage deacetylase activity and standard error of three trials are shown. 




Table ‎C.2. Percent remaining deacetylase activity after incubation of a single 
concentration of each C5-modified SAHA analog with HDAC1, HDAC2, HDAC3, and 
HDAC6 using the ELISA-based activity assay.a  
Compound 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 
SAHAb 1 µM  8.9±0.1 8.3±0.2 14±3 7.9±1.6 
34a (C5-methyl) 0.025 µM 67±6 81±3 80±2 63±3 
34b (butyl) 0.25 µM 84±3 83±3 74±3 35±6 
34c (hexyl) 1.25 µM 64±5 72±1 71±2 28±1 
34d (phenyl) 0.125 µM 83±1 85±1 86±2 63±4 
34e (benzyl) 1.25 µM 69±1 74±1 74±1 17±2 
a The means and standard errors for a minimum of two independent trials are 
shown. This data is associated with Figure 4.2. b Previously reported values using 










Figure ‎C.53. Dose dependent curves of the C5-butyl SAHA analog (34b) with 
HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 isoforms, with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 4.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table C.3). 
Table ‎C.3. Percentage remaining deacetylase activity after incubation of C5-butyl 
SAHA analog (34b) with HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8.a 
a Means and standard errors of at least three independent trials with the C5-butyl 
SAHA (34b) concentrations shown. Data is associated with Figure C.53 and Table 
4.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
4.0 x 10-6 182 253 273   
2.0 x 10-6 373 381 443   
1.6 x 10-6     222 
1.0 x 10-6 526 604 575   
8.0 x 10-7    286 352 
5.0 x 10-7 684 731 837   
4.0 x 10-7    482 503 
2.5 x 10-7 814 831 923   
2.0 x 10-7    607 694 
1.0 x 10-7    7011 836 





Figure ‎C.54. Dose dependent curves of the C5-n-hexyl SAHA analog (34c) with 
HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 isoforms, with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 4.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table C.4). 
Table ‎C.4. Percentage remaining deacetylase activity after incubation of C5-n-hexyl 
SAHA analog (34c) with HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8.a 
a Means and standard errors of at least three independent trials with the C5-n-hexyl 
SAHA (34c) concentrations shown.  Data is associated with Figure C.54 and Table 
4.2. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-5  142 123   
8.0 x 10-6 223 211 274   
4.0 x 10-6 374 416 394   
2.0 x 10-6 548 575 679   
1.6 x 10-6     212 
1.0 x 10-6 665 705 711   
8.0 x 10-7    344 354 
5.0 x 10-7 772     
4.0 x 10-7    543 515 
2.0 x 10-7    664 705 
1.0 x 10-7    697 788 





Figure ‎C.55. Dose dependent curves of the C5-benzyl SAHA analog (34e) with 
HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 isoforms, with error bars depicting 
the standard error of at least three independent trials. IC50 values associated with 
Table 4.2 were determined by fitting data to a sigmoidal curve using KaleidaGraph 
4.1.3 (Synergy Software) (Table C.5). 
Table ‎C.5. Percentage remaining deacetylase activity after incubation of C5-benzyl 
SAHA analog (34e) with HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8.a 
a Means and standard errors of at least three independent trials with the C5-beznyl 




Deacetylase activity (%) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
1.6 x 10-5  191 234   
8.0 x 10-6 272 301 437   
4.0 x 10-6 452 493 533   
2.0 x 10-6 548 625 8512   
1.6 x 10-6     191 
1.0 x 10-6 775 773 856   
8.0 x 10-7    263 332 
5.0 x 10-7 844     
4.0 x 10-7    432 472 
2.0 x 10-7    543 654 
1.0 x 10-7    763 825 




Table ‎C.6. Fold selectivity of SAHA and C5-SAHA analogs 34b, 34c, and 34e for 
HDAC6 or HDAC8 over HDAC1, 2, and 3.a 
Compound 
HDAC6 fold selectivity HDAC8 fold selectivity 
HDAC1 HDAC2 HDAC3 HDAC1 HDAC2 HDAC3 
SAHA 1 3 0.6 b 0.06 c 0.2 c 0.04 c 
C5-butyl SAHA 
34b 
3 4 5 3 3 4 
C5-hexyl SAHA 
34c 
5 6 7 5 6 7 
C5-benzyl SAHA 
34e 
11 13 21 8 9 15 
a Fold selectivities were calculated from the IC50 values in Table 4.2. 
b SAHA 
displayed 1.65-fold preference for HDAC3 versus HDAC6.  c SAHA displayed 16-
fold, 6-fold, and 27-fold preference for HDAC1, 2, and 3, respectively, over HDAC8. 
C.3. In cellulo selectivity testing 
         A)            B) 
         
Figure ‎C.56. Western blots analysis of acetyl-histone H3 (Lys9) (AcH3) and acetyl-
α-tubulin (Lys40) (AcTub) after treatment with SAHA or the C5-benzyl SAHA analog 
34e. U937 cells were treated with SAHA (5 µM), DMSO (1%) or C5-benzyl SAHA 
analog 34e at the specified concentrations, before lysis, SDS-PAGE separation, 
transfer to a PVDF membrane, and western blotted with AcH3 or AcTub antibodies. 
GAPDH levels in the samples were also probed as a gel load control. A DMSO 
control sample was included for comparison to inhibitor treated samples. These 
three trials (parts A-B) are associated with the third trial shown in Figure 4.3. 
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C.4. In vitro cancer cell growth inhibition 
Table ‎C.7. Percentage of viable cells after treatment of Jurkat cell line with of C5-
butyl SAHA 34b, C5-hexyl SAHA 34c, C5-benzyl SAHA 34e, and SAHA.a 
 Viable cells (%) 
Compound 1 µM 10 µM 
34b (butyl) 67  6 39  2 
34c (hexyl) 101  6 24  2 
34e (benzyl) 71  9 50  5 
SAHA 49  6 5  3 
a Means and standard errors for a minimum of four independent trials are shown. All 


















APPENDIX D  
D.1. Compound characterization of the biaryl indolyl benzamide inhibitors 
 
 
Figure ‎D.1. 1HNMR spectrum of 40. 
 





Figure ‎D.3. 1HNMR spectrum of 42b. 
 






Figure ‎D.5. 1HNMR spectrum of 44b. 
 






Figure ‎D.7. 1HNMR spectrum of 48. 
 





Figure ‎D.9. 1HNMR spectrum of Bnz-1. 
 
 





Figure ‎D.11. 13CNMR spectrum of Bnz-1. 
 
Figure ‎D.12. High resolution mass spectrum of Bnz-1 using a Waters LCT-MS 





Figure ‎D.13. HPLC spectrum taken at 254 nm of Bnz-1. The peak at 23.579 is Bnz-
1. The calculated area and height under each peak, along with % area, is shown in 
the table below the spectrum. 
 





Figure ‎D.15. 1HNMR spectrum of Bnz-3 enlarged in the aromatic protons region. 
 







Figure ‎D.17. High resolution mass spectrum of Bnz-3 using a Waters LCT-MS 
premier TOF instrument. 
 
Figure ‎D.18. HPLC spectrum taken at 254 nm of Bnz-3. The peak at 22.773 is Bnz-
3. The calculated area and height under each peak, along with % area, is shown in 





Figure ‎D.19. 1HNMR spectrum of Bnz-2. 
 






Figure ‎D.21. 13CNMR spectrum of Bnz-2. 
 
Figure ‎D.22. High resolution mass spectrum of Bnz-2 using a Waters LCT-MS 





Figure ‎D.23. HPLC spectrum taken at 254 nm of Bnz-2. The peak at 23.057 is Bnz-
2. The calculated area and height under each peak, along with % area, is shown in 













D.2. In vitro screening with HDAC isoforms 
Table ‎D.1. Percent remaining deacetylase activity after incubation of a single 
concentration of each compound with HDAC1, HDAC2, HDAC3, and HDAC6.a  
 Deacetylase activity (%) 
Compound HDAC1 HDAC2 HDAC3 HDAC6 
SAHA (20 nM)  61±3 55±2 67±1 65±1 
Cpd-60 (28 nM) 19±5 59±6 90±2 101±3 
Bnz-1 (200 µM) 15±2 27±1 - - 
Bnz-1 (20 µM) 54±3 77±2 - - 
Bnz-2 (20 µM) 21±1 44±3 - - 
Bnz-2 (2 µM) 48±1 71±2 - - 
Bnz-3 (2 µM) 19±2 63±1 91±1 103±6 
Bnz-3 (200 nM) 64±6 83±3 93±2 108±9 
a The means and standard errors for a minimum of two independent trials are 












Figure ‎D.24. Dose dependent curves of Cpd-60 with HDAC1 and  HDAC2 isoforms, 
with error bars depicting the standard error of at least three independent trials. IC50 
values associated with Table 6.1 were determined by fitting data to a sigmoidal 
curve using KaleidaGraph 4.1.3 (Synergy Software) (Table D.2) 
Table ‎D.2. Percentage remaining deacetylase activity after incubation of Cpd-60 








a Means and standard errors of at least three independent trials with the Cpd-60 
concentrations shown. Data is associated with Figure D.24 and Table 6.1. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 
1.6 x 10-7  31  1 
8.0 x 10-8  52  5 
4.0 x 10-8 14  1 67  3 
2.0 x 10-8 33  3 74  1 
1.0 x 10-8 53  4 82  5 
5.0 x 10-9 71  4  





Figure ‎D.25. Dose dependent curves of Bnz-3 with HDAC1 and  HDAC2 isoforms, 
with error bars depicting the standard error of at least three independent trials. IC50 
values associated with Table 6.1 were determined by fitting data to a sigmoidal 
curve using KaleidaGraph 4.1.3 (Synergy Software) (Table D.3) 
Table ‎D.3. Percentage remaining deacetylase activity after incubation of Bnz-3 with 










a Means and standard errors of at least three independent trials with the Bnz-3 
concentrations shown. Data is associated with Figure D.25 and Table 6.1. 
Concentration (M) 
Deacetylase activity (%) 
HDAC1 HDAC2 
2.0 x 10-6 28  4  
1.0 x 10-6 38  7  
5.0 x 10-7 54  5  
2.0 x 10-7 70  4  
1.0 x 10-7 77  4  
5.0 x 10-8 80  4  
3.2 x 10-5  21  3 
1.6 x 10-5  35  2 
8 x 10-6  44  6 
4 x 10-6  59  5 
2 x 10-6  66  6 
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HDAC proteins have emerged as interesting targets for anti-cancer drugs due 
to their involvement in cancers, as well as several other diseases. Several HDAC 
inhibitors have been approved by the FDA as anti-cancer drugs, including SAHA 
(suberoylanilide hydroxamic acid, Vorinostat). Unfortunately, SAHA inhibits most 
HDAC isoforms, which limit its use as a pharmacological tool and may lead to side 
effects in the clinic. In this work we were interested in developing isoform selective 
HDAC inhibitors, which may decrease or eliminate the side effects associated with 
non-selective inhibitors treatment. In addition, isoform selective HDAC inhibitors can 
be used as biological tools to help understand the HDAC-related cancer biology. Our 
strategy was based on synthesis and screening of several derivatives of the non-
selective FDA approved drug SAHA substituted at different positions of the linker 
region. Several SAHA analogs modified at the C4 and C5 positions of the linker 
were synthesized. The new C4- and C5-modified SAHA libraries, along with the 




cellulo for HDAC isoform selectivity. Interestingly, several analogs exhibited dual 
HDAC6/HDAC8 selectivity. Enantioselective syntheses of the pure enantiomers of 
some of the interesting analogs were performed and the enantiomers were screened 
in vitro. Among the most interesting analogs, (R)-C4-benzyl SAHA displayed 520- to 
1300-fold selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3, with IC50 values 
of 48 and 27 nM with HDAC6 and 8, respectively. Docking studies were performed 
to provide structural rationale for the observed selectivity of the new analogs. In 
addition, rational design, synthesis, and screening of several other biaryl indolyl 
benzamide HDAC inhibitors is discussed, and some showed modest HDAC1 
selectivity. The new biaryl indolyl benzamides can be useful to further develop 
HDAC1 selective inhibitors. The dual HDAC6/8 selective inhibitors can be used as 
lead compounds and as a chemical tool to study HDAC related cancer biology. The 
observed enhancement of selectivity upon modifying the linker region of the non-
selective inhibitor SAHA shows that modifying current drugs, like SAHA, could lead 









AHMED THABET NEGMELDIN 
Educational background 
Ph.D. in Chemistry, 2017 (Organic Chemistry) 
Wayne State University, Detroit, MI, 48202, USA 
M.Sc. in Pharmaceutical Sciences, 2011 (Pharmaceutical Organic Chemistry) 
Faculty of Pharmacy, Cairo University, Cairo, Egypt 
B.Sc. in Pharmacy and Pharmaceutical Sciences, 2006 
Faculty of Pharmacy, Cairo University, Cairo, Egypt 
Fellowships, Scholarships and Awards 
 2017: Willard R. Lenz, Jr. Endowed Memorial Scholarship, Wayne State University.  
 2017: Graduate school symposium award for 2nd place in the best poster presentation competition. 
 2017: Wayne State University graduate school micro-credentials for demonstrating best practices in oral 
presentation, and for best practices in academic poster design. 
 2016-2017: Thomas C. Rumble University Graduate Fellowship, Wayne State University.  
 2016: Dr. Cal Stevens memorial scholarship (travel award for outstanding record in research), Wayne State 
University. 
 2016: Clifford G. Drouillard Annual Chemistry Award for outstanding record in departmental service and/or 
research, Wayne State University. 
 2016: James C. French Graduate award for outstanding academic and research record, Wayne State University. 
 2016: Graduate Student Professional Travel Award (GSPTA), Wayne State University. 
 2015: Graduate School honor citation for excellence in teaching award, Wayne State University. 
 2014: Norman A. LeBel Endowed Graduate Award in Organic Chemistry, Wayne State University. 
 2014: Departmental honor citation for excellence in teaching award, Wayne State University. 
 2012-2016: Graduate Teaching Assistant Award and scholarship, Wayne State University. 
 2006: Honors, Faculty of Pharmacy, Cairo University, Cairo, Egypt. 
Publications 
 Ahmed T. Negmeldin and Mary Kay H. Pflum, "The structural requirements of histone deacetylase inhibitors: C4-
modified SAHA analogs display dual HDAC6/HDAC8 selectivity" (Eur. J. Med. Chem., Submitted). 
 Ahmed T. Negmeldin and Mary Kay H. Pflum, "The structural requirements of histone deacetylase inhibitors: SAHA 
analogs modified at the C5 position display dual HDAC6/8 selectivity" (Bioorg. Med. Chem. Lett., 2017, Accepted). 
 Ahmed T. Negmeldin, Geetha Padige, Anton V. Bieliauskas, and Mary Kay H. Pflum, "Structural requirements of 
HDAC inhibitors: SAHA analogues modified at the C2 position display HDAC6/8 selectivity", ACS Med. Chem. 
Lett., 2017, 8 (3), 281-286. 
 Jehad Almaliti, Ayad A. Al-Hamashi, Ahmed T. Negmeldin, Christin L. Hanigan, Lalith Perera, Mary Kay H Pflum, 
Robert A. Casero, Jr., and L. M. Viranga Tillekeratne, "Largazole Analogues Embodying Radical Changes in the 
Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue", J. Med. Chem., 2016, 59 (23), 
10642-10660. 
 Anton V. Bieliauskas, Sujith V.W. Weerasinghe, Ahmed T. Negmeldin, and Mary Kay H. Pflum, "The structural 
requirements of histone deacetylase inhibitors: SAHA analogs modified on the hydroxamic acid", Arch. Pharm. 
(Weinheim, Ger.), 2016, 349 (5), 373-382. 
 Geetha Padige, Ahmed T. Negmeldin, and Mary Kay H. Pflum, "Development of an ELISA-Based HDAC Activity 
Assay for Characterization of Isoform-Selective Inhibitors", J. Biomol. Screen., 2015, 20 (10), 1277-1285. 
 Magdalene K. Wambua, Dhanusha A. Nalawansha, Ahmed T. Negmeldin, and Mary Kay H. Pflum, "Mutagenesis 
Studies of the 14 Å Internal Cavity of Histone Deacetylase 1: Insights toward the Acetate-Escape Hypothesis and 
Selective Inhibitor Design", J. Med. Chem., 2014, 57 (3), 642-650. 
 Manal M. Kandeel, Lamia W. Mohamed, Mohamed K. Abd El-hamid, Ahmed T. Negmeldin, "Design, Synthesis, 
and Antitumor Evaluation of Novel Pyrazolo[3,4-d]pyrimidine Derivatives", Sci. Pharm., 2012, 80 (3), 531-545. 
 Manal M. Kandeel, Lamia W. Mohamed, Mohamed K. Abd El-hamid, Ahmed T. Negmeldin, "Synthesis of novel 
arylsubstituted pyrazolo[3,4-d]pyrimidines and their evaluation as cytotoxic agents", Int. J. Chem. Sci. Tech., 
2011, 1 (4), 126-140. 
